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Wilms' tumour is a paediatric kidney cancer that arises during embryogenesis from
pluripotent renal precursor cells. Multiple genetic loci have been linked to the
etiology of Wilms' tumour, but only the Wilms' tumour suppressor gene, WT1, has
been cloned and shown to play a direct role in Wilms' tumourigenesis. In humans,
germline mutations of WT1 are associated with both Wilms' tumours and urogenital
malformations. Analysis of the mouse knockout for WT1 revealed a failure of
kidney and gonad development, establishing a fundamental role for WT1 in early
urogenital development. The WT1 gene encodes multiple isoforms of a nuclear
protein containing four zinc fingers which acts as a transcription factor and is
predicted to have a role in RNA processing. Although there are a number of clues
as to the function ofWT1, important questions remain unanswered.
The WT1 knockout is embryonic lethal, dying at midgestation. This prevents
insight into the role of WT1 in later embryogenesis and post-natal development.
Also the embryonic lethality of the WT1 knockout mouse precludes any studies of
the role of WT1 in Wilms' tumourigenesis. The characterization of WT1 as a
transcriptional regulator suggests that identification of its target genes may provide
insight into its function at various stages of normal development and during
tumorigenesis. Whilst numerous WT1 target genes have been suggested, mainly
through the use of promoter-reporter constructs in cell lines in vitro, many lack
evidence to indicate a physiological relevance. With the limitations of these
previous studies in mind, this thesis describes the use of gene targeting in
embryonic stem cells, to develop two different genetic systems to facilitate the
investigation ofWTl function.
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Firstly, using the Cre/LoxP system a conditional null allele for WT1 was generated
by targeting the WT1 locus in embryonic stem cells. LoxP sites were positioned
either side of exon 1 of WT1, and correctly targeted embryonic stem cells were used
to generate mice. Together with tissue-specific transgenes directing expression
inducible and non-inducible forms of Cre recombinase in vivo, this conditional
WT1 mouse model will provide a powerful tool to further investigate the role of
WT1 in development and disease.
Secondly, WT1 null embryonic stem cells were generated through sequential gene
targeting of both alleles of WT1. These WT1 null embryonic stem cells were used
to identify endogenous genes regulated, directly or indirectly, by WT1 and also to
identify interacting protein partners. To identify candidate WT1 target genes, WT1
null embryonic stem cells were studied in an in vitro differentiation system.
Analysis of gene expression profdes using Affymetrix Genechip arrays, identified a
set of differentially expressed transcripts, which may represent WT1 regulated
genes. Interestingly, these included Wnt-4 and BF-2, two genes crucial for the
development of the kidney.
The biological activity of WT1 is modulated by its interaction with several known
protein partners. To identify other protein partners, in vitro differentiation of
embryonic stem cells, followed by immunoprecipitation of endogenous WT1
associated complexes coupled to MALDI-TOF analysis, was used to identify
interacting protein partners. From this study, an interaction of WT1 with
heterogeneous nuclear ribonucleoprotein U (hnRNP U) was identified, a protein
involved in transcriptional repression, the packaging and processing of RNA, and
chromatin remodeling.
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Using a selection of lineage specific markers on differentiating embryonic stem
cells, it was observed that WT1 is expressed in neuronal progenitors in vitro.
Extending the analysis in vivo, WT1 was expressed in the ventral half of the neural
tube in a domain that corresponds to location of neuronal progenitors. Specifically
WT1 expression was detected in a progenitor domain that gives rise to motor
neurons. WT1 expression was also present in motor neurons as shown by co-
staining with Islet-1. The expression of WT1 in the progenitors of the neural tube
opens the possibility that WT1 may have role in patterning of the neural tube.
In summary, the development of these two systems will provide important
resources to further understand the function of WT1. The WT1 conditional null
mouse will permit the role WT1 in vivo to be examined, whilst the WT1 null ES
cells provide an in vitro experimental system in which to screen for candidate WT1
target genes and interacting protein partners. The power of this system has been
demonstrated in this thesis by the identification of a set of candidate WT1 target
genes and an interaction with hnRNP U.
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1. Wilms' Tumour and Mammalian Kidney Development
Wilms' tumour is a paediatric kidney malignancy of embryonic origin that has an
incidence of 1 out of 10,000 infants (Breslow et al., 1988). It serves as a striking
example of cancer arising through inappropriate development (Hastie, 1994). To
begin to understand the how Wilms' tumours develop, it is important to understand
how normal mammalian kidney development proceeds (For reviews see Saxen,
1987; Lechner and Dressier, 1997; Kuure et al., 2000).
In mammals, the kidney develops in three stages: pronephros, mesonephros and
metanephros. Kidney development begins with the differentiation of the
intermediate mesoderm to form the pronephric duct. The pronephric duct
contributes to the formation of the first kidney, the pronephros. The pronephros is a
transitory, non-functional structure which develops early during development, at
around E8 in the mouse. In mammals, the pronephric duct degenerates, leaving
only the caudal portion, which forms the Wolffian duct.
The next stage is the development of the mesonephros, which begins at around E9.5
in the mouse. Initiation of the mesonephros is triggered when the pronephric duct
reaches the presumptive mesonephric mesenchyme and induces the mesenchymal
cells to condense. Condensation of the mesenchyme leads to the formation of the
mesonephric tubules that develop into nephrons. The mesonephric nephrons range
from simple epithelium to convoluted tubules complete with glomeruli. The
mesonephros remains the permanent kidney in amphibians and fish, and may also
function transiently in mammals. Eventually, however the mammalian
mesonephros starts to regress and this leads to complete absence of the organ in
females by around El 5. In males, the caudal portions of the tubules and Wolffian
duct remain and develop into structures of the male genitals.
1
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The third and final structure to develop is the functional mammalian kidney, the
metanephros, which starts to form around E10.5-E11 in the mouse (Figure 1.1).
Development of the metanephros is dependent upon reciprocal inductive
interactions between the epithelial ureteric bud and metanephric mesenchyme. The
ureteric bud develops from the caudal portion of the Wolffian duct, through
inductive signals from the metanephric mesenchyme (Figure 1.1 (a)). During recent
years, experiments have indicated that the Ret/GDNF signalling pathway is part of
this inductive event which initiates ureteric bud outgrowth. GDNF is first expressed
in the metanephric blastema before induction. Its cognate receptor, c-Ret, is
expressed in the mesonephric duct and becomes restricted to the growing ureteric
tip once induction occurs. The evidence to support the roles for GDNF and c-Ret in
providing the inductive signal for ureteric bud initiation, comes from analysis of the
mouse knockouts of either GDNF or c-Ret (Schuchardt et al., 1994; Sanchez et al.,
1996; Pichel et al., 1996). Both mouse models exhibit kidney agenesis or
dygenesis, as a result of a failure of the ureteric bud to develop from the
mesonephros.
Once initiated, the ureteric bud then invades the metanephric mesenchyme and
branches (Figure 1.1 (b) and (c)). Upon contact with the ureteric bud, the
metanephric mesenchyme is induced to condense along the surface of the bud and
begins to form a blastema of cells adjacent to the tips of the branching ureteric bud.
This marks the next stage in the development of the metanephric kidney in which
the metanephric mesenchyme is induced to form nephrons (nephrogenesis).
Signalling molecules expressed at the tips of the ureter initiate the induction of
nephrogenesis. Studies using in vitro ureteric bud cell lines, and protein purification
of conditioned medium from these cell lines, has identified leukaemia inhibiory
factor (LIF) as being a signalling molecule that induces nephrogenesis (Barasch et
al, 1999). Unlike the crucial role for GDNF and c-Ret, there appears to be some









Figure 1.1 Kidney Development in the Mouse
a) The ureteric bud develops from the Wollfian duct at around E10.5 b) The ureteric bud grows into the
metanephric mesenchyme. The mesenchyme surrounding the tips of the bud is induced to condense
c) From E11.5 onwards, the condensed mesenchyme induces the ureteric bud to branch d) From E12.5
onwards, in association with ureteric branching morphogenesis, mesenchyme undergoes a mesenchymal-to-
epithelial transformation to form the nephron. This occurs through the comma and s-shaped stages.
The expression pattern of some of the genes involved in the process are shown (Figure taken from Vainio and
Lin. 2002)
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(Stewart et al., 1992; Escary et al., 1993). During nephrogenesis, the metanephric
blastema undergoes an epithelial conversion via comma- and S-shaped structures to
form a spherical cyst called the renal vesicle, which eventually matures to form the
functional nephron (Figure 1.1 (d))
It is thought that Wilms' tumours arise from the pluripotent metanephric blastemal
cells following the induction of differentiation as tumours often go on to develop
tubular and glomerular-like structures (Hastie, 1994). A typical Wilms' tumour is
classified as triphasic, consisting of undifferentiated blastema, epithelial structures,
and stromatous components, all of which derive from the blastema during normal
development of the kidney. Normally, in humans the metanephric mesenchyme has
undergone conversion to epithelial structures by 36 weeks of gestation (Hastie,
1994). After this time, nephrogenesis ceases and any mesenchymal cells that have
persisted and have failed to generate epithelium are thought to either give rise to
stromal cells or undergo apoptosis. Any persistence of blastemal cells is abnormal
and represents structures known as nephrogenic rests which are thought to represent
precursor lesions to Wilms' tumour. Nephrogenic rests are found in 40% of
unilateral and 100% of bilateral Wilms' tumour (Beckwith et al., 1990). Therefore,
it would appear that Wilms' tumour represents a malignancy in which its
development is closely tied to the normal organogenesis of the kidney.
1.2 Wilms' Tumour Suppressor 1 (WT1) Gene
Considerable insights into the mechanisms underlying tumourgenesis have come
from identifying tumour predisposition genes (Ponder, 2001). Clues to the
chromosomal location of the first Wilms' tumour predisposition gene to be
identified, WT1, came through the observation that Wilms' tumours often develop
in children with a rare condition called aniridia, or lack of an iris. The close
association between spontaneous aniridia and Wilms' tumour led to the isolation of
a region on the short arm of chromosome 11. Patients presenting with a
4
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chromosome 1 lp deletion syndrome, known as WAGR (Wilms' tumour, Aniridia,
Genitourinary anomaly, mental Retardation) have constitutional hemizygous
deletions of chromosomal region 11 pi3 (Francke et al., 1979). High resolution
molecular mapping on these constitutional deletions led to the identification and
cloning of the Wilms' tumour predisposition gene, WT1, at thel lp 13 locus (Call et
al., 1990; Gessler et al., 1990).
It was assumed that the gene would be a tumour suppressor gene, and as in the case
of Rbl in Retinoblastoma, inactivation of both copies of WT1 would lead to
tumourigenesis (Knudson, 1971). This was demonstrated to be the case when
constitutional mutations within the WT1 gene was detected in two individuals with
Wilms' tumours and genital abnormalities (Pelletier et al., 1991). Subsequently, it
was also demonstrated that inactivation of WT1 has been shown to occur in the
nephrogenic rests, the precursors to Wilms' tumours (Park et al., 1993). However
WT1 is deleted or mutated in only approximately 10% of sporadic Wilms' tumours,
implicating a role for WT1 in the aetiology of the malignancy, but highlighting that
the disease does not always conform to the simple two-hit model (Gessler et al.,
1994; Little and Wells, 1997). The complexity of Wilms' tumour could be
explained by the presence of several other distinct Wilms' tumour suppressor
genes. Additional genomic loci associated with sporadic Wilms' tumour have been
mapped to chromosome 1 lpl5, 16q, 3q, 4q, 9p and 20p (For a review see Menke et
al., 1998). However to date only the WT1 gene at 11 p 13 has been cloned and
shown to play a direct role in the aetiology ofWilms' tumour.
1.2.1 Structure of WT1
The WT1 gene consists of 10 exons spanning 50 kb of genomic sequence and
generates a transcript of around 3 kb (Call et al., 1990; Gessler et al., 1990; Haber
et al., 1991). Translation of the WT1 transcript reveals a protein that contains
several motifs characteristic of a transcription factor. It encodes for a protein which
5
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contains 4 zinc fingers of the Kruppel-type at the C-terminus, and at the N-terminus
a proline/glutamine rich putative transactivation domain (Figure 1.2). These two
motifs are features commonly found in bona fide transcription factors, such as
EGR1 and SP1, and therefore suggested a transcriptional function for WT1.
However, understanding the precise function of the WT1 gene is complicated by the
fact that it can potentially encode 24 protein isoforms
1.2.2 WT1 Protein Isoforms
The WT1 gene encodes up to 24 different protein isoforms through a combination
of alternative splicing, alternative translational initiation and RNA editing.
There are two alternatively spliced exons (Haber et al., 1991). One alternative
splicing event results in either inclusion or exclusion of exon 5 which encodes for
17 amino acids N-terminal of the four zinc fingers; the second event results from
variation in the splice donor site used at the end of exon 9, resulting in the absence
or presence of 3 amino acids (lysine-threonine-serine;KTS) between the third and
fourth zinc finger.
Depending on the absence or presence of the two splice inserts, the WT1 proteins
have a molecular mass of 52-54 kDa (Morris et al., 1991). Added to the alternative
splice forms, there is also an alternative non-ATG translational initiation site (CTG)
which is located 204 bp upstream of the major ATG start site. This produces WT1
isoforms that have an additional 68 amino acid N-terminal extension and a
molecular mass of 60-62 kDa (Bruening et al., 1996).
The WT1 mRNA is also edited. In adult rat kidneys and testis, as well as in adult
human testis, a thymidine residue in exon 6 of WT1 (position 839 in rat and
position 1222 in human) is changed to a cytosine residue (Sharma et al., 1992;
Sharma et al., 1994). Within the WT1 protein this leads to an isoleucine to proline
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activity of the isoform. The edited isoform represses transcription from the EGR1
promoter 25-30% less efficiently that the unedited version (Sharma et al., 1994).
With regards to its biological significance in vivo, it appears that RNA editing is not
a mechanism by which WT1 is altered during tumourgenesis, as the analysis of
primary Wilms' tumours did not detect RNA editing of WT1 in the specimens
(Gunning et al., 1996). Therefore, the biological effects ofRNA editing in the WT1
mRNA remains unclear.
1.2.3 Evolutionary Conservation of Protein Isoforms
So are all of these WT1 isoforms important? WT1 has been cloned from a variety
of different organisms. Comparison of WT1 sequence from mouse, rat, chick,
alligator, xenopus, zebrafish and fugu reveals extensive conservation across
species, suggesting an important role for the gene throughout vertebrate evolution
(Sharma et al., 1992; Kent et al., 1995; Miles et al., 1998). With regards to the
particular motifs ofWT1, across the zinc fingers, between human, mouse and rat,
there is 100% amino acid sequence identity. In all the isolated WT1 sequences from
vertebrates, there is conservation of the +KTS alternative splice form (Kent et al.,
1995). In fugu, there is an alteration in the KTS amino acid sequence, with a
proline replacing the threonine to produce KPS instead of the KTS. The biological
significance of this amino acid change from KTS to KPS is unknown, however the
KPS is still alternatively spliced (Miles et al., 1998). Overall, the conservation of
the KTS alternative splice variant emphasises the importance of this splice form in
vertebrate development. The conservation of these two isoforms over 450 million
years of evolution suggests that they serve distinct functions in development.
Recently, the development ofmouse models that produce only KTS or -KTS insert
confirmed that the KTS isoforms are crucial during urogenital development
(Hammes et al., 2001) (See section 1.7.4).
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In contrast, the 17 amino acid alternative splice site, the proline/glutamine rich
domain, the alternative CTG start site and the occurrence of RNA editing are not
conserved between all vertebrates, being present only in mammals (Sharma et al.,
1992; Kent et al., 1995; Miles et al., 1998). Therefore, does the increased
complexity of WT1 in mammals indicate a role for WT1 in more mammalian-
specific developmental processes? The recent mouse model knockouts of the
mammalian-specific isoforms would indicate otherwise (See section 1.7.5)
1.3 Functions of WT1
1.3.1 WT1 as a Transcription Factor
WT1 has many structural properties that are typical of a transcription factor,
including a glutamine/proline rich N-terminus, nuclear localisation signal and four
zinc fingers with a Kruppel-type motif. The zinc fingers 2, 3 and 4 of WT1 share
close structural homology with the three zinc fingers of EGR1. The WT1 zinc
finger domain has been shown to bind to the characteristic CG-rich EGR1 DNA-
binding element, although with a lower affinity than EGR1 (Rauscher et al., 1990).
A second potential WT1 DNA-binding site motif has been identified as containing
TCC repeats (Wang et al., 1993 (a)). This motif has been mapped to the WT1-
responsive promoters of PDGF-A and also EGFR. A more refined and specific
WT1 binding site, termed WTE, has been identified by PCR selection of genomic
DNA sequences with high affinity for WT1, coupled with extensive mutational
studies (Nakagama et al., 1995). WT1 demonstrates a 20-30 fold higher affinity for
the WTE binding site than EGR1 and has been identified in the promoters of
amphiregulin and SF-1, which appear to be physiologically authentic WT1 target
genes (Lee et al., 1999; Wilhelm et al., 2002).
Although the zinc fingers ofWT1 confer sequence-specific DNA-binding activity,
the presence of the KTS insert between zinc fingers 3 and 4 greatly effects the
9
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binding affinity of WT1 for DNA (Rauscher et al., 1990). Initially, it was thought
that only the -KTS isoforms could bind to the EGR1 consensus DNA-binding site.
Subsequently further studies identified DNA sequences that both -KTS and +KTS
could bind to, although with different affinities (Bickmore et al., 1992). WT1 -KTS
and +KTS bound to the same overlapping DNA sequence of the IGFII, PDGF-A
and Pax2 genes. Recently, in a study of IGFII gene regulation by WT1, the
isoforms were found to have opposite effects, with the -KTS activating the IGFII
P3 promoter, whilst the +KTS represses its activity (Caricasole et al., 1996).
Therefore, the KTS splice variants appear to exhibit differential transcriptional
regulation of the same target genes.
Studies using nuclear magnetic resonance (NMR) techniques have investigated the
structural consequences of insertion of the KTS sequence between zinc fingers 3
and 4, both in free solution and complexed with DNA (Laity et al., 2000). The
NMR spectra indicated that the two isoforms are nearly identical in structure in the
absence of DNA. However, upon binding to DNA it was shown that the KTS
insertion disrupts important interactions of the linker region and other zinc fingers,
lowering the stability of the zinc finger/DNA complex. This provides structural
information relating to the observed alternative affinity of the -/+ KTS isoforms for
DNA.
1.3.2 Transcriptional Targets of WT1
What are the target genes that WT1 transcriptionally regulates? As described above
the identification of potential WT1-specific DNA-binding motifs has led to the
identification of numerous putative WT1 target genes which contain WT1 binding
sites within their promoters. Extension of these findings has shown that the
promoters of these potential WT1 target genes can be modulated by WT1 in
transfections assays (Table 1.1) (For a review see Reddy and Licht, 1996; Lee and





































Table 1.1 Published WT1 Target Genes
(Compiled from the reviews by Reddy and Licht (1996) and Lee and Haber (2001))
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both transcriptional repression and activation. The list of potential target genes
described in the literature as being either transcriptionally activated or repressed by
WT1 has been established mainly through two in vitro approaches.
The first approach has employed the use ofWT1 promoter-reporter constructs and
electrophoretic mobility shift assays (EMSA). This approach follows a strategy in
which the promoter region of a potential WT1-regulated gene is co-transfected into
heterologous cell lines along with a WT1 expressing plasmid. The transcriptional
repression or activation is assayed to ascertain whether WT1 has an effect upon the
regulation of this gene. EMSA is then used to identify potential WT1 consensus
sequences within that promoter. However the interpretation of the data from these
assays is difficult. Various factors, including the number of WT1 binding sites
within the promoter, the cell type used in the experiment, the choice of expression
vector and also the particular isoform ofWT1 employed in the assay, have all been
shown to affect the outcome of this assay. For example, the promoter of the EGR-1
gene is activated by WT1 in Saos-2 and U20S, human tumour cell lines, whilst
WT1 represses the same promoter in mouse NIH3T3 cells (Maheswaran et al.,
1993;Englert et al., 1995).
The second approach has been to establish cell lines overexpressing single WT1
isoforms and then screen for changes in gene expression profiles between
expressing and non-expressing cell lines. Following this methodology, U20S
osteosarcoma cell lines with tetracycline-inducible expression of -KTS and +KTS
WT1 isoforms were screened for altered gene expression profiles using
oligonucleotide microarrays containing 6800 human transcripts (Lee et al., 1999).
From this analysis, amphiregulin (a member of the epidermal growth factor family)
was shown to be up-regulated following expression of the -KTS isoform (Lee et
al., 1999). In vitro, the WT1 -KTS isoform was shown to bind directly to the
amphiregulin promoter through the presence of a WTE binding element, resulting
in transcriptional activation of amphiregulin. Immunohistochemistry and RNA in
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situ hybridisation studies reveal that WT1 and amphiregulin, in vivo, share the same
temporal and cell type-specific expression pattern in the developing kidney. It was
also demonstrated that in embryonic kidney rudiments, recombinant amphiregulin
stimulates epithelial differentiation in vitro. Therefore these observations suggest
that amphiregulin is a physiologically relevant target for transcriptional control by
WT1. However, apart from amphiregulin, no other previously reported WT1 target
genes were altered in this in vitro system.
Utilising the same tetracycline inducible system described above, a rat embryonic
kidney cell line, derived from the undifferentiated renal mesenchyme using SV40
large T antigen, was used to identify potential WT1 targets (Palmer et al., 2001).
Cells derived from the embryonic kidney were chosen to enable the identification
of more physiological relevant targets for WT1 regulation. From this study, the
authors identified podocalyxin, a major structural membrane protein component of
the podocytes as being regulated by WT1 (Palmer et al., 2001). Characterisation of
the promoter demonstrated the presence ofWTE elements. Expression analysis of
podocalyxin in the developing kidney was shown to mirror that ofWT1 (Palmer et
al., 2001). This system confirmed transcriptional regulation of amphiregulin by the
-KTS isoform, however it was unable to detect any changes in the expression of
other reported candidate genes (EGR1, IGF-II, PDGF-A, Bcl-2, IGFR, C-Myc and
EGFR).
Overall, the approach of using cell lines expressing single isoforms has its
limitations. Originally, the WT1 over-expression studies usually employed cell
lines that were not physiologically relevant to the in vivo expression pattern ofWT1
i.e. these cell types do not normally express WT1 (Englert et al., 1997; Hosono et
al., 1999; Lee et al., 1999). Although successful at identifying amphiregulin, other
more genuine WT1 target genes may have been missed. It is also unclear whether
the alteration of gene expression following over-expression of single WT1 isoforms
reflects the situation in vivo, where normal physiological concentrations and ratios
13
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of splice forms ofWT1 are present. The correct ratio of different WT1 isoforms has
been shown to be crucial in development and disease. This is most evident in the
expression of the KTS isoforms, as demonstrated by Frasier syndrome patients and
shown in the KTS mouse models (Hammes et al., 2000). Therefore, although
providing interesting and potential WT1-regulated targets, a more physiologically
relevant system is required for the study of WT1 in the transcriptional control of
gene expression.
In an attempt to tackle these issues, there has been a move towards the use ofmore
developmentally-appropriate cell lines which promote the identification of
legitimate downstream gene targets. These cell lines will possess the correct
cofactor combination required for the proper interaction of WT1 to target genes.
Added to this, assays have also been developed which allow the identification WT1
transcriptional targets by "knocking-down" WT1 in cells lines that endogenously
expresses this gene. In this approach, a dominant-negative isoform ofWT1 is used
to inhibit the function of the endogenous wild-type protein. Dominant-negative
WT1 mutations are found in patients with Denys-Drash syndrome (Pelletier et al.,
1991). The DDS mutations all lie within the zinc fingers of WT1, and ablate the
ability ofWT1 to bind to DNA and function as a transcriptional regulator (Pelletier
et al., 1991; Englert et al., 1995). Furthermore, since WT1 self-associates, it is
assumed that the mutant protein is capable of blocking the activity of the wild-type
protein, thereby acting in a dominant negative fashion (Holmes et al., 1997).
Employing this approach, a polyoma-transformed mouse mesonephric cell line,
Ml5, expressing a dominant-negative DDS isoform of WT1 (Ml5 DDS), was
screened for altered gene expression in comparison to wild-type Ml5 cells lines
using nylon based cDNA macroarrays (Sim et al., 2002). Comparison of the
expression profiles ofMl 5 and M15 DDS clones identified Wnt-4 as being down-
regulated in the Ml5 DDS cells. While several potential WT1 binding sites were
detected in the Wnt-4 promoter, no evidence could be gathered to establish whether
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the regulation ofWnt-4 by WT1 was direct (Sim et al., 2002). The significance of
an interaction with Wnt-4 is discussed below. Again, further analysis of the
expression of some of the reported WT1 candidate genes failed to detect any
change in their expression (Bcl-2, C-Myb, C-Myc, CSF-1, EGR1, IGF2, IGFR1,
PDGF-A, RARa, and TGF[31).
Using the same approach of stably expressing a WT1 DDS isoform, but this time in
a Wilms' tumour cell line, connective tissue growth factor (CTGF) was identified
as being a potential WT1-regulated transcriptional target (Stanhope-Baker and
Williams, 2000). The authors assessed the validity of CTGF as a WT1 target by
promoter-reporter assays. In these assays, they showed that the CTGF promoter is
repressed by WT1. The physiological significance of CTGF regulation by WT1 is
enhanced by the fact that CTGF shares homology to NovH, a gene that has been
postulated to be potential WT1 target (Martinerie et al., 1996). CTGF and NovH
contain a domain that is commonly present in the family of proteins called the
Insulin-Like Growth Factor Binding Proteins (IGFBPs). It is interesting to note that
a recent study has suggested that WT1 may regulate two members of the IGFBP
family, IGFBP-3 and IGFBP-4 (Wagner et al., 2001) (Discussed in Chapter 5).
These proteins modulate the biological activity of the insulin like growth factors,
IGF-I and IGF-II. Since IGF-II is over-expressed in a subset of Wilms' tumours,
this proposed regulation of CTGF by WT1 may play a role in the tumourgenesis
and disease progression in patients with WT1 mutations (Cui et al., 2001).
In summary, whilst many potential transcriptional target genes have been identified
for WT1, there are few for which there is compelling evidence to indicate that they
are genuine physiological targets in vivo. In only one case, that of SF-1, has genetic
and transgenic studies been carried out in vivo to support the idea that it is a direct
target gene for WT1 (Wilhelm et al., 2002).
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1.3.3 WT1 in RNA Metabolism
Although compelling evidence exists for WT1 acting as a transcription factor,
recent data also supports a role for WT1 in post-transcriptional processes. The
initial evidence that WT1 may act as a post-transcriptional regulator came from the
study of the subnuclear localisation of the WT1 in cell lines and tissues which
endogenously express WT1 (Larsson et al., 1995). In this study, a proportion of
WT1 was concentrated in nuclear 'speckles' that correlated with the expression
pattern of proteins involved in RNA splicing. The authors demonstrated that WT1
co-immunoprecipitated with known splicing factors including U1-70K, U2-B" and
P80 coilin. When individual isoforms of WT1 were over-expressed in a cell line
negative for endogenous WT1, the +KTS isoforms preferentially associated with
nuclear speckles, whilst the -KTS isoforms were spread diffusely throughout the
nucleus and in areas where the classical transcription factors, TFIIB and SP1, are
abundant. These results were reproduced and extended to show that the subnuclear
localisation of WT1 +KTS was RNase, but not DNase, sensitive (Englert et al.,
1995, Caricasole et al., 1996). Using a variety of biochemical techniques, it was
demonstrated that WT1 was enriched by oligo(dT) chromatography, along with the
splicing proteins U2AF65 and hnRNP Al, and the U5 small nuclear RNP-
associated protein, pi 16 (Ladmomery et al., 1999). Gel filtration and sedimentation
profiles suggested that WT1 was present in the RNase-sensitive fractions. This
suggested that WT1 protein is commonly found to be associated with nuclear poly
(A)+ RNP.
Further work focusing upon the potential role of WT1 in post-transcriptional
processes demonstrated that WT1 interacts with the ubiquitous splicing factor,
U2AF65 (Davies et al., 1998). This interaction, characterised by using a two-yeast
hybrid approach coupled with in vitro binding assays and co-immunoprecipitation,
demonstrated that the +KTS isoforms preferentially associated with U2AF65. WT1
has also been shown to interact with a novel protein, WTAP (WT1 -associated
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protein). WTAP is the mammalian orthologue of the Drosophila gene, fl(2)d, which
is required for female specific splicing of Sxl and Tra pre-mRNAs in the
Drosophila sex determination pathway (Little et al., 2000; Penalva et al., 2000).
Both of these proteins are components of the splicing machinery, and the
association of WT1 with these proteins links WT1 directly to a role in RNA
splicing.
Following the observed association of WT1 +KTS isoforms with the splicing
machinery, computer modelling was used to postulate the existence of an RNA
recognition motif (RRM) in the N-terminal domain of WT1. This hypothetical
model suggested that this domain shared structural homology to the RNA
recognition motif of the splicing factor U1A (Kennedy et al., 1996). Therefore,
mounting data suggests that WT1, apart from its role as a transcription factor, is
also is involved in post-transcriptional functions and specifically may play a role in
RNA splicing.
If WT1 does actually bind RNA in vivo, what are the specific RNA target
transcripts? The only RNA sequence identified as a target for WT1 is located in
exon 2 of the IGFII mRNA, and is bound by both -KTS and +KTS isoforms, with
the +KTS isoforms binding with a higher affinity (Caricasole et al., 1996). More
recently, Bardeesey and Pelletier identified three groups ofRNA ligands that bound
to WT1 from a random ligand pool (Bardeesy and Pelletier, 1998). Using EMSAs,
they found that zinc fingers 2-4 were responsible for recognition of the RNA targets
by WT1, and that the presence of the KTS insert dramatically decreased the affinity
of WT1 for the RNA ligands. Whilst this method identified several sequences, the
significance of these sequences remains to be established.
In summary, WT1 appears to have two distinct regulatory functions, with -KTS
isoforms involved in transcriptional control, whilst +KTS isoforms influence post-
transcriptional control. Taken together, the distinct nuclear localisation of the WT1
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+KTS isoforms, the coelution of WT1 with poly(A)+ cellular fractions, and the
association of WT1 with splicing proteins U2AF65 and WTAP, have raised the
possibility that this isoform may mediate some aspect of mRNA processing.
However further studies are required to demonstrate a clear role for WT1 in post-
transcriptional RNA processing also to identify physiologically relevant mRNA
targets.
1.4 Cellular Functions of WT1
What does WT1 do at the cellular level? Studies have indicated that WT1 has a role
in growth suppression and apoptosis.
Observations from gain-of-function experiments point to a role for WT1 in growth
suppression. The importance of WT1 in the control of cell growth was
demonstrated when isoforms of WT1 were introduced into a Wilms' tumour cell
line expressing an aberrantly spliced WT1 transcript. This resulted in the
suppression of proliferation (Haber et al., 1993). It was also demonstrated that
microinjection of WT1 cDNA into NIH3T3 cells synchronised in early G1 stage,
blocked cell cycle progression into S phase (Kudoh et al., 1995). This phenomenon
was also observed using CV-1, Cos-7, F9 or PI9 cell lines. Another study found
that over-expression of the WT1 (-KTS) isoform in Saos-2 cells and U202 cells
resulted in a 25% increase in cells arrested in the G1 cell cycle phase arrest (Englert
et al., 1995). This cell cycle effect was shown to correlate with transcriptional
activation of p21.
WT1 loss-of-function experiments using WT1 antisense oligos have demonstrated
that suppression of endogenous WT1 expression in K562 cells induces G2/M arrest
(Algar et al., 1996; Yamagami et al., 1998). Therefore, WT1 may therefore play a
role in the control of two cell cycle checkpoints: WT1 over-expression induces
Gl/S arrest whilst WT1 knockdown induces G2/M arrest.
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In WT1 null mice, the mesenchymal cells of the kidney blastema fail to undergo
differentiation and degenerate via apoptosis indicating a crucial requirement for
WT1 for their survival (Kreidberg et al., 1993). WT1 has also been shown to
suppress P53-induced apoptosis (Maheswaran et al., 1995) suggesting a role for
WT1 in promoting cell survival. In contrast, ectopic expression ofWT1 can induce
apoptosis in a number of cells lines (Englert et al., 1995; Menke et al., 1997; Murata
et al., 1997; Smith et al., 1998).
The work in various cell systems has indicated a role for WT1 in growth
suppression and regulation of apoptosis (For review see Little et al., 1999; Lee and
Haber, 2001). Although the results do provide some clues to the function ofWT1 at
the cellular level, variability between cell lines and the variation of effects when
over-expressing single isoforms of WT1 indicates that a more physiologically
relevant system is required. Also conclusions based upon cancer-derived cell lines
is limited, as these cells lines are often restricted in their ability to respond to
potential cellular differentiation signals. Therefore recently several groups have
used pluripotent cell lines to study WT1. One of the most interesting is the
differentiation of embryonal carcinoma and embryonic stem cells with retinoic acid
(Scharnhorst et al., 1997). The treatment of F9 and PI9 embryonal carcinoma cells
with retinoic acid triggers differentiation into endodermal (F9) or endodermal and
ectodermal (PI9) and is accompanied by induction of endogenous WT1 proteins
(Kudoh et al., 1996; Scharnhorst et al., 1997). Therefore this system could be used
to ascertain what happens in cells that endogenously express all WT1 isoforms in
their strictly defined physiological ratio and what effect loss-of-function for WT1
would have on this system.
1.5 Expression ofWT1 during Development
The expression pattern ofWT1 has been analysed in detail by a number of authors
during mouse and human embryonic development in an attempt to gain further
19
Chapter 1 Introduction
insights into its role in development (Pritchard Jones et al., 1990; Armstrong et al.,
1993;Rackley et al., 1993; Moore et al., 1998).
1.5.1 WT1 Expression during Kidney Development
WT1 expression is detected throughout the three stages of kidney development.
WT1 is first detected in the nephrogenic mesenchyme of the intermediate
mesoderm prior to the formation of the pronephros at E8.5 in mouse (Pritchard
Jones et al., 1990; Armstrong et al., 1993). With the formation of the mesonephros,
the cellular caps of the mesonephric ducts express WT1. As the ureteric bud
develops from the mesonephric duct, the metanephric mesenchyme expresses low
levels ofWT1. However as the metanephric blastema condenses around the ureteric
bud, an up-regulation of WT1 expression occurs in the blastema. During the
mesenchymal-to-epithelial conversion to form the renal vesicle, WT1 expression
increases and continues in the renal vesicle. The renal vesicles then undergo a
series of morphological changes as they differentiate to form epithelial structures
known as comma-shaped and S-shaped bodies. During this process, WT1
expression becomes localised to the cells at the proximal part of the S-shaped body
(Pritchard-Jones et al., 1990). These cells flatten to form the podocytes of the
presumptive glomerulus. WT1 expression within the metanephric kidney becomes
restricted to the podocytes of the glomeruli, where it remains expressed throughout
postnatal development and continues in adulthood. The remaining structures of the
nephron, including the proximal and distal convoluted tubules and the loop of
Henle, do not express WT1
After the induction of the metanephric mesenchyme by the ureteric bud, at least
two separate cell populations are found in the mesenchyme. In close proximity to
the ureteric bud are a tubular epithelial population of cells within the nephrogenic
zone. More peripheral to the ureteric bud is the stromal cell population. Within this
context, cells of the metanephric mesenchyme that are not induced, or do not
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undergo nephrogenesis, form either the supporting stroma of the kidney or undergo
apoptosis. As the blastemal cells of the metanephric mesechyme undergo transition
to form the stromal component of the kidney, WT1 expression is lost (Prichard-
Jones et al., 1990; Armstrong et al., 1993)
1.5.2 WT1-Regulated Genes involved in Kidney Development
The involvement of several developmentally-regulated proteins in nephrogenesis
and their relation to WT1 has been established. Work from mouse models has
demonstrated that WT1 is required at multiple stages throughout kidney
development, from the induction of the ureteric bud to the formation of the nephron
(see section 1.7). The fundamental role of WT1 in kidney development has been
highlighted by the failure of WT1 null mice to develop metanephric kidneys
(Kreidberg et al., 1993). There is no induction of the ureteric bud to branch from
the mesonephric duct and this leads to the cells of the metanephric mesenchyme to
undergo apoptosis. The apoptosis of the blastemal cells in the WT1 null mice may
result either from a direct survival signal effect of WT1 itself or, indirectly, as a
consequence of disrupted survival signals from the ureteric bud.
The absence of WT1 may result in either the up- regulation of apoptosis-inducing
factors or the down-regulation of survival factors. With this in mind, WT1 has been
shown to transcriptionally activate the expression of Bcl-2, which encodes an anti-
apoptotic protein (Mayo et al., 1999). Bcl-2 is expressed in the normal
undifferentiated metanephric mesenchyme, and therefore the absence ofWT1 in the
blastemal cells may lead to possible down-regulation of Bcl-2, and hence lead to
the observed apoptosis of these cells. Support for Bcl-2 being a potential target
gene of WT1 during early nephrogenesis is the observation that Bcl-2 knockout
mice have an aberrant kidney phenotype. Bcl-2 knockout mice have smaller
kidneys, which contain fewer nephrons, and the metanephtic blastema displays a
greater susceptibility to apoptosis (Novack and Korsmeyer, 1994).
21
Chapter 1 Introduction
In the condensing mesenchyme, WT1 may promote kidney development by
transcriptionally inducing amphiregulin (Lee et al., 1999). Due to the overlapping
expression pattern of amphiregulin and WT1 during nephrogenesis, it is possible
that activation of amphiregulin by WT1 facilitates ureteric bud branching at the
earliest stages of nephrogenesis (Lee et al., 1999). However amphiregulin is not the
sole factor involved in branching of the ureteric bud as the mouse knockout of
amphiregulin does not exhibit aberrant kidney development, indicating that other
factors are also involved in this process (Luetteke et al., 1999).
Recently Wnt-4 has been identified as a potential WT1 -regulated gene (Sim et al.,
2002). During mouse metanephric kidney development, Wnt-4 expression is first
detected in the metanephric mesenchyme that condenses around the tips of the
invading ureteric bud. Wnt-4 expression continues during the formation of the
comma and S-shaped bodies but is lost when fusion of the epithelial tubules to
collecting ducts occurs (Stark et al., 1994). Mice homozygous null for Wnt-4
exhibit small agenic kidneys, consisting of undifferentiated mesenchyme
interspersed with branches of collecting duct epithelium. This indicates a crucial
role for Wnt-4 in the transition of the mesenchyme to epithelium that occurs during
the development of the nephron. Therefore, this links WT1, via regulation ofWnt-
4, to the mesenchymal-epithelial transition during the early developmental stages of
metanephric kidney formation.
1.5.3 WT1 Expression in Gonadal Development
In mammals, the gonads and kidney are derived from the intermediate mesoderm
and a common precursor, the urogenital ridge. Gonadal development in the mouse
begins as a thickening of the coelomic epithelium of the urogenital ridge, known as
the primary sex cords at El 1. This thickening of the epithelium marks the first stage
of gonadal development, which is followed by development of a prominent gonadal
ridge at around El2. This first step of gonadal development establishes the
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bipotential, or indifferent, gonad. This indifferent gonad has the capacity to
differentiate into completely separate sexual structures, the ovary or the testis.
WT1 is expressed in the proliferating cells of coelomic epithelium of the urogenital
ridge and is also present in the underlying mesenchyme of the gonadal ridge. At
around El3 in mouse, sexual differentiation of male and female gonadal
development begins. In the ensuing development of the gonad, WT1 expression
becomes restricted to the Sertoli cells of the testis, and the granulosa cells and
surface epithelium of the ovaries (Armstrong et al., 1993). Expression in the Sertoli
and granulosa cells continues into adult life, with expression of the gene within
these cells related to the state of maturation of their associated germ cells
(Armstrong et al., 1993; Rackley et al., 1993; Moore et al., 1998).
1.5.4 Other areas ofWT1 expression
In addition to the expression in the developing urogenital system, WT1 is also
expressed in the mesothelium lining of organs within the thoracic and abdominal
cavities, including the surface of the diaphragm, gut mesenteries and the inner
surface of the coelomic cavity (Armstrong et al., 1993; Rackely et al., 1993; Moore
et al., 1998). In the wall of the thoracic cavity, WT1 is expressed in the cells
adjacent to differentiating muscle in the intercostal region, and within the
developing musculature of the body wall (Moore et al., 1998). Further expression
was also detected in the early pro-epicardium, the epicardium and the sub¬
epicardial mesenchymal cells of the heart (Moore et al., 1998). WT1 is also
expressed at high levels in the spleen.
Other sites of expression include discrete pockets of staining in the nervous system.
WT1 expression has been detected in the spinal cord and also in the ventricles of
the brain (Armstrong et al., 1993; Rackely et al., 1993; Moore et al., 1998). WT1
expression has also been detected in the haematopoietic system, with expression
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detected in early haematopoietic precursors in the bone marrow (King-Underwood
et al., 1996; Maurer et al., 1997; Baird and Simmons, 1997).
1.6 The Involvement of WT1 in Disease
The identification of WT1 mutations in human patients has provided important
insights into the functions of WT1. Developmental defects present in patients
suffering from WAGR, Denys-Drash and Frasier syndrome has demonstrated a
fundamental role for WT1 in the development of the urogenital system. Denys-
Drash syndrome (DDS) and Frasier syndrome (FS) are two related conditions
caused by mutations of the WT1. Both syndromes are characterized by male
pseudohermaphroditism, a progressive glomerulopathy, and the development of
genitourinary tumours. DDS and FS have previously been distinguished by
differences in nephropathy, with DDS patients demonstrating diffuse mesangial
sclerosis (DMS) in contrast to focal and segmental glomerulosclerosis (FSGS) in
FS patients.
Denys-Drash syndrome (DDS) is a rare congenital childhood syndrome that
includes symptoms of diffuse mesangial sclerosis, partial gonadal dysgenesis and a
predisposition to Wilms' tumour. Patients suffering from DDS have been shown to
be constitutionally heterozygous for WT1 point mutations (For review see Little
and Wells, 1997). Analysis of the point mutations show that 92% of the WT1
mutations in DDS are present in the zinc finger regions. Most of the mutations are
missense mutations within exon 8 and 9, which code for zinc finger domains 2 and
3. All mutations alter the structure of the DNA binding domain by disrupting the
conformation of the zinc finger regions ofWT1.
Frasier syndrome (FS) is caused by mutations in the splice donor site in intron 9 of
one WT1 allele, resulting in the loss of expression of the WT1 +KTS isoforms
(Barbaux et al., 1997; Klamt et al., 1998). This effects the balance in ratios of the
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KTS isoforms, leading to the severe developmental defects. Although FS patients
generally only develop glomerulopathy of the kidney and not Wilms' tumour, there
has been one reported case of Wilms' tumour in a patient with FS (Barbosa et al.,
1999).
WAGR patients have a constitutional heterozygous deletion of chromosome 11 p 13
(Francke et al., 1979). Children inheriting these deletions suffer from Wilms'
tumour, aniridia, mental retardation, and boys in particular, suffer from mild
pseudohermaphroditism; hence the full syndrome is known as WAGR (Wilms'
tumour, Aniridia, Genitourinary abnormalities, Mental retardation).
Given the expression pattern ofWT1 in a range of different tissues, it seems likely
that the gene may also be involved in the development of a range of tumour types.
WT1 expression has been detected in haematopoetic progenitors, suggesting a role
for WT1 in early haematopoetic development. In WAGR patients, there is an
increased rate of leukaemia as a secondary malignancy, and it has been shown that
a WT1 mutation was found in the remaining allele of one WAGR patient with
leukaemia (Pritchard-Jones et al., 1994; Hartley et al., 1994). WT1 mutations have
been shown to be involved in the development of some types of leukemias. It has
been shown that heterozygous WT1 mutations are present in approximately 15% of
acute myloid leukaemias (King-Underwood and Pritchard-Jones, 1998).
The mesothelium is another tissue in which WT1 is expressed (Armstrong et al.,
1993). However examination of 32 cases of malignant mesotheliomas identified
only one sample with a WT1 mutation present (Park et al., 1993 (b)). Recent
evidence points to a possible role for WT1 in the etiology of breast cancer. Using
immunohistochemistry it has been demonstrated that WT1 expression is present in
normal breast tissue, localised to the myoepithelial cells that are present in the ducts
of the breasts (Silberstein et al., 1997). Analysis of breast tumours by the same
authors observed a reduction or absence of WT1 in 60% of breast tumours. Using
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RT-PCR they also reported that WT1 isoforms lacking exon 5 and KTS were
specifically expressed in tumours. The conclusion of this study was that the loss of
WT1 correlated with tumourigenesis (Silberstein et al., 1997). Contrary to these
findings, another group has demonstrated that WT1 is not expressed in normal
breast epithelium, but that it is highly expressed in the majority of primary breast
tumours analysed (27 of 31 tumours) (Loeb et al., 2001).
1.7 Mouse Models ofWT1
1.7.1 WT1 Knockout Mice
To determine the role of WT1 in vivo, Kreidberg et al generated a mouse which
lacked the first exon and 0.5kb of upstream sequence of WT1, removing the
translational start site and producing a null mutation (Kreidberg et al., 1993). On a
129/C57BL/6 background, adult heterozygous mice appeared phenotypically
normal after 10 months of age. The homozygous WT1 null mice however exhibited
severe abnormalities in the development of the kidney and gonads (Kreidberg et al.,
1993).
In WT1 knockout mice there is an arrest in the development of metanephric kidney.
Specifically, at El 1 the ureteric bud, which induces the metanephric mesenchyme,
does not branch from the mesonephric duct. Furthermore whilst the metanephric
mesenchyme forms, it undergoes apoptosis (Kreidberg et al., 1993). WT1 null
metanephric mesenchyme was assayed in vitro to see whether spinal cord explants,
strong inducers of mesenchyme induction, could rescue the WT1 phenotype and
induce the metanephric mesenchyme. Mesenchyme from the WT1 null mice failed
to undergo induction, whilst wild-type mesenchyme did undergo induction. This




Therefore, the analysis of WT1 null mice indicates that the presence of WT1 is
required for two steps during the first stages of kidney development. Firstly, its
expression in the undifferentiated mesenchymal cells is required to initiate signals
from the metanephric mesenchyme that promotes ureteric bud invasion. Secondly
its expression the metanephric mesenchyme is required for either the survival of, or
the reception of a survival signal, by the metanephric mesenchyme from the
ureteric bud.
Alongside the failure of kidney development, WT1 null mice fail to develop
gonads. Analysis of gonadal development in the WT1 null mice indicates that the
thickening of the epithelium of the urogenital ridge is markedly reduced and the
gonadal ridge is significantly smaller than that of wild-type littermates (Kreidberg
et al., 1993). Recent studies into the role of WT1 in early gonadal development
indicates that WT1 regulates the expression of SF-1, a gene that it important for the
development of the gonad (Wilhelm et al., 2002). Analysis of SF1 null mice
demonstrates that in the absence of SF-1, gonadal development does not proceed
past the early bipotential progenitor stage (Luo et al., 1994). Therefore, as is the
case in development of the kidney, WT1 is fundamental for the early stages of
gonadal development. It is required for the establishment and maintenance of the
early bipotential progenitors of the gonad, possibly through the regulation of SF-1.
Renal abnormalities caused by gene knockouts are not normally lethal until the
immediate postnatal period. WT1 null mice die between E13 and E15. Histological
examination reveals that the hearts of the WT1 null mice are malformed and exhibit
ventricular myocardium hypoplasia. The embryos are edemic and pericardial
bleeding was observed (Kreidberg et al., 1993). In addition to the malformation of
the heart, they also exhibited incomplete diaphragmatic separation of the thoracic
and abdominal cavities, and aplastic lungs.
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1.7.2 YAC Complementation of the WT1 Knockout Mice
In an attempt to rescue the WT1 embryonic lethality, and to explore the later role of
WT1 in development, a human WT1 YAC construct was introduced to complement
the WT1 null mice (Moore et al., 1999). The authors were able to show that the
human WT1 YAC was able to completely rescue the heart defects and mid-
gestation lethality, with the null mice rescued until birth. From this, the authors
concluded that WT1 was crucial for correct epicardial development.
Recent work has extended these findings and suggested a crucial role for WT1 in
the development of the epicardium and of the heart (Moore et al., 1999; Perez-
Pomares et al., 2002). The epicardium generates a population of epicardially
derived cells (EPDCs) that invade a variety of developing heart tissues in a well-
defined spatiotemporal manner (Perez-Pomares et al., 2002). These EPDC
progenitor cells retain the potential to differentiate into coronary smooth muscle,
cardiac fibroblasts and coronary endothelium. Closer analysis of the expression of
WT1 in the epicardium layer demonstrates that WT1 is expressed in both in the
epicardium and the EPDC progenitor cells that delaminate from this layer (Moore
et al., 1999; Perez-Pomares et al., 2002). Initially, WT1 is present in the
undifferentiated progenitor cells as they begin their migration into the developing
myocardial layer of the heart. However as they migrate deeper into the myocardial
layer and undergo terminal differentiation to produce smooth muscle and
endothelial cell lineages, the expression of WT1 becomes down-regulated. This
down-regulation of WT1 correlates with the upregulation of lineage-specific
differentiation. When the development of the epicardium is delayed there is a
reduction in the number of migrating invasive WT1 positive progenitor EPDCs,
resulting in abnormalities within the coronary vessels and thinning of the
ventricular myocardium (Perez-Pomares et al., 2002). In relation to the
development of the heart in the WT1 null mice, analysis of the epicardium layer
demonstrates that the epicardium develops abnormally, and there is a reduction in
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the number of progenitor EPDCs (Moore et al., 1999). Therefore the correct
formation of the ventricular myocardium is dependent upon the invasion of WT1
positive progenitor EPDCs.
The YAC complementation experiments also pointed to an important role for WT1
in the formation of the adrenal gland (Moore et al., 1999). In the analysis of the
complemented WT1 YAC mice, it was noted that the adrenal gland was absent.
Interestingly WT1 expression has not been reported in the adrenal gland, but is
restricted to the outer mesothelial lining (Rackley et al., 1993). This suggests that
the WT1 might be required in the early stages of adrenal gland formation, possibly
during a developmental stage when the gonad and adrenal gland originate from a
common progenitor population.
The YAC rescue experiments also highlighted the continuous requirement for WT1
during nephrogenesis. The analysis of the complement YAC WT1 null mice
illustrated a varying degree of kidney development ranging from complete absence
of kidneys to the development of hypoplastic kidneys. However, the YAC rescue
experiments only partially rescued nephrogenesis in the WT1 null background, with
nephrogenesis arrested at the comma shaped bodies (Moore et al., 1999). The
failure to obtain complete rescue could be explained by too low an expression level
of the human YAC transgene, with levels of only approximately 10% of WT1
levels being achieved (Guo et al., 2002).
To further dissect the role of WT1 in nephrogenesis, the YAC complementation
experiments were repeated using a human YAC that spanned 470 kb of the WT1
locus (Guo et al., 2002). Using this larger YAC, and depending on the expression
levels of WT1 transgene, this construct could fully rescue the WT1 null
nephrogenic phenotype. In rescued mice that possess two copies of the human WT1
YAC, and hence a higher level of WT1 expression, 75% of the transgenic mice
developed two kidneys. Although born with two kidneys, the YAC rescued
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transgenic mice developed glomerular sclerosis. Extending the analysis of these
mice, it was demonstrated that the expression levels of podocalyxin and nephrin,
two podocyte specific genes, were down-regulated in rescued YAC transgenic
mice. The authors concluded that the onset of the renal disease and the reduced
expression of the podocyte specific genes were a direct consequence of reduced
levels of WT1 during nephrogenesis. However the possibility exists that the
observed phenotype of the YAC rescued mice could be due to an inherent
development defect in the kidney, caused by the inability of the human YAC to
fully rescue the WT1 nephrogenic phenotype. However in conjunction with the
earlier YAC experiments, it establishes that WT1 is required for the later stages of
nephrogenesis.
1.7.3 The Effect of Genetic Backgrounds on the WT1 Knockout
Phenotype
The original study describing the phenotype ofWTl knockout mice was carried out
on a 129/C57BL/6 genetic background (Kreidberg et al., 1993). The WTl mutation
has been bred onto different mixed mouse backgrounds with the effect of delaying
embryonic lethality until birth (Herzer et al., 1999). As with the YAC
complementation studies, this system allowed the requirement of WTl for
organogenesis in the later stages of embryogenesis to be assessed. It was
demonstrated that on a mixed genetic background, WTl null mice where asplenic,
implicating a crucial function for WTl in spleen development (Herzer et al., 1999).
This failure of spleen development was found to correlate with an enhanced rate of
apoptosis of the progenitors that form the spleen.
By breeding the WTl null mutation on a mixed background, WTl has been also
shown to be required for normal development of the retina (Wagner et al., 2002). In
the developing retina, WTl transcripts are initially detected throughout the neural
retina and in the developing lens vesicle of E12 mice. Between E15 and PI, WTl
expression becomes restricted to the presumptive retinal ganglion cell layer. In the
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WT1 null mice at El2, there was a reduction in the number of retinal progenitor
cells. At El8 the WT1 null mice have a retinal layer that was consistently thinner
than that of age-matched littermates. This reduction in the retinal layer was shown
to be caused by an increase in apoptosis of retinal ganglian cells (Wanger et al.,
2002). Therefore, the abnormalities in the WT1 null mutant retinas indicate that
WT1 is required for two stages during retinogenesis, firstly in the maintenance and
proliferation of retinal progenitor cells, and then in the development of retinal
ganglion cells (Wagner et al., 2002).
1.7.4 +/- KTS Knockout Mouse
Considerable evidence suggests that the WT1 KTS isoforms have different
biochemical functions, however what are their properties in vivo? Recently, by gene
targeting, mouse models have been generated which express either WT1 (+KTS) or
the WT1 (-KTS) isforms in isolation (Hammes et al., 2001). To ablate the +KTS
specific isoforms, a mutation was introduced into the second splice donor site,
mimicking a mutation found a human patient with Frasier syndrome (-KTS
isoforms only generated, Frasier mice). The -KTS specific isoforms were ablated
by destroying the first splice donor site (+KTS isoforms only generated, KTS
ablation mice). These models allow the in vivo properties of the KTS isoforms to be
analysed.
The development of the heterozygote Frasier and KTS ablation mice was normal,
and adults were fertile producing normal numbers of offspring. However after a
period of 2-3 months, a proportion of the Frasier mice (70%) presented with
glomerular sclerosis and died due to renal insufficiency. This phenotype mimicks
what has recently been observed in the WT1 heterozygous null mice, but at an
accelerated rate (Menke et al., in press).
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In both Frasier and KTS ablation mice, homozygous mice survived until birth, but
then died 24 hours after birth. Analysis of kidney development demonstrated that
although there were differences in the gross development of the kidney, in contrast
to the WT1 null mice, nephrogenic induction was initiated and both mouse models
demonstrated presence of glomeruli. Histological analysis of the Frasier (-KTS
isoforms only) kidneys demonstrated that there was an increase in the stromal
tissue of the kidney and a decrease in nephrogenic zone, although the number of
glomeruli generated appeared to be normal. Closer inspection of the podocytes
revealed their architecture was disrupted and foot process formation was impaired.
The podocytes lacked the typical flatting of the glomerular basement membranes
(GMB) and analysis of markers of the GBM, synaptopodin and a3 integrin, showed
aberrant expression.
Histological analysis of the KTS ablation (+KTS isoforms only) showed a more
severe phenotype in the kidney. The kidneys were small, with an increase in the
stromal component and a decrease in the nephrogenic zone. The number of
glomeruli was reduced, and the glomeruli that did form were small and
dramatically contracted. There was no expression of synaptopodin or a3 integrin.
Overall, this indicated that both WT1 KTS isoforms are required for specifically for
the differentiation and formation of glomeruli.
In the analysis of the gonadal development, there were distinct phenotypes in the
Frasier and KTS ablation mice. In all homozygous XY Frasier mice there was
complete sex reversal, whilst in the KTS ablation mice the gonads were
dramatically reduced in size and mainly consisted of undifferentiated mesenchyme,
with an absence of differentiated cell types. Therefore, it would appear that -KTS
isoforms maybe required for the survival of the gonadal primordium, and that the
+KTS isoforms are involved in the male sex determination pathway. This
requirement for -KTS isoforms in the survival of the bipotential gonadal
progenitors correlates well with the regulation of SF-1 by -KTS isoforms (Wilhelm
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et al., 2002). The apparent role of +KTS isoforms in male sex determination
correlates with the potential regulation of Sry by WT1 (Hossian and Saunder,
2001). Sry, the mammalian testis determining gene, is responsible for the
differentiation of the gonadal primordium along the male sex determination
pathway. In the Frasier mice, the levels of Sry were reduced to a level of 25% of
that ofwild-type littermates.
Although the KTS models demonstrate a crucial role for the individual isoforms in
the correct formation of the kidney and gonad, it would appear that in the
development of the adrenal gland, heart and spleen, there is a level of redundancy
with each isoform being able to perform identical functions. Also it would appear
that unlike the situation in the WT1 null mice, the initial stages of nephrogenesis
are also unaffected.
1.7.5 Mammalian Isoforms of WT1
Mouse knockouts ofWT1, or one of the evolutionary conserved KTS isoforms, has
clear implications for the role WT1 and the KTS isoforms in kidney and gonadal
development (Kreidberg et al., 1993; Hammes et al., 2001). However, what are the
functions of the mammalian specific isoforms ofWT1? One suggestion is that the
WT1 mammalian isoforms maybe involved in mammalian-specific developmental
processes such as embryonic implantation or lactation.
To determine the function of the mammalian exon 5 containing isoforms, mouse
models were generated in which these isoforms were ablated using gene targeting
(Natoli et al., 2002). Surprisingly mice homozygous for the absence of exon 5
developed normally, and both males and females were fertile (Natoli et al., 2002).
Recently a mouse model to determine the function of the mammalian-specific CTG
isoforms during development has also been generated through gene targeting
(Miles et al., 2003). The CTG isoforms contain a 68 amino acid N-terminal
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extension that arises from an upstream CTG initiator codon. Proteins derived from
this alternative start site behave in a similar manner to WT1 isoforms derived from
the main ATG start site; they are localised to the cell nucleus and are capable of
mediating transcriptional repression in reporter assays (Bruening et al., 1996 (b)).
Western blot analysis of a range of tissues and cell lines shows that the CTG
isoforms are present in all WT1 expressing tissues and cells lines, including ovary,
uterus kidney and Wilms' tumour (Bruening et al., 1996). Ablation of the CTG
isoforms was achieved by introducing a translation stop sequence downstream of
the CTG start site (Miles et al., 2003). As with the exon 5 knockout mice, CTG null
mice were observed to be viable and healthy up to one year of age. Therefore, both
models indicate that the mammalian-specific WT1 isoforms are dispensable for
mammalian development. Why the mammalian WT1 gene produces numerous
proteins isoforms remains unclear.
1.8 Aims and Summary of Project
There are several genomic loci associated with sporadic Wilms' tumour which have
been mapped, but only the Wilms' tumour suppressor gene, WT1, has been cloned
and shown to be directly involved in urogential development. Studies of the
expression pattern, patients with WTJ mutations, and also the generation of a WT1
knockout mouse model, have demonstrated that WT1 has a fundamental role in the
development of the genitourinary system.
The WT1 gene is an example of a gene that generates several proteins isoforms,
with each isoform possessing differing biochemical properties. It serves as a
paradigm for mutlifunctional proteins, in that it appears to be involved in
transcriptional regulation and also post- transcriptional RNA processing
Taking into account some of the findings from the study of WT1 gene function, it
would appear that WT1 has several roles during development. Firstly, WT1 is
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expressed in the developing nephrogenic and gonadal lineages. In both of these
lineages, there is a mesenchymal-to-epithelial transition. On the basis of the WT1
expression in these tissues, it was proposed that WT1 may mediate this transition
(Pritchard-Jones et al., 1990). From the study of the WT1 knockout mouse and the
YAC complementation experiments, it is clear that WT1 is crucial for this event
and mediates the terminal differentiation of these two lineages. However, in
contrast to the situation in the nephrogenic and gonadal lineages, mounting
evidence suggests that in the other sites ofWT1 expression it would appear that its
function may be required to maintain cells in an undifferentiated progenitor state. In
the heart, WT1 is expressed in the epicardially derived progenitor cells. As the
progenitor cells undergo terminal differentiation to form the smooth muscle and
endothelial cell lineages, the expression of WT1 becomes down-regulated. This
down-regulation of WT1 correlates with the upregulation of lineage specific
markers. In the haematopoetic system, WT1 is expressed in haematopoetic
progenitors in the bone marrow, and then is down-regulated as differentiation to
specific lineages occurs. And finally in the retina, WT1 expression has been
detected in retinal progenitor cells and then is down-regulated upon terminal
differentiation.
Although there are a number of clues as to the function of WT1, important
questions remain unanswered, particularly the role of WT1 in the adult. WT1
expression in the adult is restricted to discrete pockets of expression in the Sertoli
cells, mesothelium and the podocytes. From studies of the WT1 heterozygous null
mice, data suggests that WT1 has a role in the maintenance of normal physiology of
the kidney. However the function of WT1 in the mesothelium and the Sertoli cells
remains unclear. In addition there are no adequate mouse model to analyse the role
ofWTl in tumourgenesis.
The WT1 knockout mouse created for the molecular analysis of the role ofWT1 in
urogenital development resulted in embryonic lethality at midgestation. The
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analysis of mutant embryos revealed a failure of kidney and gonad development,
establishing a fundamental role for WT1 in early urogenital development. However
the model system is limited, as it prevents insight into the role ofWT1 in the later
stages of embryogenesis and post-natal development. The first chapter of this
thesis, Chapter 3, describes the use of gene targeting in embryonic stem cells to
generate a conditional allele of WT1 using the Cre-LoxP system. Combining
specific promoters and inducible Cre recombinase- expressing transgenic mouse
lines, the establishment of this conditional mouse model will provide a greater
understanding of the pathways and function of WT1, in both the later stages of
embryogenesis and in adulthood. It is also hoped that this strategy will produce a
mouse model that will recapitulate the human pathology of Wilms' tumour and the
associated urogenital abnormalities.
The best characterised function of WT1 is as a transcription factor. Reporter
construct assays and over-expression of single WT1 isoforms in tumour derived
cell lines have suggested putative target genes for both transcriptional activation
and repression by WT1. However, significant variation has been found using these
approaches and often the results from these assays do not often reflect the situation
in vivo. The range of physiologically relevant targets that have been identified to
date is relatively small, with only SF-1 and amphiregulin being confirmed with
some certainty. A huge problem in the study ofWT1 function and identification of
targets has been the limited availability of cell lines that express endogenous WT1
at detectable levels and also the limitations of the whole animal model. Therefore a
more suitable in vitro system may better facilitate the identification of downstream
targets.
Recently, it has been shown that differentiation of embryonic stem cells with all-
trans retinoic acid induces high level expression ofWT1. Chapter 4, describes the
use of retinoic acid differentiation in embryonic monolayer cultures to study WT1.
From the in vitro differentiation of ES cells, and the use of specific lineage
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markers, this study has established that WT1 is expressed in neuronal progenitors
within this system. Analysis of WT1 expression in vivo confirms that WT1 is
expressed in neuronal progenitors specifically in the ventral neural tube.
Chapter 5, describes the generation of WT1 null ES cell lines through sequential
gene targeting of both alleles of WT1. Using retinoic acid differentiation of ES
monolayers, followed by Affymetrix genechip microarray analysis, the effects of
WT1 loss-of-function on gene expression is examined. From this study, a number
of novel WT1 target genes are identified.
Several protein partners have been identified that either modulate the function of
WT1 as a transcription factor, affect the activity of WT1 in cell cycle regulation
and apoptosis, or which implicate a role for WT1 in RNA splicing and post-
transcriptional regulation. Thus, Chapter 6 describes the use of the RA
differentiation in ES cells followed by endogenous immunoprecipitation of WT1
and MALDI TOF mass spectrometry, to identify a novel WT1-interacting protein
partner.
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2.1 DNA Manipulations
All chemicals were analytical grade and were supplied by Sigma, Promega,
Gibco BRL, BDH, Fisher Scientific, Flowgen, and Roche. Nucleic acid
manipulations were done in 1.5 ml centrifuge tubes unless otherwise stated.
General solutions were prepared by HGU technical staff and autoclaved and
stored at room temperature.
2.1.1 Preparation of Genomic DNA
Tissue samples were re-suspended in 500 pi of tail mix buffer. 5 pi of proteinase-K
(10 mg/ml) was added with gentle mixing. The samples were incubated at 55°C
overnight, followed by a lhr incubation at 37°C with 10 pi of lOmg/ml DNAse-free
RNAse (Roche). The DNA was cleaned by 2 x phenol/chloroform extractions, plus
one chloroform extraction. DNA was precipitated from the aqueous layer with 0.6
volumes of 100 % ethanol and centrifuged at 13,000 rpm for 20 minutes at 4°C.
The supernatant was removed and the pellet was washed with 70% ethanol. The
supernatant was discarded and the pellet was allowed to dry at room temperature
and then re-suspended in ddHhO.
2.1.2 DNA quantification
For concentrations of DNA thought to be in excess of 300 ng/pl, the sample was
diluted 1:200 in ddFFO and the absorbance was read at 260/280 nm on a
spectrophotometer. For samples less than 300 ng/pl, 1-2 pi of the DNA was run on
a 1% agarose/1 x TAE ethidium bromide (1 pg/ml) stained gel, alongside known
amounts of standard DNA. The concentration of the sample was then estimated by
comparing the intensity of its fluorescence to that of the standards under a UV light.
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2.1.3 Restriction Digestions
Digestions of DNA with restriction endonucleases were carried out in the
appropriate buffer at the recommended temperature. Restriction enzymes were
supplied by Boehringer Mannheim and NEB. DNA digestion with restriction
endonucleases were performed using the optimal conditions as recommended by
the particular manufacturer. Digests were performed using lx buffer, DNA (10 ng
to 1 pg/pl) and 0.5-5 units of enzyme per ug of DNA. The total volume of enzyme
was always limited to no more than 10% of the reaction volume to avoid glycerol
inhibition of digestion. Incubations were at 37°C, unless otherwise instructed, for
periods from lhr to overnight.
2.1.4 DNA Electrophoresis
DNA molecules were separated according to their size by agarose gel
electrophoresis.
The percentage of agarose (BioGene) used to make the gel was dependent on the
size range of the DNA molecules to be separated. Digested DNA for Southern
blot analysis was run on a 0.8% agarose gel, whilst PCR products were
commonly run on agarose gels of between 1%- 2%. If DNA fragments were to
be purified from the gel then a low melting point agarose (Flowgen) was used.
The agarose gels were made in TAE buffer (20 x TAE : 0.8 M Tris, pH 8.0; 20
mM EDTA; 0.4 M acetic acid) with ethidium bromide added (0.5 p-g/ml). DNA
was mixed with 10 x loading buffer (20% ficoll; 100 mM EDTA; Orange G
(Sigma)). A DNA ladder was used to determine the size of DNA fragments.
Following electrophoresis DNA fragments were visualised on an UV trans-
illuminator.
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2.1.5 Southern Blot
Between 5-10 pg of genomic DNA was digested overnight with the appropriate
restriction endonuclease(s). The sample was then mixed with 5 pi of orange-G
loading dye, and loaded onto an ethidium bromide (0.5 pg/ml) stained agarose
(0.8% 1 x TAE gel). A suitable DNA marker ladder was used to determine the
size range of the position of the fragments of interest. Samples were
electrophoresed until the orange-G ran off the end of the gel. The gel was then
photographed with UV using a video camera and image processing system
(BioRad) and the position of the DNA size markers were noted with a ruler. The
gel was soaked in 0.25 M HC1 for 20 minutes at room temperature, with gentle
agitation. The gel was then washed twice with denaturing buffer (0.5 M
NaOH/1.5 NaCl) for 20 minutes. The gel was inverted and then placed onto a
piece of Saran wrap or cling film on the bench. The following was then placed on
top of the gel: 1 piece of membrane (Pall) soaked in 2 x SSC, 2-4 pieces of 2 x
SSC soaked 3 MM Whatman paper, followed by a 5 cm stack of dry paper
towels, a glass plate and two 500 ml bottles half filled with water (weight
approximately 0.5 kg). The blotting apparatus was left overnight. The apparatus
was dismantled and the position of the wells marked on the membrane with a
pencil. The membrane was then UV cross-linked.
2.1.5.1 Labelling of DNA probes
The labelling reaction was carried out using the Random Prime kit (Boehringer
Mannheim). 100 ng of the DNA probe to be used in the Southern blot was re-
suspended in a total volume of 10 pi of ddPEO and denatured for 5 minutes at
100°C and then transferred to ice. To this 5 pi of reaction mix (lpl dATP, lpl
dTTP, 1 pi dGTP and 2 pi reaction mix), 4 pi of lOpCi/pl 32P dCTP and 1 pi of
klenow (2U/pl). The reactions were incubated at 37°C for 1 hour. The labelled
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DNA was separated from the unincorporated nucleotides by spinning the
labelling reaction through TE equilibrated spin columns (Amersham Pharmacia).
2.1.5.2 Hybridisation and Washes
Elybridisation and washing of Southern blots was carried out in roller bottles in a
hybridisation oven at 65°C overnight. Hybridisation of probes to the blots was
carried out in Church and Gilberts solution (0.5 M Na2HPC>4 (pH7.2), 20%SDS,
0.5 M EDTA). DNA probes were boiled for 5 minutes and added to the
hybridisation solution and incubated overnight. The following day, the blot was
washed 2 x 30 minutes in 2 x SCC/0/1% SDS, 1 x 30 minutes in 1 x SSC/0.1%
SDS, and a final 1 x 30 minute wash in 0.1 SSC/0.5 SDS. The membrane was
then wrapped in Saran Wrap and exposed a Molecular Dynamics Phosphoimager
screen. The image was then scanned into the phosphoimager and analysed using
the ImageQuant software package.
2.1.6 PCR
For PCR reactions, filtered Gilson tips were used in each assay. dNTPs were
purchased as stocks of 100 mM (Abgene). Working stocks of 10 mM were made
by mixing lOpl of each of the dNTPs (dATP, dCTP, dGTP, dTTP) with 60 pi
ddH20 to a final volume of 100 pi. Stocks were stored at-20°C. dNTPs were
used in PCRs at a final concentration of 0.2 mM. Primers were purchased from
MWG Biotech as lyophilised desalted compounds. Stocks were made up to 1
pg/pl using sterile dH20. Primers were used in PCRs at a final concentration of
100 ng/pl. AmpliTbg (5U/pl) was used at 0.2 pi per 25 pi reaction (Applied
Biosystems). PCR buffer was a 10X stock and therefore diluted 1:10 for
reactions (Applied Biosystems). Mg2+ was used at a final concentration of 1.5
mM (Applied Biosystems). Routine PCRs were done in a MJ Research DNA
Engine Tetrad. 100-200 ng of genomic DNA was used for PCR reactions and
generally all PCR amplification programmes were identical (35 cycles). The
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exception was the annealing temperature, which was varied according to the
primers used:
General PCR amplification programme:
1. 94°C for 5 mins
2. 94°C for 45 sees
3. n°C for 60 sees ( variable annealing temperature)
4. 72°C for 1 min
5. 72°C for 5 mins
2.2. Microbiology
Aseptic technique was observed for all steps involving the growth of bacterial
cells (setting up cultures, pouring agar plates, selecting single colonies, and
storing bacterial stocks). Liquid cultures were grown at 37°C with vigorous
shaking and dry cultures were grown on inverted agar plates at 37°C. HGU
technical staff prepared all bacterial growth media stocks.
2.2.1 Production of electrocompetent cells
A single colony of XL1 Blue E.coli cells from an agar plate was used to
inoculate approximately 10 ml L-broth for overnight growth. The culture was
used to inoculate 2 x 400 ml fresh L-broth the following morning. Cells were
grown to an absorbance at 600 nm (Aeoo) of 0.15-1.0. Flasks were chilled on ice
for 15-30 minutes and cells were centrifuged at 4°C, 4000g for 15 minutes.
Pellets were re-suspended in 800 pi ice cold sterile 10% glycerol. The
centrifugation step was repeated and cells were re-suspended in 400 ml 10% cold
glycerol. Following a further centrifugation step, cells were re-suspended in 20
ml 10% glycerol. Cells were centrifuged once again and re-suspended in 2-3 ml
10% glycerol. The final concentration of cells was approximately 3xl010
cells/ml. Aliquots of cells were frozen in liquid nitrogen and stored at -70°C.
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2.2.2 Transformations
Competent cells were transformed with DNA by electroporation.
Electrocompetent cells were thawed on ice and 50 pi were added to each DNA
sample. The mixture was transferred to ice cold electroporation cuvettes and
allowed to sit for 1 minute on ice. Cells were electroporated using a BioRad
2_|_
electroporator set at 25pF, 2.5kV, and 200Q. 1 ml L-broth/ Mg was added to
the cells immediately following electroporation and cells allowed to recover for 1
hour by shaking at 37°C prior to plating on selective medium.
2.2.3 Isolation of plasmid DNA
Plasmid DNA was prepared using commercially available kits (Qiagen). For the
extraction of small amounts of plasmid DNA (Qiagen Plasmid Mini Kit), a single
colony was used to inoculate approximately 10 ml L-broth with antibiotic
selection (ampicillin) for overnight growth. The following morning, plasmid
DNA was extracted using the kit according to the manufacturer's instructions.
Plasmid DNA was eluted in 30 or 50 pi elution buffer. For large amounts of
plasmid DNA, single colonies were grown as described above and large cultures
of L-Broth (200-350 ml) with antibiotic selection were inoculated with 500 pi
from the 10 ml overnight cultures. The following morning, plasmid DNA was
extracted using the kit (Qiagen Plasmid Maxi Kit) according to the
manufacturer's instructions.
2.3 Mouse Embryonic Stem Cell Culture
During all procedures in ES cell culture, sterile technique was observed with use
of disposable sterile pipettes (Costar). All solutions were pre-warmed to 37°C
before use.
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2.3.1 Maintenance of ES Cells
The ES cell line, E14.1, was cultured in BHK-21 medium (Glasgow MEM)
(Gibco) supplemented with 10% FCS (Globalpharm), 0.3% glutamine (Gibco),
0.1 mM MEM non-essential amino acids (Sigma), 1 mM sodium pyruvate
(Sigma), 0.1 mM |3-mercapthoethanol (Sigma). The culture medium was also
supplemented with Leukaemia Inhibitory Factor (LIF) to maintain ES cell in
their undifferentiated state. LIF was obtained from conditioned medium derived
from Cos-7 cell, transfected with a LIF expression construct. The correct
concentration of LIF conditioned medium added to the ES cell culture medium at
any given time was derived from results of titration experiments to determine the
highest dilution of LIF which supported the ES cells in undifferentiated state.
ES cells were maintained on gelatinised plates. Plates or flasks (Costar) were
coated with 0.1% gelatin solution (Sigma) approximately 10-15 minutes before
plating. Prior to plating of cells, the gelatin solution was removed and the ES
cells were added to the flask or well in culture medium. ES cells were incubated
at 37°C in 5% C02.
2.3.2 Gene Targeting in ES Cells
The targeting vector (pWTlLoxP24 orpKreWTl) was isolated from the plasmid
backbone using the appropriate restriction enzymes, gel purified using agarase
and phenol:chloroform extracted. Following phenokchloroform extraction, the
targeting vector was precipitated with 100 % ethanol, washed in 70% ethanol and
re-suspended to a concentration of lfxg/pl in sterile ddH20. 100 p-g of targeting
vector was electroporated into the ES cell line, E14.1. lxlO7 ES cells were
electroporated using a BioRad Gene Pulser and the setting used were 3pF and
0.8 kV.
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2.3.3 Selection and Freezing of ES Clones
Following selection using G-418 (GibcoBRL)(final concentration of 250 jag/ml)
or Gancyclovir (Roche) (final concentration of 2 pM) or a combination of both,
surviving clones were picked. The media was aspirated from the plates, and the
plates washed twice in PBS. Individual clones were isolated and placed into 96
well "V" plates with trypsin to dissociate the clone. Following 5 minutes at 37°C,
the dissociated clone was transferred into a flat bottomed 96 well plate, and
normal culture medium was added. Individual ES clones were cultured for a
further 2-3 days. Once the clones has grown sufficiently, they were passaged into
24 wells and then split into two further wells, one well for freezing and other to
harvest genomic DNA.
2.3.4 Transient Expression of Cre
Correctly targeted ES clones carrying the full targeting vector, pWTlLoxP24,
were identified and expanded to carry out the transient expression of Cre
recombinase. This step removes the loxP flanked selectable cassette, and
generates ES clones with loxP sites flanking exon 1 of WT1. The Cre plasmid
used waspMC-Cre (Gift Dr K Rajewsky). Fully targeted ES cells were grown to
a final concentration of 1 x 107 in preparation for electroporation with the pMC-
Cre plasmid. 80 pg of circular pMC-Cre was electroporated into ES cells
containing the full targeting vector. Following electroporation, transfected ES
cells were seeded at a concentration of 1 x 104 in 9cm2 gelatinised dishes, in
normal LIF containing medium. The cells were grown in normal medium for
further 4 days. Following 5 days, ES cells were placed into selection with GANC
for a further 6-8 days. After 6-8 days, when clones were visible, between 30-50
clones were picked and analysed by Southern blot for the Cre mediated
recombination. The efficiency of Cre recombination and GANC selection was
established by a control transfection in which ES clones containing the full
targeting vector were electroporated in the absence pMC-Cre.
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2.3.5 Blastocyst Injections and Chimera Breeding
ES clones that contained loxP sites flanking exon 1 ofWT1 were thawed into 24
wells. Clones were cultured until they reached 50-70% confluentency in normal
ES medium. On the day of injection, ES clones were washed 3 x PBS and
trypsinised to form single cell suspensions. The blastocyst injections were carried
out by Dr. Sheila Webb. Briefly female donor mice (C57BL/6) were set up for
natural matings. The following morning they were checked for vaginal plugs,
and positive plugs were considered as being 0.5 dpc. Female mice were
sacrificed at 3.5 dpc by cervical dislocation and the blastocysts were harvested.
Typically, 10-15 ES cells were injected per blastocyst. Injected blastocysts were
collected and transferred to pseudopregnant recipient female mice.
Chimeric mice generated from the injection of WT1LoxP ES clones were set up
for germline test breeding with C57BL/6 female mice. Agouti offspring denotes
contribution of the injected ES cells to the germline. Agouti mice were tailtipped
and genotyped by PCR or Southern blot
2.3.6 Differentiation of Monolayer ES Cells with all-trans Retinoic
Acid
ES cells were seeded at a defined concentration (between 1 x 103 x 104
depending up the scale of the experiment) onto 9cm2 gelatinisized plates in
normal LIF containing media. 24 hours later the cells were washed 3 x PBS and
the media changed to ES culture media lacking LIF and supplemented with 1 uM
all-trans Retinoic Acid (Sigma). At 24 hour intervals the cells were washed 3 x
PBS and the media changed to fresh ES medium lacking LIF and supplemented
with RA.
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2.4 Protein Work
2.4.1 Preparation of Nuclear Extract and Immunoprecipitations
ES cells were seeded at 1 x 104 in 9cm2 plates. For a typical IP experiment, 20 x
9cm' plates ES cells were set up. ES cells were differentiated with 1 pM all-trans
retinoic acid as described in section 2.3.6. Following 96 hours, cells were washed
2 x with ice cold PBS and cells were scraped off into residual PBS. Cells were
collected from all plates and pooled into eppendorfs. Samples are then
centrifuged for 3 minutes at 4000 rpm at 4°C. The supernatant was removed and
the pellet was re-suspended in 600 pi of hyptonic buffer (10 mM Tris-HCl pH
7.4, 10 mM NaCl, 3 mM MgCl2, Protease inhibitor cocktail). The samples are
left on ice for 10 minutes. Following incubation on ice, the samples were
vortexed and centrifuged for 1 minute at 13,000 rpm at 4°C. The supernatant was
removed (cytoplasmic extract) and the nuclear pellet was re-suspended in an
equal volume of lysis buffer (20 mM Hepes pH 7.9, 600 mM KC1, 0.2 mM
EDTA, 20U/ml DNase, lOU/ml RNase inhibitor, Protease Inhibitor Cocktail).
The samples were left on ice for 30 minutes, with samples vortexed every 10
minutes. Following 30 minutes, the samples were centrifuged for 10 minutes at
13,000 rpm at 4°C. The supernatant was collected (nuclear protein) and stored at
-20°C.
The prepared nuclear extract was diluted _ with IP buffer (20 mM Hepes pH 7.5,
70 mM KC1, 5mM MgCl2, 0.05% NP40, 12% Glycerol, 0.1 mM ZnCl2, lmg/ml
BSA). Nuclear Extracts were firstly pre-cleared with Protein A glass beads
(Prosep), to remove reduce non-specific interactions with the sepharose A. Pre-
clearing was carried for 3 hours, rotating at 4°C. Beads were then washed 6 x 1
ml IP Buffer and the pre-cleared extract removed from the beads. Separately, the
various antibodies were bound to the beads by adding the specific antibody to
pre-washed beads (45 pi of C19 (Santa-Cruz), 9 pg of IgG and lpl of 3G6) in 1
ml of IP buffer and rotating for 3 hours at 4°C. The pre-cleared nuclear extract
was then divided for the various IPs to be carried out (WT1, hnRNP U and
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Rabbit IgG control). The nuclear extract was then added to the different bound
antibodies and the IP carried out overnight, rotating, at 4°C. The following day
the beads were pelleted by centrifugation at 2,000 rpm and the supernatant was
removed (unbound fraction). The pellet was then washed 6 x 1 ml of IP buffer.
The proteins were eluted from the beads by washing the beads 3 x 50 pi aliquots
of elution buffer (200 mM Glycine pH 2.5 and 1 mg/ml BSA) with agitation.
Each elution removed from beads, was neutralised with 1/10 volume of 1 M Tris
pH 7.5.
2.4.2 SDS-PAGE Electrophoresis
SDS-polyacrylamide gel electrophoresis (PAGE) was used to resolve proteins
according to their molecular weight. Routinely a 10% resolving gel was used
(30% acrylamide mix, 1.5 M Tris (pH 8.8), 10% SDS, 10% ammonium
persulphate, TEMED), with a 5% stacking gel (30% acrylamide mix, 1.0 M Tris
(pH 6.8), 10% SDS, 10% ammonium persulphate, TEMED).
The gel apparatus was assembled and the samples, mixed with 2 x sample buffer
(62.5 mM TrisCl pH 6.8, 2% SDS, 2% (3-mercapthoethanol, 10% glycerol, 0.1%
bromophenol blue), were boiled for 5 minutes and loaded into the wells. Running
buffer (25 mM Tris, 250 mM glycine pH 8.3 and 0.1% SDS) was added and the
gel run between 150-200V. The gel was then stained with with Coomassie blue
(0.1% Coomassie blue dye, 50% methanol, 10% acetic acid) to visualise proteins
or transferred to nitrocellulose for Western blot analysis.
2.4.3 Western Blotting
A semi-dry blotter was used to transfer proteins onto a Hybond filter. The
samples were set up on the anode plate as follows: 1 section ofWhatmann filter
cut to the size of the gel soaked in transfer buffer (0.3 M Tris, 10% methanol, pH
10.4). Next the Hybond filter cut to the same size as the gel was firstly soaked in
100% methanol and then equilibrated in transfer buffer. This was placed on top
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of the Whatmann filter. Then the SDS-PAGE gel was soaked in transfer buffer
and the carefully placed onto the Hybond filter ensuring that air bubbles were
removed from the interface between the gel and the filter. Finally a section of
Whatmann filter cut to the size of the gel soaked in transfer buffer was placed on
top. The cathode plate was then put in place and the transfer carried out at 10V
for 30 minutes.
Once the transfer had taken place, the nitrocellulose probed for the protein of
interest. Firstly the nitrocellulose filter was blocked in 5% fat free milk in TBST
(50 mM Tris -Hcl pH7.5, 150 mM Nacl, 0.1% Tween) for lhour at room
temperature or overnight at 4°C. The primary antibody was added for either
lhour at room temperature or overnight at 4°C. Following incubation with the
primary antibody, unbound antibody was then removed by 3 x 15 minute washes
in TBST. After completion of the washes, the secondary antibody conjugated
with horseradish peroxidase was then added for 1 hour at room temperature.
Following the incubation, the blot was washed 3x15 minutes with TBST.
Detection of the protein was carried out using the ECL-Plus (Amersham) as
described by the manufacturer.
If the filter was to be re-used for detection of another protein, the filter was
stripped. This was carried out by exposing the filter to stripping buffer (100 mM
(3-mercapthoethanol, 2% SDS, 62.5 mM Tris.HCl pH 6.7) and incubated at 50°C
for 30 minutes. The filter was then washed 2x10 minutes in TBST at room
temperature. Detection of the protein of interest was then carried as described
above.
2.5 RNA Manipulation
2.5.1 Preparation of RNA
Total RNA was isolated from embryos and ES cells using the RNAgents® Total
RNA Isolation System (Promega) following the manufactures instructions.
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Briefly, cells or tissues were homogenised in denaturing solution (Promega). To
the samples, 2M sodium Acetate (pH4.0) was added and the tubes mixed
thoroughly. Tubes were then incubated on ice for 20 minutes. Following
incubation, an equal volume of Phenol:Chloroform:Isoamyl Alcohol was to the
tubes. The samples were then incubated on ice for 20 minutes. The samples were
mixed by inversion and centrifuged for 20 minutes at 4°C. The aqueous phase
was removed containing the RNA and transferred to a fresh eppendorf. An equal
volume of Isopropanol was added and samples stored overnight at -20°C. To
precipitate the RNA, the sample was centrifuged for 30 minutes at 4°C. The
supernatant was removed and the pellet washed with 80% ethanol. The RNA
pellet was then dried and re-suspended in nuclease free ddFEO. RNA was then
stored at -70°C.
2.5.2 cDNA Synthesis and RT-PCR
1-5 pg of total RNA from ES cells or tissues, in 5 pi of ddFFO, was denatured for
5 minutes at 65°C and then placed on ice. To this 4 pi of 5 x reaction buffer, 1.25
pi of DNTP mix, 0.25 pi of RNA inhibitor (Roche), 1 pi of RT AMV (Roche)
and 1 pi of oligo dT were added and made up to 20 pi with ddFFO. The mix was
incubated at 42°C for 1 hour. 30 pi of lmM Tris pH 7.5 was then added and the
resulting cDNA stored at -20°C until required. RT-PCR was carried out as
described in section 2.1.6. Annealing temperatures for each RT-PCR was
optimised for every primer pair and the cycle number ranged between 24-35
cycles depending upon the abundance of the transcript. For example, control
PCRs ((3-actin) were typically performed with 25 cycles, whilst 35 cycles were
used to detect rare transcripts (T-brachury, MyoD)
2.5.3 Northern Blot Analysis
2.5.3.1 Preparation of Gels for Northern Blots
10 x MOPS (1 Litre use depc H2O)
41.2 g MOPS
10.9 g Sodium acetate, 3-hydrate
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3.7 g EDTA, sodium salt
Filter sterilise
17.5 mis of formaldehyde, (deionzed using mixed bed resin (Sigma)) and 30 mis
10 x MOPS was preheated to 50°C. 3-4.5 g of agarose was dissolved in 250 ml of
nuclease free H2O and allow to cool to 55°C. The pre-warmed formaldehyde,
MOPS and 0.5 pg/ml ethidium bromide were added, mixed, poured immediately
and the gel allowed to set. Total RNA samples were prepared using the
RNAgents® Total RNA Isolation System (Promega) as per the manufactorers
instructions. Individial RNA samples were prepared as below for loading:-
RNA 10pgin8plH2O
Deionized formaldehyde 5.5pi
Deionised formamide (Sigma) 15pl
1 Ox MOPS buffer 1.5pi
The samples were placed at 70°C for 15 minutes to denature, the loading buffer
mix was added and the samples loaded onto the gel. 8 pg RNA millenium
markers (Ambion) were loaded. 1 x MOPS was used as running buffer.
Following electrophoresis, the gel was visualised under UV, and the markers
were marked on the gel using a needle to prick the gel. The gel was then washed
in H2O with agitation, for 15 minutes. The gel was then equilibrated in 10 x SSC
for 2 x 15 minutes.
Hybond-N (Amersham) was cut to the appropriate size, wet in H2O then
equilibrated in 10 x SSC transfer buffer. A tray was half filled with transfer
buffer, a platform was placed in the tray and the platform was covered with a
wick made from 3 pieces of 3 MM paper soaked in transfer buffer. The gel was
placed upside down on the wick so that the bottom of the gel was facing up. The
gel was then surrounded with parafilm to avoid transfer buffer being absorbed on
to the paper towels. The membrane (Hybond-N) was placed on top of the gel and
rolled out with a clean pipette to remove any trapped air bubbles. Three sheets of
3 MM paper cut to size the size of the gel and saturated in transfer buffer, were
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placed on top of the membrane. Again a clean pipette was to used to roll out the
paper to avoid trapping any air bubbles. On top of the 3 MM paper, a stack of
paper towels were placed. A glass plate and a weight not exceeding 750 g was
placed on top of the stack of paper towels. The blot was left overnight to transfer.
The following day, the blotting apparatus was dismantled. Before separating the
gel and membrane, both were inverted and wells from the gel were marked on
the membrane with a pencil. The markers placed on the gel for the marker lane
were also marked on the membrane. The membrane was then UV cross-linked.
2.5.3.2 Hybridisations and Washes
For hybridisations, Ultrahyb hybridisation buffer (Ambion) was used. The
Ultrahyb solution was warmed to 60°C to completely dissolve. The membrane
was placed into the Ultrahyb buffer and pre-hybridised for 3 hours at 48°C.
Following pre-hybridisation, the labelled probe was added to the membranes and
hybridised overnight. The following day, the membranes was washed at 48°C in
2 x SSC/0.1% SDS for 30 minutes. The membranes were then washed at 65°C
with the following washes:- 1 x 30 minute wash with 1 x SSC/0.1% SDS, 1 x 20
minute wash with 0.2 x SSC/0.1%SDS and finally 1x15 minute was with 0.1 x
SSC/0.1% SDS. The membrane was then wrapped in Saran Wrap and exposed a
Molecular Dynamics Phosphoimager screen. The image was then scanned into
the phosphoimager and analysed using the ImageQuant software package.
2.6 Affymetrix Gene Chip Arrays
ES cells were harvested at the various time points and RNA was collected using
the RNAgents® Total RNA Isolation System (Promega) according to the
manufacturers recommendations. The Affymetrix Mouse U74Av2 GeneChips®
were used for analysis of gene expression (Affymetrix). Hybridisations and
analysis of the arrays was carried out by Dr. Kevin Robertson from the GTI at
the University of Edinburgh. RNA quality was checked using a Bioanalyser
(Agilent Technologies). Double stranded cDNA was prepared using the Custom
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Superscript ds-cDNA kit (Invitrogen) and biotin-labelled cRNA complex probes
prepared using the BioArray High Yield kit (Enzo, New York, US) according to
manufacturers recommendations. The cRNAs were fragmented and hybridised
to Affymetrix Mouse U74Av2 GeneChips® according to Affymetrix protocols
(Affymetrix). Data from all chips was analysed using Affymetrix Microarray
Suite (version 5.0).
2.7 MALDI-TOF
2.7.1 SDS-Polyacrylamide Gel Electrophoresis
20 [ig WT1 immunoprecipitates were mixed with 20 pi of sample buffer
containing Tris-HCl (0.06M), Glycerol (10% v/v), SDS (2% w/v), 2-|3-
mercaptoethanol (5% v/v), Bromophenol blue (0.025% w/v) and heated to 100°C
for 5 min. Electrophoresis was performed on 20pl of each sample in a
NuPAGE™ 4-12% Bis-Tris Gel (Invitrogen) at 200 Volts for 40 min. Mark 12
Unstained Standard marker (Invitrogen) was used to estimate molecular weight
within the range 200 kDa to 2.5 kDa and protein bands were visualised with
Colloidal Coomassie Blue Stain (Genomic Solutions).
2.7.2 In-Gel Tryptic Protein Digest
MALDI-ToF analysis was carried out by Mr. Nick Tomczyk from the Chemistry
Department at the University of Edinburgh. After visualisation, protein bands of
interest were excised and de-stained with 50% acetonitrile until all Coomassie
blue was removed from gel slice. Protein bands were digested using a protocol
modified from Steen et al (Steen et al., 2002). Resultant peptides were desalted
with CI8 ZipTips (Millipore) ready for MALDI-ToF analysis.
2.7.3 Mass Spectrometric Analysis
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Peptide fingerprint analysis was carried out using an Applied Biosystems
Voyager DE™ STR, MALDI -TOF instrument. Samples (0.5 pi) were co-
crystallized with 0.5 pi of a saturated solution of a-cyano-4-hydroxycinnamic
acid in 50% acetonitrile, directly onto MALDI plate. Interpretation of data was
performed with the "Voyager V5 Data Explorer" software and database
searching performed using the Protein Prospector MS-Fit program on the www
at the University of California at San Francisco
(http://prospector.ucsf.edu/ucsfhtml4.0u/msfit.htm).
2.8 Immunohistochemistry
2.8.1 Immunofluorescence on ES Cells
Undifferentiated ES were seed onto gelatinised slides placed in 9cm2 petri dishes.
ES cells were then differentiated following the method described in 2.3.6. After a
set period of time (0-96 hours), the slides were carefully washed 3 x PBS, and ES
cells were fixed in 2% PFA (PFA dissolved in PBS) for 10 minutes at 4°C. Slides
were then incubated in blocking buffer (10% FCS in TBST (50 mM Tris-Hcl
pH7.5, 150 mM NaCl, 0.1% Triton X-100)) overnight at 4°C. The following day
primary antibodies were added at the required concentration in blocking buffer,
and incubated at room temperature for 1 hour. The slides were then washed 3x5
minutes with TBST, and the secondary antibody (Alexa Fluor 594 and Alexa
Fluor 488; Molecular Probes) was added at a concentration of 1:400 and left at
room temperature for 1 hour. Finally the slides were then washed 3x5 minutes
with TBST, mounted (using vectastain containing DAPI) and visualised using a
Zeiss microscope.
2.8.2 Immunofluorescence of Tissue Sections
E9.5 and El0.5 embryos were dissected out and fixed in 4% PFA at 4°C for
lhour. The embryos were then transferred to 30% sucrose in PBS overnight.
Embryos were then transferred to 30% sucrose in PBS and left overnight at 4°C.
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The following day, embryos were transferred to O.C.T.™ (Sakura), positioned to
the plane of section required and frozen at -70°C. 10 pM section were cut using
a cryostat and placed onto slides (Superfrost, BDH)
Sections were then blocked overnight in blocking buffer (10% FCS in TBST (50
mM Tris-Hcl pH7.5, 150 mM NaCl, 0.1% Triton X-100 0.1% Nazide)) at 4oC.
The following day, sections were incubated at room temperature with the
required primary antibody for 6-8 hours. Sections were then washed 3x15
minutes in TBST. The secondary antibodies antibody (Alexa Fluor 594 and
Alexa Fluor 488; Molecular Probes) in blocking buffer, were then added to the
sections overnight at 4°C. The next day, sections were washed 3x15 minutes in
TBST, and mounted in vectashield mount. The sections were visualised using
Zeiss microscope.
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3.1 Introduction
3.1.1 Gene Targeting Strategies in ES Cells
Over the last decade, the use of gene targeting by homologous recombination in
ES cells for the production ofmouse knockout mutants, has provided important
discoveries in the field of genetics and development biology (For review see
Capecchi, 2001). Strategies for gene targeting are based around the use of two
basic types of vectors, sequence replacement or sequence insertion vectors,
which differ in their mechanisms of chromosomal integration and gene targeting
frequencies.
Replacement vectors are most frequently used for gene targeting in ES cells and
are usually employed to inactivate the function of the gene. A typical
replacement vector consists of two regions ofDNA, homologous to the genomic
target locus (arms of homology), which are interrupted by a positive selection
cassette (Thomas et ai, 1986). The commonly used positive selection cassettes
are the bacterial aminoglycoside phosphotransferase (neo) gene, which confers
resistance to the neomycin analogue G418 or the hygromycin B
phosphotransferase (hyg) gene which confers resistance to hygromycin. The
sequences in the 5' and 3' arms of homology, act as substrates for the double
reciprocal crossover or gene conversion mechanisms that transfer the drug
selection cassette into the endogenous targeted locus (Figure 3.1 (a)).
A widely used method for enriching correct homologous targeting by
replacement vectors is to use a strategy that incorporates a positive/negative
drug selection cassette (Mansour et al., 1988). As with the vector described
above, a selectable marker is included between the 5' and 3' arms of homology
which is used for positive selection. Also included in the targeting vector is a
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Figure 3.1 Gene Targeting in ES Cells using Sequence Replacement Vectors
a) Sequence replacement vector for homologous recombination using positive selection. The targeting vector
contains arms of homology which are interupted by a positive selection cassette, in this example, the neomycin
expression cassette. Cross over points for homologous recombination are depicted by an X.
b) Sequence replacement vector for homologous recombination using positive/negative selection. The targeting
vector includes the same features as above, however a negative selection cassette, the HSVtk gene, is also included.
Following homologous recombination the positive selection cassette is incorporated into the target locus and the
negative selection cassette is lost.
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drug selection cassette for negative selection that is located at the end of either
the 5' or 3' arms of homology (Figure 3.1 (b)). The most commonly used
negative selection cassette is the herpes simplex virus thymidine kinase (HSVtk)
gene. This confers sensitivity to the guanosine analogue, gancyclovir (GANC).
Typically a replacement vector will randomly integrate into the genome of the
majority of electroporated ES cells. These cells will retain resistance to positive
selection with G148 and sensitivity to GANC. However in ES cells in which the
replacement vector has integrated correctly to the targeted endogenous site, the
positive selectable cassette will be incorporated into the locus, whilst the
negative selection cassette {HSVtk) will be lost. Therefore the growth of
electroporated ES cells in both G148 and GANC will enrich for the correct
homologous targeting event, as randomly integrated ES clones, with an active
HSVtk gene, will not survive the selection with GANC (Figure 3.1 (b)).
In contrast to the mechanisms of replacement vectors which undergo
homologous integration by double reciprocal cross-over, insertion vectors
undergo homologous recombination via a single cross-over, initiated by linear
ends within a region of homology. Targeting vectors are designed to include a
contiguous stretch of homologous gene sequences and a positive selection
marker cassette that is included to disrupt the target gene. Insertion vectors are
linearised at a point within the homology region and the linear ends acts as a
substrate for chromosomal integration of the vector. Due to the insertion vectors
being incorporated into the endogenous locus via a single crossover site,
frequencies of homologous recombination are higher than that for replacement
vectors. The frequency of targeting with insertion vectors is 5-10 fold higher
than replacement vectors using the same homologous sequences (Hasty et al.,
1991) (Figure 3.2 (a)).
The use of insertion vectors allows for the introduction of more subtle genetic
alterations to a target genomic locus. Often the presence of a neomycin gene















jz r— i - 3 6
Targeted Locus / 3 3 3
Figure 3.2 Gene Targeting in ES Cells using Sequence Insertion Vectors
a) An example of a sequence insertion vector used for homologous recombination. Homologous
recombination occurs at a single cross over event (marked by an X)
b) Strategy for Hit and Run targeting in ES cells. A sequence insertion vector is introduced into
ES cells carrying a specific mutation. This sequence insertion vector includes a positive and
negative selection cassette. Following homologous recombination, a second selection process
using GANC, is carried out for an intrachromosal recombination event, which results in the
excersion of vector sequence.
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the targeted locus. This was exemplified by the replacement of a hypersensitive
site in the beta globin locus control region (LCR) with a neomycin selectable
cassette (Fiering et al., 1995). The insertion of the neomycin cassette into this
hypersensitive region resulted in a 2-5 fold reduction in expression of all of the
genes in the beta globin locus. In mice derived from these ES cells, which were
homozygous for the deletion/replacement mutation, this caused embryonic
lethality. In removing the neomycin cassette by FLP site-specific recombinase
in ES cells, mice derived from these cells demonstrated nearly full expression of
all the beta globin genes on the mutated chromosome. Therefore the presence of
the neomycin cassette at the beta globin LCR region adversely affected the
expression levels of genes within the targeted locus.
To overcome this problem, insertion targeting vectors can be used in a gene-
targeting strategy called "hit and run". The insertion vector is composed of a
genomic sequence homologous to the gene of interest, a positive selectable
marker gene and a negative selectable marker gene. Following the introduction
of the targeting vector into ES cells and positive selection, correct homologous
recombination leads to the complete integration of the vector into the target
locus. This results in a partial duplication interrupted by plasmid sequences and
selection markers (positive and negative) within the target genomic locus. Next
the homologously targeted ES cells are exposed to negative selection and
reselected. Only clones that undergo an intrachromosomal homologous
recombination event, which occurs spontaneously at a low rate in ES cells, can
survive the selection procedure. These clones lose the heterologous plasmid
sequences, including the selection cassettes, during this recombination event
and what remains is a correctly targeted ES clone with a desired point mutation
or modification in the target gene (Figure 3.2 (b)).
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3.1.2 Conditional Knockouts
Classical gene targeting described above normally involves the insertion of a
heterologous sequence of DNA encoding for a selection cassette {neo or hyg)
into the endogenous locus, disrupting the function of the allele. This strategy is
the most appropriate for testing the function of a gene that is involved in
development or involved in particular biological functions. However this
approach has its limitations if one is faced with a gene whose ablation results in
embryonic lethality. Although pointing to a crucial role for this gene during
embryogenesis it renders the mouse model useless for the study of the loss of
function of that gene in later developmental processes and in adult physiology.
To circumvent these limitations, the discovery and application of the
bacteriophage PI Cre/LoxP system recombination and the Saccharomyces
cerevisiae recombinase FLP/FRT system have enabled the development of
conditional knockouts. This strategy of gene targeting allows inactivation of an
endogenous gene in the mouse to be controlled in both a temporal and spatial
manner. These two systems rely on the function of integrase site specific
recombinases, Cre and FLP recombinase, which specifically recognise the
presence of 34 bp recognition sites, loxP and FRT respectively.
The FLP/FRT system is derived from yeast and relies upon the action of 43 kDa
FLP recombinase that recognises the 34 bp FRT sites. This system has been
successfully used to remove F7?r-flanked selection cassettes in ES cells,
however in comparison to the Cre/LoxP system, the FLP/FRT has been reported
to work less efficiently in ES cells and transgenic mice (Fiering et al., 1995;
Buchholz et al., 1996).
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3.1.3 CrelLoxP System
Cre is the 38 kda product of the cre (cyclisation recombination) gene of
bacteriophage PI and is a site-specific DNA recombinase. Cre recognises a 34
bp site on the PI genome called LoxP and efficiently catalyses reciprocal
conservative DNA recombination between pairs of LoxP sites. LoxP sites
consist of two 13 base pair inverted repeats (CRE recognition sites) separated
by an 8 base pair spacer (Figure 3.3 (a)). If two loxP sites are orientated in the
same direction, the intervening DNA will be excised, with one loxP site
remaining (Figure 3.3 (b)). Conversely if two loxP sites are orientated to face
each other, the intervening DNA will be inverted (Figure 3.3 (c)).
The first report demonstrating the use of Cre recombinase to mediate site
specific recombination in transgenic mice was made by Lakso et al (Lakso et
al., 1992). In this study the Cre/LoxP system was used to activate a dormant
transgene in mice. It had been previously demonstrated that directed expression
of the simian virus SV40 large tumour antigen (SV40 large T antigen), in the
murine lens, induced the development of malignant tumours (Mahon et al.,
1987). A construct was designed in which a STOP sequence flanked by loxP
sites was inserted between the lens specific promoter (alpha A-crystallin) and
the SV40 large tumour antigen gene sequence. This STOP sequence prevented
the expression of the SV40 large T antigen. There was no detection of the
expression of the SV40 large T antigen in transgenic mice carrying this
construct and all exhibited normal development of the lens. These transgenic
mice were then crossed onto Cre expressing line of transgenic mice which Cre
expression was under the control of either the murine alpha A-crystallin
promoter or the human cytomegalovirus promoter (CMV). In all double
transgenic offspring, mice developed tumours in the lens. Further analysis
confirmed that tumour formation was a result of SV40 large T antigen






5' - ATAACTTCGTATA GCATACAT TATACGAAGTTAT - 3'
3'- TATTGAAGCATAT CGTATGTA ATATGCTTCAATA -5'
LoxPSite
Figure 3.3 The Cre/LoxP System
a) Structure ot the LoxP site. The LoxP site (34 bp) consists of two 13 bp inverted repeats and
an asymmetric 8 bp spacer region.
b) Cre -Mediated Deletion. LoxP sites placed in the same orientation, following Cre recombination,
results in excersion of the intervening DNA, with one loxP site remaining.
c) Cre -Mediated Inversion. LoxP sites placed in the opposite orientation to each other, following
Cre recombination, results in inversion of the intervening DNA.
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The first reported example of conditional ablation of an endogenous gene
through Cre/LoxP targeting in ES cells was the conditional ablation of DNA
polymerase (3 gene (pol|3) in T cells (Gu et al., 1994). Conventional knockout
of the DNA pol |3 gene results in embryonic lethality, therefore loxP sites were
inserted either side of the first exon of the DNA pol/3 gene by homologous
targeting in ES cells (Gu et al., 1994; Sugo et al., 2000). Crossing the DNA
pol(3flox mice onto a thymocyte-specifc Cre expressing transgenic mouse line,
resulted in specific ablation of DNA pol|3 in mature T cells. To date there have
been numerous reports of genes in which a conditional knockout approach
through homologous recombination in ES cells, using the CrelLoxP system, has
answered many important biological and development questions.
3.1.4 Examples of Conditional Knockouts using CrelLoxP
3.1.4.1 Nkx3.1 Induces Prostatic Intraepithelial Neoplasia
The homeodomain-containing transcription factor Nkx3.1, is a putative tumour
suppressor that is expressed in a largely prostrate-specific and androgen-
regulated manner (Bieberich et al., 1996; Bhatia-Gaur et al., 1999). Although
no mutations in the Nkx3.1 gene have been found in a survey of prostate tumour
specimens, loss of Nkx3.1 protein expression has been observed in -40% of
human prostate tumours and in -20% of prostatic intraepithelial neoplasia (PIN)
lesions and correlates with tumour progression (Voeller et al., 1997; Bowen et
al., 2000). The Nkx3.1 gene also maps within the minimal deleted region of
8p21 that is lost in prostate tumours making it a strong candidate for a prostrate
tumour suppressor gene (Voeller et al., 1997). As Nkx 3.1 plays a key role in
the development and differentiation of the prostatic epithelium, it provides an
important link between development and carcinogensis in the prostate gland.
In the mouse, conventional knockout of the Nkx3.1 gene by insertion of a
neomycin cassette, leads to developmental defects of the prostate gland,
including defects in ductal branching morphogenesis, prostatic secretions, and
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epithelial hyperplasia and dysplasia (Bhatia-Gaur et al., 1999). The prostatic
epithelial hyperplasia and dysplasia that develops in Nkx3.1 null mice supports
a role for Nkx3.1 in growth suppression in the prostatic epithelium. However
this phenotype prevents any further analysis of the precise role of Nkx3.1 in
prostatic carcinogenesis.
Using CrelLoxP mediated recombination in adult prostate, conditional ablation
of one or both alleles of Nkx3.1 leads to the development of preinvasive lesions
that resemble human features of PIN (Abdulkadir et al., 2002). Therefore using
this system, the authors were able to circumvent the developmental defects
resulting from the absence of Nkx3.1 and demonstrate a role for Nkx3.1 as a
prostate tumour suppressor and also provide evidence to support its function in
tumour initiation.
3.1.4.2 Rapid Colorectal Adenoma Formation in Conditional APC
Mice
Mutations in the APC gene have been demonstrated to be responsible for
Familial Adenomatous Polyposis coli (FAP), a disease characterised by the
development ofmultiple colorectal adenomas (Nishisho et al., 1991; Joslyn et
al., 1991). Analysis of colorectal adenomas from FAP patients has shown that
although they carry germline mutations in the APC gene, their tumours show
inactivation of the wild-type allele flchii et al., 1993). Inactivation of both
copies of the APC gene also occurs frequently in sporadic colorectal adenomas
(Miyoshi et al., 1992; Smith et al., 1993). However although this data strongly
suggests that APC is acting as a tumour suppressor, the mechanisms of
transformation of colorectal epithelial cells to adenomas following the
inactivation ofAPC remain unclear.
Several mouse models carrying mutations in the APC gene have been
established as experimental models for FAP (Su et al., 1992; Fodde et al.,
1994). However complete deficiency in APC results in embryonic lethality
(Moser et al., 1995. Conditional gene targeting using the Cre/LoxP system
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allowed the development of a mouse model for APC ablation specifically to be
carried out in colorectal epithelial cells (Shibata et al., 1997). LoxP sites were
targeted into the introns surrounding exon 14 of the APC gene. Mice
homozygous for loxP modifications were phenotypically normal. However,
upon infection of the colorectal region with an adenovirus expressing Cre
recombinase, the mice developed colorectal adenomas within 4 weeks. Analysis
of the adenomas demonstrated an ablation of exon 14 of the APC gene. This
system therefore provides a mouse model for the investigation of the steps in
adenoma formation, which develop from the specific inactivation ofAPC.
3.1.5 Current Mouse Model ofWT1 Loss-of-Function
To determine the role of WT1 in development, a replacement type targeting
vector was used to replace the first exon of WT1 and 0.5 kb upstream sequence
of WT1 with a neomycin resistance gene (Kreidberg et al., 1993). Heterozygote
mice appeared phenotypically normal up to 9 months of age. Homozygous WT1
null mice however died between El3 and El5 due to developmental defects of
the heart (Kreidberg et al., 1993). The WT1 null mice also completely lack
kidneys and gonads. The arrested development of the kidney and gonad at a
very early stage prevents any analysis of the role of WT1 in later stages of
nephrogenesis and gonadogenesis. Also the embryonal lethality of the WT1 null
mice, makes the analysis of the role ofWT1 in the later stages of development
and adult physiology impossible.
Therefore an alternative approach to investigate the role of WT1 in
embryogenesis, urogenital development and adult physiology is to conditionally
inactive WT1. As shown by the examples above, the CrelLoxP system is a
powerful approach that can be applied to ablate WT1 in a spatial and temporal
manner. This system will permit questions to be directly asked about the role of
WT1 in development and disease.
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3.2 Strategy for Conditional Knockout ofWT1
The strategy chosen to generate a conditional allele of WT1 is to flank exon 1
with loxP sites such that Cre recombinase will delete exon 1 to produce a null
allele. This will be similar to the original mutation produced by Kreidberg et al,
who replaced a similar genomic interval with a neomycin gene to produce a
WT1 null allele (Kreidberg et al., 1993) (Figure 3.4). In the absence of Cre,
targeted clones will be identical to the wild-type allele apart from the presence
of the 5' and 3' loxP sites (34 bp each). Upon exposure to Cre recombinase, a
null allele will be produced due to the excision of DNA sequence encoding for
exon 1. This genomic deletion removes the transcriptional and translational start
sites that lies between the two loxP sites producing a null WT1 allele.
3.2.1 Targeting Vector and Targeting of Embryonic Stem Cells
The design of the targeting construct and initial ES cell homologous targeting
was carried out by Dr. Lustig-Yariv. Briefly, the construct was obtained from
screening a 129/Ola BAC genomic library. A 6 kb Bglll fragment was isolated
encompassing 2.5 kb upstream of exon 1 and 2 kb of intron 1 and inserted into
pBluescript. Synthetic oligonucleotides were inserted at the Aatll site, 0.5 kb
upstream of exon 1, which coded for a loxP site. An expression cassette
containing the Herpes Simplex thymidine kinase (HSVtk) and neomycin {neo)
genes, each under the control of the phosphoglycerate kinase promoter (Pgk-
HSVtk-Pgk-Neo), flanked by loxP sites, was inserted 3' of exon 1 into the
EcoR V site 1 kb downstream of exon 1, to produce the full targeting construct,
pWT!LoxP24. The three loxP sites inpWTlLoxP24 were present in the same
orientation to enable CVe-mediated deletion of the intervening DNA (Figure
3.4).
The construct was designed to allow a 2-step strategy to be employed. The first
step is to target the WT1 endogenous locus with the pWTlLoxP24 construct by
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step relies on positive selection, in this case provided by the presence of a
neomycin gene and selection in G418. The next step is to remove this selectable
cassette. Following this step the ES cells will revert back to a targeted allele that
will be identical to the wild-type allele, apart from the presence of the 5' and 3'
loxP sites. To achieve this the neomycin cassette was included in the
pWTlLoxP24 targeting vector as part of a loxP flanked cassette containing the
HSVtk gene. This Pgk-HSVtk-Pgk-Neo selection cassette allows for a positive-
negative selection procedure. Homologously targeted clones are transiently
transfected with a Cre expression vector and colonies resistant to gancyclovir
(TK"ve) are isolated, in which the double selectable cassette has been excised.
The linearised targeting vector pWT!LoxP24 was electroporated into in El4
(129/Ola) ES cells. Cells were selected with G418 for 10 days. 290 clones were
picked which survived G418 selection and from these 190 were screened via
Southern Blot, using a Pstl genomic digest and 3' external probe, i.e. outside
the region of homology of the targeting vector. From the 190 screened, 5 clones
were identified as being homologously targeted at the WT1 locus (12.5, 13.5,
14.17, 17.5, 20.4) using the 3' external probe.
These 5 clones were subjected to Southern blot analysis to confirm the earlier
findings made by Dr. Lustig-Yariv. A Southern blot using a f?g///restriction
digest of genomic DNA and a probe located upstream of the 5' loxP site and
exon 1 produced the 5 kb band and 4 kb band fragments expected for
homologous recombination (Figure 3.6 (b)). A Southern blot was then
performed using a probe external to the 3' end of the targeting vector on Pstl
digested genomic DNA. Positive clones were detected with a 5 kb wild-type and
2 kb targeted fragment arising from the insertion of a novel Pstl restriction site
within the targeting vector (Data not shown). The use of the 2 probes verifies
that there is one site of insertion for targeting vector and that this is at the WT1
endogenous locus.
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3.2.2 Generation of WT1 Floxed ES Clones
The next step is to take the homologously targeted ES clones from the fist round
of targeting and to remove the selectable marker. This will generate ES clones
in which only loxP sites either side of exon 1 would remain. These ES clones
would then be used to inject blastocysts and generate the conditional WTI
knockout line ofmice.
Transient transfection of a homologously targeted clone with pMC-Cre plasmid
results in the partial recombination between the 3 loxP sites. From the
transfection three possible outcomes are possible: Type 1 recombination
(recombination between loxP sites flanking the selection cassette) produces
clones in which the selection cassette is excised, leaving the WTI exon 1
flanked by loxP sites. Type II recombination (recombination between the two
outer loxP sites) removes the full genomic interval between the 3 loxP sites
which includes exon 1 and the selection cassette, leaving effectively a null
allele. Type III recombination (recombination between the loxP sites
surrounding exon 1) generates clones where exon 1 is excised, leaving the
selection cassette at the locus (Figure 3.5). ETsing negative selection with GANC
following the transient transfection with Cre, clones that undergo type III
recombination (HSVtv've) are non-viable as they will not survive the GANC
selection due to the presence of the HSVtk gene. Similarly, ES cells that have
not been transfected with the pMC-Cre plasmid, are also non-viable as they will
also retain the HSVtk gene. Therefore following Cre treatment and efficient
gancyclovir selection, cells selected and screened will possess either an exon 1
allele, flanked by loxP sites, or a complete deletion of the genomic sequence
spanning the exon 1 locus.
Homologously targeted ES clone, 14.17, was transiently transfected with
supercoiled pMC-Cre and 30 gancyclovir resistant clones were analysed by
Southern blot using a Bglll digest of genomic DNA and a probe located
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Figure 3.5 Effects of Cre-Mediated Recombination at the Targeted WT1 Locus
a) Type I Recombination: Recombination between the LoxPsites flanking the selection cassette
b) Typell Recombination: Recombination between the LoxP sites flanking Exon 1 of WT1
c) Type III Recombination: Recombination between the outer LoxP sites
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upstream of the 5' loxP site and exon 1. From the transfection, both type 1 and
type II recombination events were detected (Figure 3.6). There was no detection
of clones that had undergone type III recombination. Southern blot analysis
would have detected bands of 5 kb and 3 kb for this event. Similarly no clones
were detected that had not undergone Cre mediated recombination. Therefore
the identification of clones harbouring only type I and type II recombination
demonstrates that the Cre-loxP system and the drug selection is working
efficiently.
3.2.3 Generation of Chimeras and Germline Testing
Two independent ES clones that contained exon 1 flanked by loxP sites, WT1-
LoxP.3 and WTl-LoxP.26, were injected into C57/BL6 blastocysts to generate
chimeric mice. The blastocyst injections were carried out by Dr. Sheila Webb.
From the injections, 5 chimeras were obtained, in which 4/5 were male,
indicating a good contribution to blastocyst development by the male ES cell
clones. From the coat colour it was also apparent that the level of chimerism
was high, ranging from 60-80%.
The 4 male chimeric mice were tested for germline transmission of the targeted
allele. Male chimeric mice were mated with C57/BL6 female mice. From these
matings, transmission of ES (129/Ola) cells can be identified by the presence of
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Figure 3.6 Southern Blot Analysis following Cre-Mediated Recombination of ES Cell Clone 14.17
a) Diagram showing the Southern blot used to analyse ES clones following Cre-mediated recombination
b) 10 ng of genomic DNA was digested with Bglll. Digested DNA was Southern blotted and then probed
with he 5' probe (red box). ES clones carrying the full targeting vector, generate 5 kb and 4 kb bands, floxed
ES clones generate a 5 kb band and heterozygous WT1 null ES cells generate 5 kb and 2 kb fragments.
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Chimera Number Live Births
Number Agouti
Offspring
Chimera 16 12 1
Chimera 17 46 4
Chimera 18 127 16
Chimera 19 59 2
Chimera 20 11 0
Table 3.1 Breeding of LoxP Chimeric Mice
From the breeding of chimeras, 23 agouti offspring were obtained from 255 live
births. To follow transmission of the targeted allele, a PCR screen was used to
detect the presence of the 5' loxP site. Primers were designed to span the region
in which the 5' loxP site had been inserted. The wild-type allele generates a
PCR product of 200 bp whilst the WTl-LoxP targeted allele will generate a 234
bp PCR product, indicating the presence of the loxP site. Analysis of the agouti
offspring indicated that none were carrying the WTl-LoxP targeted allele, as all
displayed the wild-type 200 bp product (Figure 3.7 (a)). This was surprising, as
one would expect 50% of the agouti offspring to be transgenic.
Due to the lack of transmission, skin biopsies were taken from chimeras 18 to
confirm that the chimeras were generated from correctly targeted ES clones. A
PCR screen using the primers spanning the 5' loxP site showed that the chimera
was generated from correctly targeted ES cells, as 2 of the biopsy samples were
positive for presence of the 5' loxP site (Figure 3.7 (b)).
Although the litter sizes from the C57/BL6 test matings were normal, the
presence of agouti offspring was a rare occurrence, with only 1 or 2 agouti mice
per litter of 6-8. Therefore could the absence of ES cell derived mice carrying
the WT1 targeted allele indicate that the modifications to the WT1 locus might

































Figure 3.7 PCR analysis of the 5' LoxP Site
a) PCR analysis for the 5' LoxP site of agouti offspring from the breeding of chimera 18
with female C57/BI6, indicates that none carry the targeted WT1 allele.
b) PCR analysis for the 5' LoxP site from skin biopsies of chimera 18, demonstrates that the
chimeras are generated from correctly targeted ES cells, which carry a loxPsite at the WT1
locus.
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pWTlLoxP24 targeting vector, care was taken to place the loxP sites in genomic
regions that were not highly conserved between mouse and human (Figure 3.8).
Added to this, the loxP sites were orientated in the genome to avoid adding an
extra translational ATG start site into the WT1 locus, as this sequence was
present within the loxP sites. The presence of the 3' loxP site can be excluded
from having a negative effect on germline transmission of the targeted allele, as
this loxP site was present in ES cells generated for the ablation of the WT1 CTG
isoforms (Miles et al., 2003). In the targeting of ES cells to ablate the CTG
isoform, Cre/LoxP was used to remove the selectable cassette following
homologous recombination. Once the selectable cassette was removed
following transient expression of Cre, a single loxP site remained in the first
intron of WT1. Chimeras generated from this targeting event produced germline
transmission of the CTG targeted allele (Miles et al., 2003). Therefore could the
problem lie in the position of the 5' loxP site? This loxP site lies 0.5 kb from the
start site in the 5' UTR region. Could the 5' loxP site be adversely affecting
transcription of the WT1 targeted allele? Even if there were an affect of placing
the loxP site in the 5' position, this would have to produce a dominant effect at
the targeted allele producing a hypermorphic WT1 allele or induce ectopic
expression ofWT1 at the targeted WT1 locus to cause embryonic lethality. This
is because the WT1 heterozygote null mutation does not result in embryonic
lethality and WT1 heterozygote null mice are generated at the expected
Mendelian ratio (Kreidberg et al., 1993). Therefore it was decided to carry out
detailed analysis of ES clones WTl-LoxP.3 and WTl-LoxP.26 that were used to
generate the chimeras.
As already demonstrated in figure 3.7, the two clones were correctly targeted
for the 5' loxP site. However using a PCR for the 3' loxP site, with primers that
should generate a PCR product of 200 bp for wild-type and 234 bp product for
3' loxP targeted alleles, only a wild-type product of 200 bp could be detected in
the 2 clones (Figure 3.9 (a)). This was in contrast to a DNA sample from the
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Figure 3.8 DOTPLOT comparison of Human and Mouse WT1 Genomic Sequence Upstream of the ATG
DOTPLOT comparison of the human and mouse WT1 genomic sequence surrounding the region in which
the 5' LoxP site is positioned. This indicates that the 5' LoxP site is positioned in a genomic region that is not
conserved between human and mouse.
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intron 1 of the WT1 locus. PCR on DNA from CTG knockout heterozygote and
homozygote mice clearly shows the present of the 3' loxP site and the wild-type
allele in the heterozygote mice, whilst in the homozygote mice this reverts to a
single product of 234 bp indicating both alleles contain the 3' loxP site.
A Southern Blot was then performed using a probe external to the 3' end of the
targeting vector on PstI digested genomic DNA. As shown previously, the first
round of targeting produces homologously targeted clones with an insertion of a
novel PstI restriction site within the targeting vector. This produces 6 kb and 2
kb fragments on a PstI digested genomic DNA Southern blot. In the WTl-LoxP
clones the same 6 kb wild-type and 2 kb bands should still be present, as the
novel PstI site lies outside of the region where loxP recombination occurs.
When both loxP clones were analysed using this Southern blot, only the wild-
type 6 kb band could be detected on the Southern Blot (Figure 3.9 (b)).
Therefore both the 3' loxP PCR and the Southern Blot indicated that the region
surrounding the 3' loxP site has been disrupted during the Cre mediated
recombination of the parental clone, 14.17. This was an unexpected finding as
Cre mediated recombination has been not been reported to be an inaccurate
process.
3.2.4 Generation of WT1-LoxP ES clones from 12.5 and 20.4
Due to the problems associated with WTl-LoxP clones derived from the Cre
treatment of 14.17, another 2 homologously targeted clones, carrying the full
targeting vector, were selected for Cre treatment (12.5 and 20.4).
From transfections of clones 12.5 and 20.4, 30 subclones in total were isolated
following selection in gancyclovir for 8 days. Clones were firstly screened by
Southern blot using a Bglll restriction digest of genomic DNA and hybridisation
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Figure 3.9 Analysis of the 3' LoxP Site by Southern blot and PCR Demonstrates Disruption of the
Genomic Region following Cre-mediated Recombination
a) PCR analysis of the 3' LoxP site in floxed ES clones used to generate chimera 16-20 (from ES clones
WT1-LoxP.3 and WT1-LoxR26) demonsrates that following Cre-mediated recombination, the genomic region
surrounding the LoxP site is disrupted. In contrast, the floxed ES clones used to generate chimeras 54 and 55
(from ES clones WT1-LoxP.4 and WT1-LoxP.29) following Cre-mediated recombination, do contain a 3' LoxP site,
as detectable by PCR.
b) Southern blot analysis of Pstl digested genomic DNA probed with a 3' probe, confirms that the unique Pstl
site present in the targeted WT1 locus, is lost in the WT1-LoxP.3 and WT1-LoxP.26 ES clones, which were
generatedfollowing Cre-mediated recombination of homologously targeted ES clone 14.17. In contrast, floxed
ES clones (WT1-LoxP4 and WT1-LoxP.29) generated from Cre-mediated recombination of homologously
targeted ES clones 20.4 and 12.5, retain the unique Pstl site.
c) Southern blot analysis of Bglll digested genomic DNA probed with a 5' probe, confirms that all of the ES
clones following Cre-mediated recombination, have lost the selectable marker cassette.
Figure 3.10 PCR analysis of the 5' LoxP site
PCR for 5' LoxP site in the floxed ES clones used to generate
chimeras 16-20 (WT1-LoxP.3 and WT1-LoxP.26) and chimeras 54
and 55 (WT1-LoxP4 and WT1-LoxP.29), indicates that all ES clones
contain a loxPsite upstream of the ATG start site.
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transfection of 12.5 or 20.4 exhibited type III recombination. Similarly all
clones had undergone Cre mediated recombination as none contained the
complete targeting vector. Two clones were selected, in which type I
recombination has occurred, WT1 -LoxP.4 and WT1 -LoxP.29 for further
analysis.
Firstly these two clones were analysed using the PCR screen for the presence of
the 5' and more importantly the 3' loxP site. PCR for the 5' loxP site showed
that both clones carried the correct insertion of the loxP site into the WTJ locus
as shown by the presence of the wild-type 200 bp and the loxP targeted 234 bp
product (Figure 3.10). PCR for the 3' loxP site also showed that both clones
possessed the 3' loxP site as shown by the presence of the 200 bp product
denoting the wild-type allele and also the 234 bp product for the loxP targeted
allele (Figure 3.9).
Next the clones were analysed to ensure that the novel PstI site was still present.
Both clones were screened by Southern blot using PstI digested genomic DNA
and hybridised with the 3' external probe. Both clones showed the correct 6 kb
and 2 kb fragments indicating that the PstI site was still present (Figure 3.9).
Therefore from the PCR and Southern Blot analysis, the region surrounding the
3' loxP site is intact and had not been disrupted during the Cre mediated
recombination step.
3.2.5 Generation of Chimeric Mice and Germline Transmission
Correctly targeted ES clones WTl-LoxP.4 and WTl-LoxP.29 were injected into
blastocysts to produce chimeras. From the injections, 3 chimeras were obtained,
2 males and 1 female. Both male chimeras (chimera 54 and chimera 55)
exhibited high levels of chimerism, estimated to be approximately 70%-80%.
Chimera 54 (12.5) and chimera 55 (20.4) were mated with C57/BL6 females to
test for germline transmission. Transmission of the ES cells through the
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igure 3.11 Germline Transmission of the Conditional WT1 Targeted Allele
) Figure showing the Southern blot used to genotype the WT1 conditional allele
) 10 (xg of genomic DNA was digested with Bglll and EcoRV. Digested DNA was probed by Southern blot with the 5' probe
ed box) which distinguishes the WT1 conditional targeted allele from the wild-type allele, on the basis of the absence of the
ndogenous EcoRVsite in the targeted locus. A wild-type WT 1 allele generates a 4 kb fragment, whilst a WT 1 conditional
llele generates a 6 kb fragment.
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Unlike the first set of chimeras where litters contained 1 or 2 agouti offspring in
a litter of 6-8, the litters from both chimeras contained a high percentage of
agouti offspring, with some litters containing 75% agouti pups.
The agouti offspring from both chimeras were genotyped by Southern blot on
genomic DNA digested with Bglll and EcoRV and hybridised with the 5'
external probe (Figure 3.11 (a)). The Southern blot distinguishes the wild-type
allele from the targeted allele, due to the insertion of the HSVtk-Neo selectable
cassette into the endogenous locus during homologous recombination.
Originally this selectable cassette was inserted in the targeting vector at an
EcoRV site. This EcoRV site is destroyed during the cloning process to generate
pWTlLoxP24 and subsequently following homologous recombination in ES
cells is destroyed in the WT1 endogenous locus. Therefore a wild-type allele
generates a 4 kb fragment, whilst correctly targeted allele generates a 6 kb
fragment (Figure 3.11 (a)). Southern Blot analysis confirmed that both chimeras
generated from the two independent clones had produced germline transmission
of the WT1 targeted allele (Figure 3.11 (b))
The next step was to cross the conditional WT1 heterozygote mice to
homozygousity ensuring that the modifications to the WT1 locus does not
produce a phenotype in the offspring. Conditional WT1 heterozygotes,
generated from the floxed ES clone WTl-LoxP.29, were intercrossed giving rise
to normal Mendelian ratios of wild-type, heterozygote and homozygote
offspring as determined by Southern Blot (Figure 3.11 (b)). Conditional WT1
homozygous mice were phenotypically normal up to 8 weeks of age.
3.3 Discussion
This chapter describes the targeting of the WT1 locus to establish a of a
conditional knockout mouse model for WT1, using the Cre/loxP system.
Although successful in obtaining a conditional WT1 mouse, difficulties were
observed during the Cre-mediated manipulation in vitro. The first chimeras
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generated from loxP flanked clones failed to produce germline transmission of
the conditional allele. Subsequent analysis demonstrated that during the in vitro
CVe-mediated recombination steps, there was a disruption to the genomic region
which lies in the first intron of WT1. This was an unexpected finding, given that
the process of Cre mediated recombination has not been reported to be an
inaccurate process. Subsequent generation of chimeras from other two ES
clones derived from an independent parental did not show any disruption of the
genomic region surrounding intron one, and the conditionally target allele was
successfully transmitted through the germline.
However caution must be taken in the interpretation of the data presented in this
chapter with regards to the targeting of the WT1 allele. Although the original
parental clones were characterised using two probes, the failure to use an
external 5' probe, allows the possibility that the clones were not correctly
targeted. Also an alternative explanation for the lack of transmission of the
targeted allele may have been due to the possibility that the starting material
used prior to the Cre treatment was a mixed clone, containing wild-type ES
cells. Therefore upon gancyclovir selection a non-targeted population could
have been enriched, and used in subsequent blastocyst injections. Future work
will aim to confirm that a conditional allele has been established using the
appropriate diagnostic Southern blots.
If successful, then this mouse model will provide an important resource for
dissecting the in vivo role of WT1 in development and disease. The mouse
model will enable the crucial questions to be asked regarding the function of
WT1 during development. One on the most important issues is whether this
mouse model can recapitulate the pathology of Wilms' tumour and provide a
tool to investigate the development of the disease. Using suitable Cre lines,
would conditional ablation of WT1 during this induction phase of
nephrogenesis promote a predisposition to the onset of Wilms' tumours? In
combination with inducible tissue specific Cre lines, the role of WT1 in the
adult, including its expression in the podocytes and Sertoli cells, can also be
addressed. Therefore the creation of a conditional knockout for WT1 in
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combination with suitable Cre expressing lines will begin to tackle some of the
questions surrounding the role, and function of WT1, in development and
disease.
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4.1 Introduction
The restricted and dynamic spatio-temporal in vivo expression pattern ofWT1,
and also the limited availability of cell lines that express WT1 at detectable
levels, has hampered investigations into the function and regulation ofWT1. The
majority of studies have been carried out on cell lines that are engineered to
ectopically express single WT1 isoforms or transformed tumour cell lines.
Although they have provided insights into the function of WT1, these studies
may not represent fully the in vivo situation, which may explain the often
contradictory conclusions drawn from such studies (For review see Reddy and
Licht, 1996; Little et al., 1999; Lee and Haber, 2001).
The establishment of murine embryonic stem (ES) cell lines has led the way to
many new experimental approaches in the field of mammalian development
biology. ES cells are pluripotent cells derived from the inner cell mass of
developing blastocysts (Evans and Kaufman, 1981). ES cells are derived without
the intervention of any immortalising agent, do not undergo either crisis or
senescence, and retain a diploid karotype. They can proliferate without apparent
limit and can readily be propagated clonally. They are maintained
undifferentiated in vitro in the presence of Leukemia Inhibitory Factor (LIF)
(Williams et al., 1988; Smith et al., 1988).
ES cells retain the potential for multi-lineage differentiation and produce a range
of well-differentiated progeny. The establishment of various in vitro
differentiation protocols has permitted the differentiation of ES cells along
neuronal, cardiogenic, myogenic, hematopoietic, epithelial, adipogenic and
chrondogenic lineages (For review see Keller, 1995; Wobus, 2001). An
important finding during the differentiation of ES cells is that tissue specific
genes, proteins, ion channels and receptors are differentially expressed in a
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pattern closely resembling the pattern observed during mouse embryogenesis.
This has been exemplified by the commitment of ES cells to the haematopoietic
lineages. The haematopoietic system of the mouse is established early during
embryogenesis from the extraembryonic mesoderm of the yolk sac.
Differentiating ES cells as embryoid bodies (EBs), it has been demonstrated that
the initial stages of haematopoietic development within EBs occurs in a ordered
pattern similar to that within the embryo (Keller et al., 1993). Therefore the
differentiation of ES cells in vitro provides a powerful model system for
addressing questions related to lineage commitment. However it also offers
several advantages over comparable approaches in the whole embryo.
Firstly, ES cells in culture provide access to populations of early precursors that
are difficult if not impossible to access in vivo. An example of this is the study of
oligodendrocyte development in the CNS. Oligodendrocytes are post-mitotic
cells that myelinate axons in the vertebrate central nervous system (CNS). They
develop from proliferating oligodendrocyte precursor cells (OPCs), which arise
in restricted regions of the ventral ventricular zone of the developing brain and
spinal cord. In the mouse they are first detected as a narrow band in the ventral
neuroepithelium around E12.5-13. So far it has only been possible to purify
OPCs from the rat optic nerve (Raff et al., 1988; Barres et al., 1994). However
they cannot be purified in large enough quantities to carry out conventional
biochemical assays. Added to this is the inability to isolate CNS progenitor cells
that give rise to the OPCs. This prevents the analysis of the earliest steps of
oligodendrocyte differentiation. Using a genetically modified ES cell line which
permits the selection of neuroepithelial cells in vitro, and in combination with
appropriate signal molecules that promote OPCs in vivo, Billon et al were able
obtain large quantities of OPCs (Li et al., 1998; Billon et al., 2002). From the
starting population of OPCs, they were able then to differentiate OPCs to obtain
oligodendrocytes. Employing markers to follow the fate of OPCs to
oligodendrocytes, they were able to show that they differentiate following a
schedule that is similar to that observed in vivo.
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Secondly, and highly relevant for this study of WT1, is the study of ES cells
carrying targeted mutations of genes, which are normally embryonic lethal in
vivo. The developmental potential of these ES cells can be determined in culture.
An example of this is the study of the transcription factor, Serum Response
Factor (SRF). SRF is a ubiquitously expressed MADS box protein, which
mediates the rapid transcriptional response to extracellular stimuli, e.g. growth
and differentiation signals (Norman et al., 1988; Treisman et al., 1994). It has
been shown that SRF is essential for murine embryogenesis. SRF homozygous
null (SRF"7") embryos die at around E6.0 at the onset of gastrulation, with a
failure to form detectable mesoderm (Arsenian et al., 1998). However what is
unclear is whether SRF"7" embryonic cells are generally incapable of
differentiating into mesodermal cells derivatives or that the embryos do not
provide the required signals for mesoderm formation. In order to analyse this
defect, SRF"7" ES cells were generated and the effect of loss of SRF was studied
in vitro (Weinhold et al., 2000). The authors were able to show that there was an
impairment of mesodermal differentiation in vitro, and this could be modulated
in a non-cell-autonomous fashion (Weinhold et al., 2000).
4.1.1 Retinoic Acid Induced Differentiation of ES Cells
Retinoic acid (RA) is a potent inducer commonly used to trigger differentiation
of ES cells (For review see Rohwedel et al., 1999). In vivo, retinoic acid is
derived from the two step metabolism of vitamin A to retinal and its subsequent
oxidisation to retinoic acid. It has been demonstrated that retinoic acid is
essential for normal embryonic development and the regulation of growth and
differentiation of a diverse range of cell types. It functions in the development of
several organs during embryogenesis, including spinal cord motor neurons
(Sockanathan and Jessell, 1998), eye (Wagner et al., 2000), heart (Niederreither
et al., 2001) and kidney (Batourina et al., 2001). RA functions by acting as a
ligand for nuclear receptors, which in turn transcriptionally regulates RA target
88
Chapter 4 A Role for WT1 in Neuronal Development
genes, by binding to retinoic acid response elements (RAREs) within their
promoters.
The treatment of embryonal carcinoma (EC) cells and embryonic stem (ES) cells
with all-trans retinoic acid (RA) has been shown to induce high levels of WT1
expression (Scharnhorst et al., 1997). WT1 protein was first detected in PI9 EC
cells following 4 days of induction with RA, whilst WT1 mRNA was detectable
after 3 days. The authors suggested that the slow kinetics of WT1 expression
after treatment of EC cells with RA was a result of cell differentiation and the
emergence of a specific WT1 expressing cell lineage within the system, rather
than a direct transcriptional effect of RA.
Immunofluorescence of differentiating PI9 EC cells, treated with RA as a
monolayer for 6 days, showed that nuclear staining for WT1 was present in
approximately 80% of the cells. In an attempt to identify if there was a specific
lineage within the RA differentiated EC cells that were expressing WT1, double
immunofluorescence was used with a small set of lineage specific markers. The
study revealed subpopulations of WT1 positive RA differentiated EC cells co-
expressed either endodermal, epithelial or astrocytes markers. Therefore this
indicated that there was not a single predominant lineage present in the RA
treated EC cells which expressed WT1. Overall this is an intriguing finding given
the restricted expression pattern of WT1 in vivo. It also indicates an
accumulation of populations ofWT1 positive cells, which could be amenable to
manipulation and detailed study, and could be representative of cell-types found
during normal differentiation process in which WT1 is expressed.
The aim of this chapter was to extend the study of RA induction of WT1
described in EC cells to ES cells. The induction ofWT1 in monolayer cultures of
ES cells by RA has been reported previously, however no description of the
lineages which express WT1 in this system have been described (Scharnhorst et
al., 1997; Wagner et al., 2001).
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4.2 Differentiation of ES cells with RA Leads to
Expression of WT1
The first step was to ensure that RA does induce the expression of WTl in
monolayer ES cells cultures, and to also analyse further the kinetics of that
expression. As the original study by Scharnhorst et al used all-trans retinoic acid
at a concentration of 1 qM, this concentration was used for all subsequent work
presented in this chapter and thesis (Scharnhorst et al., 1997).
Wild-type ES cells were seeded in normal LIF containing medium in triplicate.
24 hours later, the cells were washed three times in PBS and the medium
replaced by a) - LIF media, b) -LIF media supplemented with RA, c) normal
LIF containing media. The medium was changed every 24 hours and fresh RA
supplemented medium was added to the cultures. Following 96 hours the cells
were harvested and total RNA and nuclear protein prepared from each culture
condition.
Northern blot analysis was carried out using a full-length murine WTl cDNA. To
confirm equal loading of RNA samples, the blot was stripped and reprobed with
a probe specific for |3-Actin. As a positive control for WTl expression, total
RNA from the Ml5 cell line was also used. The Ml5 cell line is a polyoma
transformed mouse mesonephric cell line that expresses endogenously high
levels ofWTl (Larsson et al., 1995). No signal for WTl was seen in the RNA
prepared from undifferentiated ES cells or in RNA prepared from ES cells in
which the LIF had been withdrawn (Figure 4.1 (b)). In the RNA sample prepared
from ES cells exposed to RA, a band of 3 kb corresponding to WTl mRNA was
present (Figure 4.1 (b)). The level ofWTl expression in the RA differentiated
ES cells was comparable to that of the Ml 5 cell line.
Next the expression ofWTl protein was analysed from each of the conditions.



































Figure 4.1 WT1 is Expressed in ES Monolayer Cultures Differentiated for 96 hours with all-trans
Retinoic Acid (RA)
a) 40 [xg of nuclear protein from undifferentiated ES cells, ES cells grown in media lacking LIF and ES cells
grown in media lacking LIF and supplemented with 1^M of RA, was separated on 10% SDS PAGE gel
and transfered onto nitrocellulose. The blot was probed for WT1 using the C-19 antibody.
b) Total RNAfrom M15, undifferentiated ES cells, ES cells grown in media lacking LIF and ES cells
grown in media lacking LIF and supplemented with 1^M of RA, were analysed by Northern blot. The blot
was probed with a 32P labelled WT1 cDNA probe. To control for loading, the blot was stripped and probed
with a 32P labelled p-actin probe
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onto nitrocellulose. An antibody for WT1, which is directed against the C-
terminus of the protein (C-19), was used to probe the blot for the presence of
WT1. No WT1 protein was detected in the undifferentiated ES cells or in the ES
cells grown in the absence of LIF. However in the sample which was
supplemented with RA, following 96 hours of differentiation, a characteristic
doublet for WT1 at 52-54 kDa can be detected (Figure 4.1 (a)). These bands
correspond to different WT1 isoforms and arise from alternative translation
initiation sites and the presence/absence of the 17 amino alternatively spliced
exon 5.
4.2.1 Kinetics of WT1 Expression
Having established that all-trans retinoic acid induces ES cells to express WT1,
the kinetics ofWT1 induction by RA were investigated. Wild-type ES cells were
plated and induced to differentiate in the absence of LIF and in the presence of
RA. Total RNA was collected at the following time points: 18 hours; 24 hours;
36 hours; 48 hours; 60 hours; 72 hours; 90 hours; 96 hours. 5p.g of RNA was
reverse transcribed to produce cDNA from all time points. To control for cDNA
quantity, RT-PCR analysis was carried out for (3-actin. All samples were
normalised with respect to the [3-actin control (Figure 4.2 (a)).
To ascertain when WT1 is first expressed during RA differentiation, semi¬
quantitative RT-PCR for WT1 was carried out. Primers for WT1, spanning from
exon 4 to exon 6, were used to detect expression ofWT1. The WT1 transcripts in
this RT-PCR give two bands corresponding to the absence or presence of the
alternative splice variant, exon 5. Figure 4.2 shows that expression of WT1 is
first detected at 48 hours following RA differentiation. This expression continues
culminating in high expression at 96 hours. In contrast, the expression of the
POU transcription factor Oct-4 is down-regulated, with no expression detectable
after 72 hours (Figure 4.2 (a)).
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Figure 4.2 Analysis of the Kinetics of WT1 Induction in RA Treated ES Monolayer Cultures
a) 5 ng of total RNA was reversed transcribed to produce cDNA.To control for the quantity of cDNA,
samples were normalised with respect to p-actin (25 cycles). The expression of WT1 mRNA was
analysed by semi-quantitative RT-PCR using primers spanning exon 5 of WT1 (26 cycles). The
expression of Sonic Hedgehog mRNA (26 cycles) was also analysed as it represents a direct target
of the RA pathway, whilst Oct-4 was analysed to show the differentiation of the ES cells (27 cycles).
b) Expression of the WT1 protein was analysed by Western blot. 40 ug of nuclear protein from
ES treated with RA for 24, 48, 72 and 96 hours, was separated on a 10% SDS PAGE gel and
transfered onto nitrocellulose. The blot was probed for WT1 with the C-19 antibody. To control
for loading the blot was stripped and probed for p116, a U5 small nuclear RNP-associated protein.
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The induction profile ofWT1 protein was analysed by collecting nuclear protein
from RA differentiated ES cells at 24, 48, 72, 96 hours (Figure 4.2 (b)). 40 pg of
nuclear protein was separated on a 10% SDS PAGE gel and transferred onto
nitrocellulose. The C19 WT1 antibody was used to probe the blot for the
presence of WT1. WT1 protein was detected after 72 hours of induction with
RA. As a control for loading, the blot was stripped and reprobed with an
antibody for PI 16, demonstrating equal loading of protein (Figure 4.2 (b)).
Analysis of the kinetics ofWT1 induction in the ES monolayer suggests that the
expression of WT1 is a result of either cellular differentiation or the emergence
of a specific WT1 expressing cell lineage, rather than a direct transcriptional
effect of RA. This is supported by analysis of the induction of Sonic Hedgehog
(Shh), which has been demonstrated to be a direct transcriptional target of the
retinoic acid pathway (Riddle et al., 1993; Chang et al., 1997). The expression of
this transcript can be detected at the first time point taken 18 hours after the
addition of RA (Figure 4.2 (a)). This is in contrast with WT1 expression, which
is detected after 48 hours. Furthermore analysis of the murine WT1 promoter
failed to detect the presence of a retinoic acid response elements (RAREs), which
are present in the proximal promoters of RA target genes (Qian et al., 2000),
supporting the notion that WT1 is not a direct transcriptional target of the
retinoic acid pathway.
4.2.2 Analysis of Lineages generated from RA
Having established that RA differentiation of ES cells leads to expression of
WT1, we next carried out immunofluorescence for WT1 on differentiated ES
cells following 96 hours of RA treatment. Using the C-19 antibody, a nuclear
staining pattern for WT1 was detected in approximately 75% of differentiated ES








Figure 4.3 WT1 is Expressed in 80% of RA Treated ES Monolayer Cultures and WT1 Positive Cells Co-express
Vimentin
a) Antibody staining was carried out for WT1 (red) on undifferentiated ES cells and ES cells treated RA for 96 hours.
Cells were stained with dapi (blue) to visualise the nuclei. (Magnifcation x 20)
b) Co-staining for vimentin (red) and WT1 (green) was carried out on undifferentiated ES cells and ES cells treated with
RA for 96 hours. (Magnification x 10)
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within the RA differentiated monolayer system that was expressing WT1 by
using immunofluorescence.
Given the restricted expression ofWT1 in vivo to cells that possess mesenchymal
properties, we used vimentin as a marker as it is expressed predominately in cells
of mesenchymal origin, to see if WT1 expression was present in mesenchymal
lineages. In the differentiated monolayer cultures, vimentin expression is high,
with the majority of vimentin positive cells being also WT1 positive. This would
suggest that mesenchymal cells are present in the RA differentiated monolayer
which also express WT1 (Figure 4.3 (b)). To determine whether endothelial
lineages were present, differentiated ES monolayer cultures were assayed for the
expression of Flk-1. Staining of differentiated ES cells showed no detectable
expression of Flk-1 (Data not shown).
To gain further insights into the lineages that were being expressed during the
RA differentiation of ES cells, the expression of a variety of lineage and tissue
specific transcripts was assayed. The expression of marker genes indicative of
the three germ layers, mesoderm, endoderm, ectoderm and also some markers of
specific lineages including neuronal, myogenic and haematopoietic were
analysed by semi-quantitative RT-PCR. 5pg of RNA from the different time
points of the RA differentiation protocol (0, 18, 24, 36, 48, 60, 72, 90, 96 hours)
were reverse transcribed to produce cDNA. As a control for the RT-PCR and
detection of specific transcripts, RNA from wild-type whole mouse embryos at
E9.5 was prepared and reverse transcribed to produce cDNA. To control for
cDNA quantity, RT-PCR analysis was carried out for |3-actin, and all samples
were normalised with respect to this control ((3-actin) (Figure 4.2 (a)).
The transcripts chosen for mesodermal lineages were T-brachyury, which is
expressed in early mesoderm, the myogenic regulatory specific transcripts, myf5
and myoD and finally (3-globin, a definitive marker of blood. All three transcripts
were detected in the cDNA sample generated from the E9.5 whole embryos.
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Figure 4.4 RA Treatment of ES Cell Monolayers leads to expression of Neuronal and
Neuroectodermal lineage markers
Total RNA was collected from undifferentiated ES cells (0 hours) and ES cells treated with RA for
18, 24, 36, 48, 60, 72, 90 and 96 hours, and also E9.5 dpc wild-type whole embryos. 5 (ig of total
RNA was reverse transcribed to produce cDNA.To control for the levels of cDNA, RT-PCR for p-actin
was carried out (26 cycles) and all samples were normalised with respect to this control.
The levels of various lineage specific transcripts were assayed by semi-quantitative RT-PCR.
Nestin (27 cycles) and Pax-6 (27 cycles), for T-Brachyury, pH1, MyoD, Myf5, Ihh and AFP 35 cycles
were carried out on the RNA from RA treated ES cells, whilst 26-28 cycles were used to detect the
transcript in the RNA from the E9.5 embryos.
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However there was no detection of these transcripts in the RA differentiated ES
cells. Similarly there was no expression of alpha-fetoprotein or Indian Hedgehog,
markers of endoderm. Analysis of Pax6, a marker for the neuroectodermal
lineages, was detected in the cultures, as was the expression of nestin, a marker
for neuronal progenitors (Figure 4.4).
Therefore, the analysis of a select panel of transcripts and antibodies, indicate
that within the ES monolayer, there is an absence ofmesodermal and endodermal
lineages and presence of early neuronal and neuroectodermal lineages.
4.3 Expression of WT1 in Neuronal Progenitors
4.3.1 WT1 is Co-expressed with the Neuronal Stem Cell Marker
Nestin
RT-PCR analysis demonstrates that within the monolayer system, there is
expression of the early neuronal specific marker, nestin (Figure 4.4). In the
original study by Scharnhorst et al, WT1 expression was present in
subpopulations of RA differentiated EC cells that co-expressed GFAP
(Scharnhorst et al., 1997). The authors hypothesised that the co-expression of
WT1 and the astrocyte specific marker GFAP may reflect the situation in vivo,
given the reported expression ofWT1 in a domain of the CNS (Armstrong et al.,
1993; Rackley et al., 1993; Moore et al., 1998). In vivo, nestin is an intermediate
filament protein expressed during the development of the CNS and is a
characteristic marker of CNS progenitor cells (Lendahl et al., 1990). As the
multipotential CNS progenitor cells terminally differentiate to become neurons
and astrocyctes, nestin is down-regulated and replaced by expression of
neurofilaments and glial fibrillary acidic protein (GFAP) respectively. A similar
transition is observed in muscle development, in which nestin is transiently
expressed in presomitic mesoderm and in striated cells of the myotome layer of
the somites (Lendahl et al., 1990). This expression is replaced by desmin in
mature muscle. Nestin expression has also been detected in mesenchymal cells of
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the developing pancreas (Selander and Edlund, 2002). However the absence of
T-Brachyury, myoD and myF5, discounts the presence of mesodermal and/or
muscle differentiation in the monolayer differentiation system and points to
neuronal lineages being the probable cause of nestin expression.
Given the presence of nestin in the RA induced monolayer system, the question
is whether a population of cells that possess characteristics of neuronal
progenitors be expressing WT1? To answer this question, double
immunofluorescence was performed using an antibody specific for nestin (Gift
Dr. Meng Li) along with WT1. Monolayer cultures differentiated with RA for 96
hours were analysed for the co-expression of nestin and WT1. A subpopulation
of cells that co-expressed nestin and WT1 were detected in the RA-differentiated
system (Figure 4.5). However there were also cells that expressed WT1, but were
nestin negative. This indicates that not all WT1 positive cells within the
monolayer at 96 hours represent cells that have characteristics of neuronal
progenitor cells. To determine whether these WTl+ve nestin"ve cells represented
more mature neuronal cell types, which have down regulated nestin expression,
the pan-neuronal markers, neurofilament 68 kDa and (3-tubulin and the astrocyte
specific marker GFAP were used in combination with WT1.
Immunofluorescence with each of the markers showed no detectable expression
at 96 hours, suggesting that WTl+ve nestin"ve cells are not mature neurons (Data
not shown). This indicates that non-neuronal lineages are present in the
differentiated cultures which also expresses WT1. The absence ofGFAP staining
in the differentiated ES cells is in contrast to the situation in EC cells
differentiated with RA, in which WTl+ve GFAP+ve were detected (Scharnhorst et
al., 1997). However the EC cultures were differentiated for a longer period of
time (6 days) and therefore may contain more differentiated neuronal lineages.
4.3.2 Expression of WT1 in Sox2 Restricted Neuronal Progenitors
The observation that WT1 was co-expressed in a sub-population of nestin
positive differentiated ES cells leads to the possibility that WT1 may be
100
Chapter 4 A Role for WT1 in Neuronal Development
expressed in early neuronal progenitors. Therefore the analysis was extended to
see whether WT1 expression was present in homogenous neuronal progenitors
that were derived from two different ES cell differentiation protocols.
Expansion and fate choice of pluripotent ES stem cells in vitro along
neuroectodermal lineages is regulated by a number of signals, for example
retinoic acid and BMP signalling, which also act in vivo to control the
proliferation and differentiation of CNS neural progenitor cells (For review see
Panchision and McKay, 2002). However the generation of neuronal lineages
from ES cells is highly variable and can lead to heterogenous cultures containing
a variety of other lineages. Typically for the induction of neuronal
differentiation, ES cells are aggregated to form EBs, exposed to neuronal
inducing signals and then dissociated onto a permissive substrate which allows
neuronal lineages to grow (Bain et al., 1995; Renoncourt et al., 1998). However
the reliance upon aggregation, and thus the variation in structural organisation
and positional information within the EBs during differentiation results in
heterogeneity within EBs. Exposure of differentiating cells to potentially
inappropriate signalling environments resulting from the juxtaposition of
temporally and spatially distinct cell populations, results in various non-neuronal
lineages being present in the EBs. Also the addition of growth factors to EBs can
drastically affect the proportions of different cell types obtained in EB
differentiation. In the absence of neuronal inducers, neurons represent a small
percentage of cells. Efficient generation of neurons from EBs requires an
additional stimulus. If that additional signal is retinoic acid, neuronal gene
expression and neuronal development is activated, with the effect of repressing
mesodermal gene expression (Bain et al., 1996). Although there have been many
modifications to this technique to increase the percentage of neurons, other
lineages may still persist in the cultures.
In an attempt to isolate a homogenous pool of neuronal progenitors, ES cells in
which a neomycin selection cassette was targeted into the Sox2 locus by
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homologous recombination were produced (Li et al., 1998). The Sox proteins
constitute a family of transcription factors related to the mammalian testis-
determining factor SRY through homology with their HMG-box DNA binding
domains. Soxl and Sox2 represent a subfamily of Sox genes (Soxl, Sox2 and
Sox3), that are expressed within the developing nervous system. Sox2 is one of
the earliest known transcription factors expressed in the developing neural tube,
and is confined to the neuroepithelium of the neural plate and dividing neural
progenitors in the early mouse embryo (Uwanogho et al., 1995; Collignon et al.,
1996; Pevny et al., 1998; Wood and Episkopou, 1999). Using this genetically
modified ES cell line, it becomes possible to obtain a starting population of
homogenous neuronal progenitors from a complex mass of cells following EB
differentiation with retinoic acid and by exposing the cultures to G418. Sox2
expressing cells, which represent neuronal progenitors will survive, whilst the
Sox2 negative non-neural cells in the differentiating cultures will be eliminated,
because they lack G418 resistance.
Using this well characterised system we analysed the expression ofWT1 at the 4
stages of the protocol via semi-quantitative RT-PCR. Using this system we can
examine whether WT1 is expressed in pure neuronal progenitors (Figure 4.6 (a)).
Total RNA was collected at the following stages of the differentiation pathway:-
(A) Day 4 (EBs differentiated in the absence of LIF for 4 days in
suspension)
(B) Day 6 (EBs differentiated for 2 days in the presence of 1 uM RA)
(C) Day 8 (EBs differentiated for 6 days in the presence of lpM RA and
G418)
(D) Day 10 (Cells dissociated and cultured in DMEM/F12 supplemented
with N2)
2 pg of RNA was reverse transcribed to produce cDNA from the samples. To
control for cDNA quantity, RT-PCR analysis was carried out for (3-actin. All
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Figure 4.6 WT1 is Expressed in Purified Neuronal Precursors Derived from ES cells via Lineage Selection.
a) ES cells were targeted via homologous recombination with a IRES-G418 selection cassette into the SOX2 locus (Li et a\, 1998).
Total RNA was collected from the following stages: ES cells were allowed to aggregate in suspension culture in the
absence of LIF for 4 days (Sample A). EBs were differentiated for a further 2 days in the presence of VM of RA (Sample B).
EBs were differentiated for a further 2 days in the presence of G418 and 1 [xM RA (Sample C). EBs were dissociated
and cultured in DMEM/F12 supplemented with N2 (Sample D).
b) 2pig of total RNA was reverse transcribed to produce cDNA. The expression of WT1, Nestin and Pax6 (26-28 cyles) were
analysed via semi-quantitavtie RT-PCR. To control for cDNA quantity the samples were normalised with respect to p-actin
(26 cyles). The expression of the transcripts in neuronal progenitors was compared to their expression in RA treated ES
monolayer culture system.
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samples were normalised with respect to the internal control ((3-actin). RT-PCR
was carried out for WT1 using primers that are specific for the exon 5 alternative
splice site (Figure 4.6 (b)).
In sample A, there is low level expression ofWT1. This sample represents RNA
collected from day 4 EBs, which have been cultured in medium lacking LIF and
allowed to aggregate and to form EBs. There is also low level expression of
nestin and Pax6 in this sample.
The level of WT1 expression has increased dramatically in sample B, which
represents RNA collected from day 6 EBs which have been differentiated for 4
days in the absence of LIF and a further 2 days in the presence of 1 uM all-trans
retinoic acid. At this point within the EBs there will be heterogeneity, with the
presence of non-neuronal lineages (Bain et al., 1995; Li et al., 1998).
WT1 is detected in sample C, but at lower levels than in sample B. Sample C
represents RNA collected from day 8 of the differentiation protocol in which EBs
have been through RA differentiation and G418 selection. The reduction ofWT1
expression in sample C, in contrast to the levels ofWT1 in sample B, may reflect
the removal of the non-neuronal cell types, which also expressed WT1. Within
this pool of cells there is expression of neuronal progenitor subtypes markers,
including Pax6, which in vivo is expressed in the dividing neural precursors
throughout the length of the embryonic tube, and the LIM homeodomain protein
Isletl, an early marker ofmotor neuron differentiation.
RNA from sample D was collected from day 10 of the differentiation protocol.
At this stage the EBs have been through G418 selection to remove non-neuronal
lineages, dissociated, plated and grown in a defined culture medium of
DMEM/F12 plus N2 supplement. At this point in the protocol, 95% of the cells
express Soxl and Sox2, with the neuronal progenitors exhibiting small, ovoid
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morphology typical of neuroepithelial cells in vivo (Li et al., 1998). There is
expression ofWT1 in this homogenous pool of neuronal progenitors.
4.3.3 Absence of WT1 Expression in Non-RA ES Derived Neuronal
Progenitors
We also analysed the expression of WT1 by RT-PCR in ES derived neuronal
progenitors which have been isolated on the basis of nestin expression (Lee et
al., 2000). The differentiation process involves 4 steps: generation of EBs
(Step2), use of a defined medium to select for nestin positive CNS progenitors
(Step3), the proliferation of nestin positive CNS progenitors in the presence of a
mitogen (Step4) and the differentiation of the CNS progenitors by the removal of
the mitogen (Step5). The protocol does not employ the use of retinoic acid as an
inducer for neuronal differentiation. Instead the ES cells are allowed to aggregate
in the absence of LIF to form embryoid bodies, dissociated and then grown in
ITSFn medium (Insulin, transfferin, selenium and fibronectin) (Okabe et al.,
1996; Lee et al., 2000). In the presence of this defined medium, nestin positive
cells are produced, which are subsequently selected for further expansion. The
nestin positive cells are then differentiated to produce functional neurons (Figure
4.7 (a)).
5p,g of RNA was obtained from stages 3, 4 and 5 of the differentiation protocol
(Gift Dr. R.D McKay). The 5 of RNA was reverse transcribed to produce
cDNA from the sample. To control for cDNA quantity, RT-PCR analysis was
carried out for |3-actin. All samples were normalised with respect to the internal
control (|3-actin). RT-PCR was carried out for WT1 using primers that are
specific for the exon 5 alternative splice site.
There was no detection ofWT1 expression in the RNA collected from stages 3, 4
and 5. As a control, cDNA from sample C of the Sox2 neuronal differentiation
protocol was included in the RT-PCR analysis. Expression for WT1 is detected
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Figure 4.7 WT1 is Not Expressed in Neuronal Progenitors Derived From ES Cells Selected by the Expression
of Nestin
a) Diagram showing the differentiation protocol used to derive neuonal progenitors from ES cells. Total RNA was
collected from stages 3-5 of the differentiation protocol
b) 5jxg of total RNA from stages 3-5 was reverse transcribed to produce cDNA. The expression levels of WT1 and
nestin were assayed by semi-quantitative RT-PCR(26-28 cycles). To control for cDNA quantity the samples were
normalised with respect to the expression levels of p-Act in (26 cycles). The expression of WT1 in the nestin purified
neuronal progenitors and post-mitotic neurons was compared with Sox2 selected neuronal progenitors.
Chapter 4 A Role for WT1 in Neuronal Development
in the Sox2 sample. In both samples there is expression of nestin at similar levels
(Figure 4.7 (b)).
4.4 Expression of WT1 in the Developing CNS
Given the expression of WT1 in neuronal progenitors derived from the Sox2
selected ES cells, could WT1 be expressed in neural progenitors in vivo? Within
the developing nervous system, several studies have reported expression ofWT1.
Sites of expression include discrete pockets of staining in the developing eye,
spinal cord and in the ventricles of the brain (Armstrong et al., 1993; Rackely el
al., 1993; Moore et al., 1998). Apart from in the eye, where the function ofWT1
has been described and a phenotype observed, no other studies have indicated
what neuronal cell type WT1 is expressed in, or have proposed a function for
WT1 expression in the CNS. Therefore we set about mapping the expression of
WT1 in the early stages of neuronal development spanning E9.5-E10.5.
4.4.1 Expression of WT1 in the Ventral Neural Tube
The WT1 mouse monoclonal antibody (H2) was used to localise WT1 expression
in E9.5 and E10.5 embryos. In transverse sections of E9.5 embryos, there was no
detectable expression of WT1 in the developing CNS. There was expression of
WT1 detected in the pronephric/mesonephric ridge (Data not shown). At El0.5,
expression ofWT1 was evident in two populations of cells in the ventral half of
the neural tube (Figure 4.8). This expression of WT1 was detected at a similar
ventral position throughout the length of the neural tube, from cervical regions to
a posterior limit of expression in the hindlimbs. There were no other sites of
WT1 expression within the CNS at El0.5. WT1 staining was detected in the
mesonephric ridge and also the mesothelium lining of the thoracic cavity (Figure
4.8 (a) and (b)). As a control, sections were processed in which primary antibody
was absent. In these sections there is no staining in either the neural tube or the
mesonephric ridge at El0.5 (Figure 4.8 (c)). This
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Figure 4.8 WT1 is Expressed in the Ventral Neural Tube
10 [xM transverse sections of E10.5 embryos were stained with WT1 (green). At the level of the (a) branchial and
(b) lumbar region, WT1 can be detected in the ventral half of the neural tube. As a control, sections from
the brachial region were processed without the addition of the primary antibody (c). The sections were stained
with dapi (blue) to visualise the nuclei. (A) neural tube (B) mesonephric ridge (C) mesothelium (Magnification x 20).
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endogenous staining is consistent with the findings from the human WT1 YAC
LacZ mice (Moore et al., 1998).
4.4.2 WT1 Expression Partially Overlaps with Nkx6.1 Expression
and with Islet 1
With the detection ofWT1 in the ventral neural tube at E10.5, the next step was
to map the expression of WT1 in relation to the well-defined ventral neural
subtypes. These have been established from the expression profile of several
transcription factors (For review see Briscoe & Ericson, 2001). During ventral
neural tube patterning the morphogen, Sonic Hedgehog (Shh), is secreted from
the notochord to regulate the regional expression of several different
transcription factors (Marti et al., 1995). Recent studies have characterised a
family of transcription factors that delineate five neuronal progenitor cell
domains in the ventricular zone of the ventral neural tube, referred to as pO, pi,
p2, pMN and p3 (For review see Jessell, 2000; Briscoe & Ericson, 2001). Using
lineage tracing experiments and genetic markers, it has been demonstrated that
distinct classes of cells arise from specific progenitor cell domains positioned
along the dorsal/ventral axis of the ventricular zone (For review see Jessell,
2000). Cell-fate specification is thought to occur through the initiation of
complex transcriptional cascades that activate appropriate neuronal subtype
determining genes, whilst simultaneously suppressing alternative pathways of
differentiation. Once determined, these cells exit the cell cycle in a regulated
manner and generate postmitotic neurons. These postmitotic neurons then
migrate to defined positions within the neural tube. Initial migration of newly
generated neurons occurs in a medio-lateral plane, i.e. more lateral the position
of a neuron, the more differentiated. Based on this V0-V3 interneurons develop
from the p0-p3 domains, respectively, and motor neurons (MNs) arise from the
pMN domain.
The three most ventral progenitor domains, p3, pMN and p2 are established by
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Irx3 (For review Briscoe & Ericson, 2001). Since Nkx6.1 marks these three
progenitor domains, a rabbit Nkx6.1 polyclonal (Gift Dr P.Serup) was used
alongside the WT1 monoclonal antibody on transverse sections of El 0.5 neural
tube (Figure 4.9). In comparison to the expression profile of Nkx6.1, which is
expressed from the mid-line in a broad ventral domain, WT1 is expressed more
laterally in comparison. Flowever there is an overlap ofWT1 staining with that of
Nkx6.1. This indicates that WT1 is expressed in domains where neuronal
progenitors are generated.
We next analysed the expression WT1 in comparison to the expression profile of
Isletl (Isl-1). Isl-1 is the first indicator of motorneuron differentiation and is
expressed by all classes of motor neurons, preceding that of other LIM
homeobox genes, thus defining an early and common step in motor neuron
differentiation (Pfaff et al., 1996). Double immunofluorescence analysis was
performed for WT1 and Isl-1 using a rabbit polyclonal antibody (Gift Dr
T.Jessell). At E10.5 strong expression of Isl-1 was evident in two bilaterally
symmetrical populations of cells in the ventral neural tube. This expression
profile represents the postmitotic motorneuron domain (MN domain). Co-
staining for WT1 shows that the majority of the WT1 positive cells also co-
express Isl-1, indicating that WT1 is expressed in motor neuron populations
(Figure 4.10). However there is also expression of WT1 in a more medial
domain, encompassing the Nkx6.1 domain, and also dorsally, which would
indicate expression in the p2/V2 domains (Figure 4.10).
4.5 Discussion
The work presented in this chapter demonstrates that WT1 expression is induced
in ES monolayers differentiated with RA. From the observed kinetics of WT1
induction in the system, it is unlikely that the expression ofWT1 is a direct result
of retinoic acid signalling pathways. This suggests that the induction of WT1 is
the result of the emergence of a specific WT1 expressing lineage.
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Using a small number of markers, either by immunofluoresence or RT-PCR
analysis, analysis of the differentiated cultures indicates that the predominant
lineages present in the culture are mainly neuroectodermal. The absence of
mesodermal lineages in the RA differentiated ES cells is in agreement with the
findings of Bain et al who demonstrated that RA treatment of embryoid bodies,
resulted in repression of mesodermal lineages, including T-brachyury, and
activation of specific neuronal transcripts (Bain et al., 1996). However there is
co-expression of WT1 and vimentin in the RA differentiated monolayer.
Although predominately expressed in mesenchymal lineages, vimentin is also
expressed in parietal endoderm cells, primary mesenchymal cells that delaminate
from embryonic ectoderm and neural crest (Lane et al., 1983; Franke et al.,
1982; Cochard and Paulin, 1984). Vimentin is also expressed by neural
progenitors in the neuroepithelium of the CNS, where its expression is
concurrent with that of nestin (Frederiksen and McKay, 1988). Co-staining of the
cultures with WT1 and nestin demonstrates that there are populations of cells that
express both markers, indicating that WT1 is expressed in differentiated ES cells
that possess characteristics of neuronal progenitors. This suggests that the
vimentin staining in not indicative of mesenchymal cells populations but due to
the presence of neuronal progenitors or neuroectodermal lineages. Although
early neuronal markers are present, there is an absence of expression of more
differentiated neuronal markers in the cultures. Also there are populations of
WT1 positive cells within the monolayer system, which do not express the
specific neuronal makers, indicating that other non-neuronal WT1 expressing
lineages are present.
From the in vitro analysis of ES derived neuronal progenitors, WT1 is detected in
neuronal progenitors, but only present in the system using RA as an inducing
agent. Why is there a difference in expression of WT1 in the two systems
employed to generate ES cell derived neuronal progenitors, when both starting
progenitor populations express the neuronal stem cells marker nestin? One
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possible explanation for the difference is that the two systems are producing
different types of neuronal progenitors.
In investigating which CNS type the non-RA induced ES cell derived neuronal
progenitors represent in vivo, expression of three position specific markers along
the anterior-posterior axis was analysed in the cultures (Okabe et al., 1996; Lee
et al., 2000). Analysis of the stages in the protocol by RT-PCR shows that there
is high expression of OTX-1 and En-1 in stages 2-4 (Lee et al., 2000). OTX-1 is
expressed during the early stages of neuroectoderm differentiation, whilst
engrailed (En-1) is expressed in the midbrain/hindbrain boundary (Davis and
Joyner, 1988; Simeone et al., 1998). However expression of Hoxa-7, a marker of
cells in the posterior spinal cord, is not detected in the neuronal progenitors
derived from this differentiation system (Okabe et al., 1996). Taken together the
expression of these genes is indicative of early midbrain/hindbrain identity
indicating the neuronal progenitors and lineages produced by this protocol have
characteristics in vivo ofmidbrain and hindbrain neurons (Lee et al., 2000).
In the RA induced ES derived neuronal progenitors, there is a shift in the type of
neuronal progenitor generated in this system. Neural progenitors formed from
EBs exposed to RA for 3 days, have been shown to lack expression of the early
midbrain markers OTX-2 and En-1, and instead show expression of HoxC5,
HoxC6 and HoxC8, markers of spinal cord identity (Wichterle et al., 2002). The
addition of RA to EBs to promote neuronal differentiation has been shown to
repress the differentiation of midbrain dopaminergic neuronal differentiation
(Kawasaki et al., 2000; Wichterle et al., 2002) and to lead to differentiation of
progenitors towards ventral CNS progenitors (Renoncourt et al., 1998; Wichterle
et al., 2002). This shift towards ventral CNS progenitors could be a result of RA
directly activating Shh transcription (Riddle et al., 1993; Chang et al., 1997). In
the developing ventral neural tube, Shh mediated signals from the notochord and
floor plate, play an essential role in the differentiation of ventral neuronal
progenitor subtypes. Shh signalling controls ventral neural fates by regulating the
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expression of several transcription factors, including the Pax genes. In vivo, Pax6
is expressed in ventral progenitors of the neural tube (Ericson et al., 1997). This
suggests that the expression of WT1 in the RA induced Sox2 system may be
indicative of WT1 expression in CNS progenitors found in the ventral neural
tube.
In vivo, WT1 appears to follow this pattern of expression in the early developing
CNS. At E10.5, there was no detection of WT1 in the developing brain, whilst
expression was detected in the neural tube. Within the neural tube, WT1
expression was observed in the ventral half in a medial population of cells that
represented neuronal progenitors, as determined by the expression pattern of
Nkx6.1. However detection of WT1 can also be found in the motor neuron
component of the neural tube, overlapping partially with that of Isl-1, but also
dorsally in an expression domain that may represent the V2 inter neurons. The
expression pattern ofWT1 appears to follow that of the Lim homeodomain gene,
Lim3 (Pfaff et al., 1996, Thaler et al., 2002). Lim3 is expressed throughout the
neural tube and is involved in the generation of two adjacent, but distinct cell
types, motor neurons and V2 inter neurons. Lim3 is transiently expressed in
neuronal progenitors that give rise to motor neurons and also to V2 interneurons
(pMN and p2) as these progenitors exit from the cell cycle and become post¬
mitotic neurons.
The expression ofWT1 in a population of neuronal progenitors in the neural tube
adds to the list of tissues in which WT1 has a been detected in progenitor
populations. For example, WT1 expression has been described in progenitor
populations in the heart, kidney, gonad and haematopoetic system. In the
epicardium of the heart WT1 expression is highest in undifferentiated
progenitors, and then becomes down regulated as the progenitors begin to
express lineage specific markers. In the neuronal tube, WT1 expression is
detected in a domains that mark neuronal progenitors, but its expression persists
in differentiated post-mitotic neurons.
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Mounting evidence suggests that WT1 has role in the development of some
neuronal lineages. WT1 has been demonstrated to be critical for normal retina
formation with a role in the proliferation of retinal progenitors and ganglia cell
development (Wagner et al., 2001). Recently it has been demonstrated that in an
in vitro retinoblastoma tumour cell line, Y-79, WT1 was associated with the
conversion of the undifferentiated Y-79 cells to neurons (Wagner et al., 2002).
However what is the function ofWT1 in the neural tube? To date, no phenotype
has been reported in the WT1 null mice involving patterning and generation of
the neural tube subtypes. A preliminary screen in WT1 null mice at El0.5
demonstrates that Isl-1 positive cells are still present at similar levels compared
to wild-type and heterozygote litter mates (data not shown). This therefore
suggests that WT1 expression is not crucial for the generation ofmotor neurons.
Recently it has been demonstrated that developmentally relevant signalling
factors can induce ES cells to differentiate into spinal progenitor cells, and
subsequently into motor neurons through a pathway that recapitulates the
developmental process in vivo (Wichterle et al., 2002). From the observed
expression of WT1 in motor neurons, this system would be highly relevant to
study the role of WT1 in the generation of motor neurons. However a more
suitable system to use would be WT1 loss-of-function experiments using the
conditional loxP mice described in chapter 3 and specific neuronal Cre
expressing mice. Currently several Cre expressing lines are published that would
be suitable to dissect the role of WT1 in neuronal development. To specifically
question the role of WT1 in motor neuron development, a Cre line under the
control of 01ig2 would be the most appropriate. 01ig2 is expressed selectively in
progenitor cells within the pMN domain and is involved in the differentiation of
motor neurons (Novitch et al., 2001). A mouse model, in which an inducible
form of Cre has been knocked into the endogenous 01ig2 locus, has been
generated (Takebayashi et al., 2002). Also recently Dr. Colin Miles has
identified a 350bp regulatory element located 5kb upstream of the WT1 start site
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that drives a LacZ reporter in the developing spinal cord. This fragment was
identified by its high conservation between fugu, mouse and human. A construct
containing the 350 bp fragment linked to a minimal Hsp68 promoter was used to
produce transgenic mice that were analysed at mid-gestation (El2.5). Analysis of
the offspring demonstrated that LacZ is detected in the ventral half of the neural
tube (Dr Colin Miles, personal communication). It is intriguing to note that this
regulatory element has been conserved from fish to mammals throughout
evolution and thus may be of functional significance. This regulatory element
would therefore be ideal for directing expression of Cre for WT1 loss-of-
function studies.
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5.1 Introduction
The embryonic lethality of the WT1 knockout mice has made it difficult to
study the potential functions ofWT1 in development. Establishing a conditional
knockout of the WT1 gene is one approach to overcome this issue, as described
in Chapter 3. In parallel with the development of a conditional knockout, an
alternative and complementary approach to study its function, is to establish
WT1 null ES cell lines. These targeted embryonic stem cells can be utilized as
an in vitro differentiation system to identify candidate WT1 target genes, and
also to study the effect of WT1 loss-of-function on cellular differentiation
pathways.
The use of an in vitro ES cell differentiation system has advantages over
immortalised cell lines in that they are not restricted to particular differentiation
processes. ES cells retain the ability to generate multiple lineages and during the
course of differentiation, express tissue specific proteins, ion channels and
receptors in a pattern closely resembling the pattern observed in vivo. In Chapter
4, the addition of RA to ES monolayer cultures has been shown to result in
high-level expression of WT1. The use of this RA differentiation protocol
provides an ideal system in which to investigate the effects of WT1 loss-of-
function on gene expression.
A similar approach has already been employed, and has identified IGFBP-4 and
cyclin G1 as potential WT1 target genes (Wagner et al., 2001). Using gene
targeting, ES cells were generated that were homozygous for point mutations in
the WT1 zinc fingers (DDS ES cells), commonly found in Deny-Drash
Syndrome patients. This modification leads to a truncation of WT1 protein in
zinc finger 3, disrupting the DNA binding region (Patek et al., 1999). Wild-type
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and DDS ES cell lines were differentiated with RA, and the gene expression
profiles of the two cell lines compared using cDNA macroarrays. The aim of
this work is to analyse the effects of loss-of-function of WT1 on gene
expression profiles in the RA differentiation system using Affymetrix Genechip
arrays.
5.1.1 Use of Microarrays
Until recently, comparing expression levels across different tissues or cells was
limited to tracking one or a few genes at a time. With the advent of microarray
technology, it as now become possible to obtain quantitative information
regarding the complete transcription profile of a cell or tissue at any given time.
There are numerous examples where microarrays have answered several
important biological and developmental questions. For example, microarrays
have been successfully used to decipher the complex transcriptional regulatory
networks involved in the developmental process of metamorphosis in
Drosophila (White et al., 1999). Metamorphosis is characterised by diverse
developmental phenomena, including cellular proliferation, tissue remodelling,
cell migration and programmed cell death. This developmental switch relies
upon the integration of a set of processes that are controlled by a transcriptional
hierarchy, which in turn co-ordinates the expression of hundreds of genes.
In Drosophila, metamorphosis is initiated in response to the hormone ecdysone,
which activates this transcriptional hierarchy. Using microarrays, the
transcriptional profile of gene expression of wild-type Drosophila during early
metamorphosis was assayed at stages spanning two pulses of ecdysone.
Changes in metabolism, myogenesis, neuronal and cellular differentiation were
all observed in response to ecdysone (White et al., 1999). The use of
microarrays to study this developmental phenomenon allowed the authors to
connect known signal transduction pathways to the ecdysone-initiated
metamorphosis. It also assigned known genes to developmental pathways
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associated with metamorphosis, and also identified genes not previously
associated with this process.
Microarrays have also been also employed successfully to identify genes whose
expression depends upon the function of a specific component of a
transcriptional network. The paired-type homeobox transcription factor, CRX,
has a pivotal role in the terminal differentiation of vertebrate photoreceptors
(Furukawa et al., 1997). Mutations in the human CRX gene result in either
congenital blindness or photoreceptor degeneration (Swain et al., 1997).
Targeted mutation of the mouse CRX results in failure of development of the
light detecting outer segment of photoreceptors (Furukawa et al., 1999). Using
microarrays. the transcriptional networks controlled by CRX in the developing
retinal tissue from CRX+/+ and CRX"7" mice were established (Livesey et al.,
2000). From this study, the authors identified a novel set of photoreceptor genes
controlled by CRX, which function in a number of different stages in
photoreceptor differentiation.
Recently, microarrays have been employed to produce a transcriptional profile
that relates to the unique properties of stem cells. To date the list of genes
known to be crucial for stem cell function, and which are used in the
purification and isolation of stem cells, is relatively small. Therefore, a list of
genes unique to stem cells would permit a greater understanding of the special
properties of stem cells in their basic biology and also their potential clinical
use. Microarray analysis ofmouse embryonic, neural, haematopoietic stem cells
and human haematopoietic stem cells by two independent groups generated a
list of approximately 200 genes that were shared by these various stem cell
populations (Ramalho-Santos et al., 2002; Ivanova et al., 2002). This list of
transcripts enriched in all stem cell populations may include genes that are
crucial for unique properties of the stem cell i.e. self-renewal and the ability to
generate multi-lineage differentiated progeny. However a comparison of the
lists for stem cell enriched transcripts showed only 15 genes that were shared
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between the two studies. Despite this relatively low number, these studies
provide an insight into the transcriptional networks that are present in the
various stem cell populations analysed. What is evident is that stem cells from
each compartment/region are distinct, in that each stem cell type can be
identified by highly enriched genes that are not present (or enriched) in other
stem cells.
The work presented in this chapter compares the gene expression profile of
wild-type and WT1 null ES cells in the RA differentiation protocol using
Affymetrix Genechip arrays. The outcome of this study may lead to the
identification of novel candidate WT1 regulated genes.
5.2 Generation of WT1 Null Embryonic Stem Cells
The strategy chosen to generate WT1 null ES cells is to apply the same
principle of Cre-LoxP conditional inactivation described in Chapter 3. From the
first round of gene targeting, one allele has been created which is lacking exon 1
of WT1, producing a WT1 heterozygote null ES cell. The next step is to use the
same targeting construct, pWTlLoxP24, and target the second remaining wild-
type allele. This approach would produce an ES cell clone in which one WT1
allele would be null, whilst the other would be a conditionally targeted allele,
with loxP sites flanking exon 1. The system would permit temporal control over
the ablation ofWT1 during the differentiation of ES cells by the administration
of Cre-recombinase. An example of how the system could be used is shown in
figure 5.1.
5.2.1 Targeting Using pWTILoxP24 Construct
Following the transient transfection of the homologous targeted parental clone,
14.17 with pMC-Cre, clones were selected in which type II recombination had
occurred (removal of the full genomic interval between the 3 loxP sites, which
includes exon 1 and the selection cassette). One clone, 14.17.3, which was
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Figure 5.1 Generation and In Vitro Application of Conditional WT1 Null ES Cell Lines
a) Diagram showing targeting of the remaining wild-type WT1 allele of the heterozygous null ES cell
with the pWTILoxP construct to create ES cells heterozygous for WT1 in which induction of Cre
expression will ablate WT1.
b) Individual clones of ES cells generated in this way can be used to compare gene expression
profiles in the presence and absence of WT 1 by transient expression of Cre recombinase.
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karotyptically normal, was chosen for the second round of gene targeting. The
linearised targeting vector, pWTlLoxP24, was electroporated into the WT1
heterozygote null ES clone. Cells were selected with G418 for 7 days. 101
clones were isolated which survived G418 selection and screened via Southern
blot, using a Bglll digestion of genomic DNA and hybridisation with a 5'
flanking probe (Figure 5.2 (a)). From the analysis, all the clones exhibited 6 kb
and 2 kb fragments, indicating that none of the clones were correctly targeted
withpWTlLoxP24 (Data not shown).
The experiment was repeated again and 227 clones were isolated. By increasing
the number of clones picked from the transfection, it was hoped that the
probability of isolating a correctly targeted clone would be increased. The
clones were analysed using the same genomic digestion and Southern blot
hybridisation. From the 227 clones analysed, one clone, 14.17.74, was identified
as being homologously targeted, by the presence of the expected 4 kb and 2 kb
fragments (Figure 5.2(b)).
The next step was to transiently transfect the targeted clone, 14.17.74, with
pMC-Cre. As demonstrated from targeting of the first allele and the generation
of floxed clones described in Chapter 3, the transient expression ofpMC-Cre
and counter selection in gancyclovir (GANC), results in either type I or type II
recombination. If the outcome is type I recombination, (recombination between
the loxP sites flanking the selection cassette) then a conditionally targeted ES
cell clone will be generated with exon 1 of WT1 flanked by loxP sites. This
clone could then be used in subsequent studies, where the loss of WT1 gene
expression would be achieved through the re-expression of Cre recombinase
(Figure 5.1). From type II recombination (recombination between the two outer
loxP sites) a WT1 null ES clone would be generated, due to the excision of exon
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Figure 5.2 Targeting of the Second Wild-type WT1 Allele with pWTILoxP24 Targeting Construct
a) Figure showing the targeting of the second wild-type WT1 allele with the pWT1LoxP24
b) Southern blot analysis confirms 14.17.74 as being homologously targeted with pWT1LoxP24.
10 |xg of genomic DNA was digested with Bglll and a Southern blot of the digested DNA was carried
out using a 5' probe (red box). The first allele deleted using the Cre/LoxPsystem generates a 2 kb band,
whilst correct targeting of the remaining wild-type allele with the pWT1LoxP24 construct generates a
4 kb band.
Figure 5.3 Transient Expression of Cre Does Not Result in Type II Recombination of the
Homologously Targeted ES Cell Clone, 14.17.74.
a) Representative Southern blot of clones selected following transient expression of Cre. Gancyclovir
resistant clones were picked following 10 days of selection. 10 |xg of genomic DNA from the clones
was digested with Bglll and a Southern blot of the digested DNA was carried out using the 5' probe.
All of the subclones exhibited only type I recombination (removal of the selectable marker cassette).
b) PCR analysis across the position where the 5' LoxP site resides demonstrates that the clone
14.17.74 does not have a LoxP site at this position.
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Following the transient expression ofpMC-Cre, 40 GANC resistant clones were
analysed by Southern blot using the same Bglll genomic digest ofDNA and 5'
flanking probe. All of the clones analysed displayed 6 kb and 2 kb fragments,
indicating that the Pgk-HSVtk-Pgk-Neo selection cassette had been successfully
removed (Figure 5.3 (a)). Flowever, none of the clones analysed by Southern
blot analysis had undergone type II recombination. This event would have
generated a single band of 2 kb by Southern blot using the genomic digest and
probe described above. Given that 80% of the clones in the targeting of the first
allele and Cre treatment under went full deletion of the targeting vector, this
was a surprising result.
Due to the absence of type II recombination, the next step was to analyse the
parental clone 14.17.74, using primers spanning the 5' loxP site to ensure its
presence in the clone. PCR analysis determined that 14.17.74 did not contain the
5' loxP site (Figure 5.3 (b)). This suggested that the recombination complex
formed during homologous recombination had resolved downstream of the 5'
loxP site, thereby not incorporating this site.
5.2.2 Targeting Using pKreWTI Construct
Due to the difficulty associated with targeting the second wild-type allele with
the pWTlLoxP24 targeting vector, the strategy chosen to generate WT1 null ES
cells was changed. Instead of employing the Cre/LoxP system, the approach
was to now generate WT1 null ES cell lines using the original targeting vector
employed in the production of the WT1 mouse knockout (gift from Dr J
Kreidberg; Kreidberg et al., 1993). Correct homologous targeting, would in one
step, generate a WT1 null ES cell line. Targeting of the remaining WT1 locus
with this replacement-type targeting vector,pKreWTl, deletes the first exon and
part of the 5' upstream sequence, and replaces this with a neomycin cassette



















































Figure 5.4 Generation of WT1 Homozygous Null ES Cells using the pKreWTI Targeting Construct
a) Figure showing the generation of WT1 null ES cells, by targeting the second wild-type allele
with the pKreWTI construct
b) Southern blot analysis confirms K1 and K46 as being correctly targeted with the targeting vector. 10 ng of
genomic DNA was digested with Bglll and a Southern blot of the digested DNA was carried out using a 5' probe
(red box). The first allele deleted using the Cre/LoxPsystem generates a 2 kb band, whilst correct targeting of the
remaining wild-type with the pKreWTI construct generates a 3 kb band by Southern blot analysis.
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vector, which is used for positive-negative selection to reduce the background
effects caused by random insertion of the construct into the genome.
Following the transient transfection of the parental clone, 14.17, with pMC-Cre,
clones were selected in which type II recombination had occurred. Using one of
these clones, 14.17.25, linearised pKreWTl targeting vector was introduced by
electroporation and clones were grown in selection of both G418 and
gancyclovir. Following 9 days of dual-selection, 123 clones were picked and
analysed by Southern blot with the Bglll genomic digest using the 5' probe.
From the 123 clones tested, 2 were correctly targeted, as identified by the
presence of a 3 kb and 2 kb bands expected for correct homologous
recombination at the WT1 locus (Clones K1 and K46) (Figure 5.4). Both clones
were karotyped and shown to be normal (Data not shown).
5.2.3 Confirmation of WT1 Null ES Cells
As shown in Chapter 4, the treatment of wild-type ES cultures with all-trans
retinoic acid (RA) induces high level expression of WT1. From the second
round of gene targeting, two independent WT1 null ES clones were obtained
(K1 and K46). To confirm that the sequential steps of Cre-LoxP inactivation of
the first allele, followed by the insertion of a neomycin cassette in the second
allele, did produce a WT1 null ES cell clone, K1 (WTE7") cells were
differentiated alongside El4 (WT1+/+) ES cells with RA for 96 hours, and
compared to K1 (WT1"7") and El4 (WT1+/+) ES cells grown in the absence of
RA. Following 96 hours, nuclear protein was harvested from the E14 and K1
RA treated clones, along with nuclear protein from the E14 and K1 clones in an
undifferentiated state.
40 pg of nuclear protein from E14 and K1 in an undifferentiated state and 40 pg
of protein from both clones differentiated for 96 hours with RA, were separated
on a 10% SDS PAGE gel and transferred onto nitrocellulose. Antibodies for









































































Figure 5.5 Western Blot Analysis and Immunofluorescence Confirms that K1 and K46 are WT1 Null ES Cell Lines
a) Nuclear protein was collected from E14 and K1 ES cell lines undifferentiated, and E14 and K1 ES cells treated with
1 [iM RA for 96 hours. 40 ng of nuclear protein was separated on a 10% SDS PAGE gel and transfered to nitrocellulose.
The blot was probed for WT1 using the N-terminal antibody (H2). To control for loading the blot was stripped and probed for
p116, a U5 small nuclear RNP-associated protein.
b) Nuclear protein was collected from E14, K1 and K46 ES cells treated with 1 RA for 96 hours. 40 ^g of nuclear protein
was separated on a 10% SDS PAGE gel and transfered to nitrocellulose. The blots were probed for WT1 using both the
N-terminal (H2) and C-terminal (C-19) antibodies. To control for loading the blot was stripped and probed for p116, a U5 small
nuclear RNP-associated protein.
c) E14 and K1 ES cells were treated with 1 RA for 96 hours and immunofluorescence for WT1 was carried out using the
C-19 antibody.
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terminus (C-19) domains ofWT1, were used to probe the blot for the presence
ofWTl.
In both E14 and K1 undifferentiated clones there is no detection ofWT1 protein
using either the C-19 or H2 antibody (Figure 5.5(a)). Following 96 hours of
differentiation with RA, two doublets, representing WT1, can be detected in the
E14 plus RA sample. These doublets arise from the alternative translation
initiation sites and the presence/absence of the 17 amino insert arising from the
alternative splicing of Exon 5. However in the lane containing protein from the
WT1 null cells (Kl) exposed to RA, there is no detection ofWT1 protein after
96 hours of induction using both the C-19 and H2 antibodies (Figure 5.5 (a) and
Figure 5.5 (b)). To ensure equal loading of the samples, the blots were reprobed
with an antibody for PI 16. This shows that each of the lanes was loaded with
approximately equal levels of nuclear protein. Therefore following induction by
RA, Kl does not produce any detectable levels ofWT1 protein as confirmed by
Western blot (Figure 5.5).
To verify the Western blot result, and to observe whole cells rather than nuclear
extract, E14 and Kl clones were grown on slides and either cultured in normal
ES cell media, or differentiated for 96 hours in the absence of LIF and in the
presence of RA. Cells were fixed, blocked and stained with both H2 and C-19
for immunofluoresence. In both undifferentiated clones there was no detectable
expression of WT1 (Data not shown). Following 96 hours treatment with RA,
approximately 70-80% of differentiated E14 (WT1+/+) cells expressed relatively
high levels of nuclear staining for WT1 (Figure 5.5 (c)). This is in contrast to
the differentiated Kl (WT1"7") cell where there was no detection of WT1, by
either C-19 or H2 antibodies (Figure 5.5 (c)). This confirms that Kl is an
authentic WT1 null ES clone.
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5.3 Morphology and Growth Rates
The suggested role for WT1 in cell proliferation and apoptosis prompted the
examination of the growth rates of the WT1 nullES cells in comparison to the
wild-type ES cells, in both the undifferentiated and RA differentiated states.
The growth rates of wild-type El4 ES cells (WT1+/+) and WT1 null ES (WTl"7")
cells (K1 and K46) were examined under culture conditions that maintain ES
cells in an undifferentiated state. Equal numbers of cells were seeded at low
densities in LIF containing medium, and cells were subsequently counted every
24 hours for a period of 96 hours. Counting of total cell numbers showed that, in
comparison to E14 cells, the WTE/_ cells proliferated normally when grown in
the presence of LIF (Data not shown). Morphologically, under these conditions
WT1""ES cells were indistinguishable from wild-type ES cells (Figure 5.7).
Also semi-quantitative RT-PCR analysis of Oct-4 expression, a key regulator of
pluripotency in ES cells, showed that both El4 and K1 expressed comparable
levels (Figure 5.16). Therefore in an undifferentiated state the loss ofWT1 has
no effect upon the normal morphology of embryonic stem cells.
In contrast to their normal behaviour in the undifferentiated state, WTE/_ ES
cells exhibited differences in cell number following treatment with RA. The cell
counts for E14 ES cells and WTl null ES cells (K1 and K46) were monitored
every 24 hours during the RA differentiation protocol (96 hours). The
experiment was carried out in triplicate for each of the clones, and was also
carried out on different passages of wild-type and WT1"7" cells (K1 and K46).
The data is presented in figure 5.6.
At 24 hours and 48 hours the cell counts were similar for both E14 and the two
WTE " ES cell clones. However by 72 hours there was an approximately 40%
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Figure 5.6 The Differentiation of WT1 Null ES Cells with RA Results in a Reduction of Cell Number Compared
with Wild-type ES Cells
4
a) E14 and K1 (WT1-/-) ES cells were seeded in triplicate wells at a density of 1x10 . Both clones were differentiated in the
absence of LIF and presence of 1 ^M RA. At 24 hour intervals, the total cell numbers for each clone were counted.
b) E14, K36 (WT1+/-), K1 and K46 (WT1-/-) were seed in triplicate wells at a density of 1x104. All clones were
differentiated in the absence of LIF and presence of 1 nM RA. After 96 hours, the total cell numbers for each
clone were counted.
Mean values from the triplicate experiments were plotted on the bar charts. Error bars correspond to +/- the Standard
Deviation of the Mean.
Undifferentiated
24 hrs + RA
48 hrs + RA
72 hrs + RA
96 hrs + RA
E14 (WT1 +/+) K1 (WT1 -/-)
Figure 5.7 WT1 Null ES Cells have Similar Morphologies to E14 ES Cells in both the Undifferentiated State and During RA
Differentiation
E14 and K1 ES cells were grown on coverslips and treated with RA for 96 hours. At 24 hour intervals, images were captured under
phase contrast (Magnification x 10)
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the wild-type ES cells. By 96 hours the difference between the RA treated WIT
/_ES cells and wild-type ES cells was around a 50 % reduction (Figure 5.7 (a)).
To ensure that the difference in cell number was not due to the effects of
sequential rounds of gene targeting in the production of the WT1""ES cells, a
WT1 heterozygote null ES cell clone (WTl+/~) was also assayed in the RA
differentiation protocol. The WT1+/" heterozygous null ES cell clone, K31, has
been through the sequential steps of gene targeting and Cre-mediated
recombination from the first round of gene targeting and has also been through
the second round of electroporation and selection with the pWTlKre plasmid.
Therefore, this clone has been selected and recloned to the same extent as K1
and K46, but was not correctly targeted with the pWTlKre targeting vector.
Analysis of the levels of WT1 protein by Western blot demonstrated that the
K31 cells expressed similar levels of protein as found in wild-type E14 ES cells
(Data not shown). This is in agreement with the situation in WT1 heterozygote
null mice in which WT1 is present at 95% of the level observed in wild-type
mice (Guo et al., 2002). Furthermore, the cell numbers for wild-type, WT1+/"
and WT1"" ES cells were counted following 96 hours ofRA differentiation. The
cell counts were similar for both the wild-type and WT1+/" clone, whilst there
was a 50% reduction in cell numbers for the WT1"" clones (K1 and K46)
(Figure 5.6 (b)). Therefore the reduction in cell number in WTr/_ ES cells is
likely to be a direct result of the absence ofWT1.
The dramatic reduction in cell numbers observed during the differentiation of
the WT1 null ES cells could reflect the loss of a particular lineage. Elowever,
the analysis of the morphologies of E14 and K1 ES cells every 24 hours during
the differentiation protocol demonstrated that there was no obvious differences
(in absence or presence of particular morphologies) represented in the two
cultures across the time course (Figure 5.7).
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5.4 Affymetrix Microarray Analysis
To analyse gene expression profiles of differentiating ES cells associated with
WT1 loss-of-function, the Affymetrix Mouse Gene Chip U74A array was used.
This array contains oligonucleotide probes specific for 6,000 known mouse
genes present in the Mouse UniGene database, and 6,000 EST sequences. The
expression profiles of the wild-type ES cells (El 4) and one of the WT1 null ES
cell lines (Kl), was analysed at various time points in the RA differentiation
protocol. The time points chosen for microarray analysis were (1) E14 and Kl
ES cells in an undifferentiated state, (2) El4 and Kl ES cells differentiated for
48 hours with RA, and (3) E14 and Kl ES cells differentiated for 96 hours with
RA.
In the undifferentiated state, there is no detectable expression of either WT1
RNA or protein in wild-type ES cells (Chapter 4, Figure 4.2). Therefore any
differences in gene expression detected between El4 and Kl in the absence of
RA exposure can be attributed to the effects of manipulation of the ES cells
through gene targeting and subsequent passages in vitro, rather that an effect of
the ablation ofWT1. The next time point taken for analysis was RNA collected
after 48 hours of differentiation with RA. This time point was chosen because in
wild-type ES cells differentiated with RA, WT1 RNA is first detected after 48
hours. This sample would allow the analysis of genes that are effected
immediately by the absence of WT1. Added to this is the analysis of the cell
numbers after 48 hours of RA differentiation. At this time point, the cell counts
between both El4 and Kl clones is similar. Therefore microarray analysis of
this sample may indicate specific changes in gene expression, pointing towards
any early cellular changes occurring in the Kl ES clone in comparison to the
El4 ES clone. The final time point for analysis was RNA collected from the two
ES clones following 96 hours treatment with RA. At this time point, 80% of
wild-type ES cells are expressing high levels of WT1, and this represents the
final point of the differentiation protocol.
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For each time point, the experiment was carried out in triplicate. ES cells, E14
and Kl, were seeded at equal concentrations and treated with RA for up to 96
hours. One RNA sample from each time point was sent for microarray analysis,
whilst the duplicate samples were stored for verification of the findings from the
arrays. Microarray hybridisations were carried out by Dr. Kevin Robertson at
the Genomic Technology and Informatics (GTI), Ehiiversity of Edinburgh.
5.4.1 Normalisation of Arrays
The Affymetrix GeneChip arrays were scanned and analysed with Affymetrix
MAS 5.0 software to identify transcripts that were classified as being absent,
present or marginal. In addition to the unique probes present on the arrays, each
array contains control probes (such as GAPDH) that control for the quality of
the biotinylated RNA samples and hybridisation protocol. Based upon the
hybridisation to the control probes, all of the 6 chips were of comparable quality
(Data not shown). Next the expression data obtained from the 6 arrays was
normalised to adjust the individual hybridisation intensities. In doing this, it
permits meaningful comparisons to be made between the different RNA
samples (Dr Kevin Robertson, personal communication).
5.4.2 Gene Expression Profiles of E14 and E14 Differentiated ES
Cells
The differences in gene expression profiles between undifferentiated El4 ES
cells and El4 cells treated with RA for 48 hours and 96 hours, were first
analysed by scatter plot analysis. This graphical representation gives an idea of
the global similarities or differences between the two RNA samples. In this
representation, each point on the graph represents a single annotated gene or
EST on the U74A array. The location of the point on the scatter plot is
determined by the difference of signal intensity of this transcript from one RNA








Figure 5.8 Scatter Plot Analysis of the Gene Expression Profiles of Wild-type E14 ES cells
Treated with RA for 48 Hours and 96 Hours
a) Undifferentiated E14 ES cells compared to E14 ES cells differentiated for 48 hours with RA
b) Undifferentiated E14 ES cells compared to E14 ES cells differentiated for 96 hours with RA
Each point represents the normalised expression level of an individual transcript within both RNA
samples. Yellow points denote transcripts that are not expressed in either RNA sample, blue
represents transcripts that are absent in one of the two samples, whilst red points denote transcripts
which are present in both samples.
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undifferentiated El4 ES cells versus El4 ES cells treated with RA for 48 and 96
hours. The signal intensities of the array for RNA collected from
undifferentiated E14 ES cells (X axis) is compared to the signal intensities
obtain from the array for RNA collected from E14 ES cells treated for 48 hours
with RA (Y axis). The distance that a point lies away from the midline (marked
in black) represents the differential expression of a gene between two sample
RNA populations. For example, a point that lies close to the midline represents
a gene that is expressed at similar levels in the two RNA populations, whilst a
point that lies further away from the line denotes a gene which is differentially
expressed between the two RNA populations. The position of a point along the
length of the line represents its level of expression in relation to other genes.
The points on the scatter plot are also colour coded. Red points represent
transcripts that are classified as being present in both RNA samples. Blue points
represent transcripts that the Affymetrix software has classified as being
marginal, in that the software can not determine whether the transcript has
hybridised to the array or not. Finally, yellow points denote transcripts that are
not expressed in the two samples.
Comparison of the scatter plot analysis of the gene expression between El 4 ES
undifferentiated and El4 ES after 48 hours and El4 ES after 96 hours of RA
treatment demonstrates that the distribution of points grows wider as ES cells
differentiate under the influence of RA (Figure 5.8). This reflects the global
change in gene expression as the homogenous ES cells differentiate to various
lineages. To begin to analyse the data sets, an arbitrary value of fold changes of
2.5 or greater was chosen to represent genes that are differentially expressed
between two samples. This value was used in all comparisons throughout the
remainder of this chapter. Using this criterion, 842 genes were differentially
expressed by 2.5-fold or greater between E14 ES cells and E14 ES cells
differentiated with RA for 96 hours.
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5.4.3 Genes Down-Regulated Following RA Differentiation of E14
ES Cells
Of the 842 genes differentially regulated in this system, 332 genes were down-
regulated during the differentiation of E14 ES cells. Figure 5.9 represents the
top 25 transcripts, ranked with regards to their fold change, that were detected
as being present in the E14 ES cells in an undifferentiated state, and then absent
in the E14 cells differentiated for 96 hours with RA. Therefore, the list
represents genes whose expression is restricted to undifferentiated ES cells, and
hence maybe associated with ES cell pluripotency. Among these transcripts are
genes known to be crucial regulators of pluripotency in ES cells including Oct-4
(136-fold decrease), Rex-1 (34-fold decrease) and UTF-1 (66-fold decrease), a
downstream target of Oct-4 (Nichols et al., 1998; Ben-Shushan et al., 1998;
Okuda et al., 1998; Nishimoto et al., 1999). The down-regulation of Oct-4
observed in the Affymetrix analysis confirms the RT-PCR data for Oct-4 as
described in Chapter 4.
The transcript with the highest fold change was Embryonic stem cell specific 1
(Esg-1), a gene with no known sequence homologies or function. This gene was
down-regulated by 209-fold in the E14 ES cells differentiated with RA for 96
hours, indicating that this gene maybe associated with ES pluripotency.
Previously this gene was described as being down-regulated during retinoic acid
differentiation of embryonic carcinoma (EC) cells, and also expressed uniquely
in ES cells and pre-implantation embryos (Astigiano et al., 1991; Bierbaum et
al., 1994). The recent work using Affymetrix Genechip arrays on a variety of
stem cells populations identified genes that were enriched in embryonic stem
cells (Santos et al., 2002). When the genes were ranked in accordance with their
enrichment, the top ranking transcript, even more abundant than Oct-4, was
Embryonic stem cell specific 1 (Esg-1) (Santos et al., 2002). Recent work on
the gene expression profile of murine ES cells, extraembryonic-restricted
trophoblast stem cells and terminally differentiated embryonic fibroblast cells,
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Figure 5.9 Top 25 Transcripts Down-Regulated During RA Differentiation of E14 ES cells
The top 25 down-regulated transcripts, which were present in undifferentiated E14 ES cells and
absent in RA treated ES cells following 96 hours, were ranked according to their fold-change.
Included is their colour-coded fold-change decrease following 48 hours of treatment with RA.
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(Tanaka et al., 2002). Data presented by the authors indicated that Esg-1 may lie
downstream of the LIF-Stat3 and Oct3/4 pathways (Tanaka et al., 2002).
As discussed above, Oct-4, Rex-1 and UTF-1 represent genes which are known
to be crucial regulators of ES cells pluripotency, whilst Esg-1 represents a novel
gene that may also be involved in this process. In the top 25 down-regulated
genes, there is also an EST (AV352144) which is down-regulated 90-fold
during the differentiation of ES cells. A BLAST search against the murine
database indicates that this EST has no know annotated gene, however it does
contain a region of homology with human Nkx2.5 domain. This transcript may
belong to the same family of proteins as EHOX, a recently isolated novel paired
like homeobox containing gene (Jackson et al., 2002). The EST has been
detected in libraries derived from ES cells, testis, morula, blastocyst and gonad,
and therefore represents a novel EST that is enriched in stem cell lineages.
Present in the list of transcripts are genes that have not been previously
associated with ES cells pluripotency (Figure 5.9).
5.4.4 Genes Up-Regulated Following RA Differentiation of E14 ES
Cells
Of the 842 genes that were differentially expressed in this system, 510 were up-
regulated during the differentiation of E14 ES cells. The top 30 transcripts,
ranked in order of their fold change, are shown in Figure 5.10. Some of these
transcripts represent direct targets of the retinoic acid pathway, or are involved
in the regulation/modulation of retinoic acid signalling, including plasminogen
activator (19-fold increase) (Chen and Gudas, 1996) and cytochrome P450 26
retinoic acid Al (Cyp26Al) (10-fold increase) (Freemantle et al., 2002). Present
in the list of the 30 induced transcripts are several markers of neuronal lineages.
Soxll, in vivo, is expressed predominantly in the neural epithelium of the
central nervous system (Uwanogho et al., 1995; Hargrave et al, 1997). Ephrin
B1 is expressed in the developing brain, where it has been
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Figure 5.10 The Top 30 Transcripts Up-Regulated During RA Differentiation of E14 ES cells
The top 30 transcripts which were up-regulated during the RA differentiation of E14 ES cells were
ranked in order of there fold change at 96 hours. Included is their colour coded fold-change increase
following 48 hours of treatment with RA.
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implicated in axonal pathfinding during the formation of neuronal networks
(For review see Mellitzer et al., 2000; Moreno-Flores et al, 2002), whilst
Peripheral Myelin Protein (PMP22) encodes a protein component of the myelin
sheath of peripheral nerves (Jetten and Suter, 2000). The up-regulation of
neuronal markers seen here is consistent with the findings from the RT-PCR
analysis in Chapter 4, which showed an increase in expression of additional
neuronal markers, namely nestin and Pax6.
Additionally, in the list of transcripts induced by RA are transcripts which show
a mesodermal/mesenchymal expression in vivo. This includes the Drosophila
Twist gene homologue (13-fold increase) which is expressed in head
mesenchyme, somites and limb buds, and is required for the development of
these structures (Wolf et al., 1991; Chen and Behringer, 1995) and vascular
smooth muscle alpha-actin (13-fold increase). There are also transcripts which
have a diverse expression pattern in vivo including Dlkl (30-fold increase), an
inhibitor of adipogenesis that also regulates embryonic pancreas formation and
differentiation of beta-cells (Carlsson et al., 1997) and T-Box2 (Tbx2) (12-fold
increase) which is expressed primarily in kidney, lung, and placenta (Campbell
et al., 1995).
Several genes encoding for transcription factors or DNA binding factors are up-
regulated in the E14 differentiated cells. The expression of the AP-1 component,
c-Jun, is increased 14-fold during the differentiation of ES cells. This induction
is in agreement with the reports of c-Jun induction in RA differentiation of EC
cells and ES cells (Pankov et al., 1994; Kelly and Rizzino, 2000). c-Jun has
been shown to activate a number of lineage specific genes, including vimentin.
An up-regulation of vimentin was seen in the Affymetrix arrays during the
differentiation process, and antibody staining in Chapter 4 demonstrated that the
majority of vimentin positive differentiated ES cells co-expressed WT1.
Another gene up-regulated was the high mobility group protein 1 (HMG-1) (34-
fold). HMG-1 belongs to a family of highly conserved chromatin-associated
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nucleoproteins that bend DNA and facilitate the binding of various transcription
factors to their cognate DNA sequences (Jayaraman et al., 1998).
By 96 hours there is a 10-fold induction in the levels ofWT1. Across the time
points taken, there is a gradual increase in the levels ofWT1 expression, from
undetectable expression in the undifferentiated state, to a 4-fold induction at 48
hours and finally a 10-fold induction by 96 hours. This induction pattern of
WT1 observed in the Affymetrix array data is in agreement with the RT-PCR
data presented in Chapter 4 showing the expression profile ofWT1 RNA.
In summary, the up-regulation of genes from multiple lineages following RA
mediated differentiation of ES cells suggests that the effects of RA are quite
heterogeneous (Figure 5.10). Whilst previous reports have suggested that RA
directs ES cells towards a predominantly ectodermal fate (Bain et al., 1995, For
review see Guan et al., 2001), this more extensive preliminary study using
Affymetrix Genechip microarrays suggests that other lineages, such as
mesoderm may be present in the monolayer cultures. However the strong up-
regulation of WT1 following RA induction makes this system ideal to
investigate the effects of WT1 loss-of-function on gene expression, and to
identify candidate WT1 regulated genes.
5.5 Comparison of Gene Expression Profiles between
K1 and E14 ES Cells
5.5.1 Undifferentiated E14 and K1 ES Clones
In comparing the gene expression profiles of the two clones from the three time
points (0, 48, 96 hours) the data from the Affymetrix Genechip arrays were first
analysed using scatter plot analysis. In the undifferentiated state, the scatter plot
analysis reveals a very tight distribution pattern along the midline. This
indicates that the expression profile of the majority of genes is unchanged
144
E14 Undifferentiated
Figure 5.11 Scatter Plot Analysis of the Gene Expression Profiles of E14 and K1 ES Cells in an
Undifferentiated State Indicates that the Samples have Similar Gene Expression Profiles
Each point represents the normalised expression level of an individual transcript within both RNA
samples. Yellow points denote transcripts that are not expressed in either sample, blue represents
transcripts that are absent in one of the two samples, whilst red points denote transcripts which are
present in both samples.
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between E14 and K1 in the undifferentiated state (Figure 5.11). Although there
were some differences between E14 and K1 ES cells in the undifferentiated
state, there was no difference in the levels of expression of the key genes
associated with ES cell pluripotency e.g. Oct-4, UTF-1, Rex-1. This indicates
that the absence of WT1 has no affect upon the normal physiology of
undifferentiated ES cells. This agrees with the findings described in section 5.3,
in that the gross analysis of the WT1 null ES cells demonstrates that they have
similar morphology and growth rates.
5.5.2 E14 and K1 ES Cell Clones at 48 hours of Differentiation
As with the comparison of gene expression profiles of the clones in an
undifferentiated state, the scatter plot analysis after 48 hours of treatment with
RA also reveals a tight distribution pattern of transcripts along the midline
(Figure 5.12). This indicates the gene expression profiles at 48 hours is again
highly similar between the two clones. At 48 hours there were 61 genes which
were differentially expressed 2.5-fold or more between E14 and K1 (Figure
5.13). Green represents the transcripts that are up-regulated in the K1 clone in
comparison to the El4 clone, whilst red depicts transcripts which are down-
regulated in the K1 clone in comparison to the El4 clone. White denotes
transcripts that have not changed between the two clones. Of the 61 transcripts,
24 were down-regulated, and 34 transcripts up-regulated in the K1 clone in
comparison to the E14 clone. From this list of 61 transcripts, 27 represent ESTs
with little or no known homologies.
5.5.3 E14 and K1 ES Cell Clones at 96 hours of Differentiation
Scatter plot analysis of the RNA samples collected after 96 hours of treatment
with RA indicated that the gene expression profiles between the two clones was
again highly similar (Figure 5.14). This was also supported by the fact that only
41 genes were differentially expressed 2.5-fold or more between the two
samples (Figure 5.15). Of the 41 transcripts, 17 genes were up-regulated and 24
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Figure 5.12 Scatter Plot Analysis of the Gene Expression Profiles of E14 and K1 ES Cells Treated
with RA for 48 Hours Indicates that Both Clones have Similar Gene Expression Profiles
Each point represents the normalised expression level of an individual transcript within both RNA
samples. Yellow points denote transcripts that are not expressed in either sample, blue represents
transcripts that are absent in one of the two samples, whilst red points denote transcripts which are
present in both samples.
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Figure 5.13 Transcripts Differentially Expressed at 48 hrs in the K1 (WT1-/-) ES clone
Transcripts which were up-regulated (green) or down-regulated (red) by 2.5 fold or greater in the K1 ES
clone following 48 hours of RA treatment, were ranked according to their fold-changes. Their fold-change
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Figure 5.14 Scatter Plot Analysis of the Gene Expression Profiles of E14 and K1 ES Cells
Treated with RA for 96 hours, Indicates that Both Clones have Similar Gene Expression
Profiles.
Each point represents the normalised expression level of an individual transcript with both
RNA samples. Yellow points denote transcripts that are not expressed in either sample, blue represents
transcripts that are absent in one of the two samples, whilst red points denote transcripts which are
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Figure 5.15 Transcripts Differentially Expressed at 96 hours in the K1 (WT1-/-) ES clone
Transcripts which were up-regulated (green) or down-regulated (red) by 2.5 fold or greater in the K1 ES
clone following 96 hours of RA treatment, were ranked according to their fold-change.Their fold-change at
48 hours is also shown.
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were down-regulated in the K1 sample compared to the El4 sample. The
majority of the transcripts are annotated genes, with only 7 representing
unknown ESTs.
5.5.4 Differentially Expressed Transcripts in the WT1 Null ES
Cells
Overall there were 102 transcripts differentially expressed between the WT1
null ES cells and the wild-type ES cells at the two time points analysed. From
this list, it is apparent that there are obvious alterations in the expression profiles
of specific gene families. Also there are appears to be equal numbers of genes
differentially up-regulated or down-regulated across the two time points in the
WT1 null ES cells, indicating that WT1 could be acting as a transcriptional
activator as well as a transcriptional repressor in the regulation of these
candidate target transcripts. Some of the transcripts from the list are discussed in
context with a possible physiological relevance to WT1.
5.5.4.1 Cellular Stress
In considering the transcripts that are differentially expressed, it would appear
that the K1 clone maybe exhibiting a response to some form of cellular stress.
Although both clones exhibit similar cell counts at 48 hours, rapid cellular
changes must be occurring over the next 24 hours, as by 72 hours there is a 50%
reduction in the cell numbers in the K1 clone. The up-regulation in expression
of the following genes, Bcl-2 associated athanogene 3 (BAG-3) (4-fold), DNA-
PKcs (3.6-fold) and Hsp70 (2.7-fold), at 48 hours suggests that the K1 ES cells
may be undergoing some form of cellular stress.
BAG-3 belongs to a family of proteins which participate in a wide variety of
cellular processes including cell survival (stress response) and apoptosis (Doong
et al., 2002). Over-expression of BAG-family proteins is found in several
cancers, and has been demonstrated to enhance cell survival and proliferation
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(Liao et al., 2001). Each member contains at least one evolutionary conversed
domain, a BAG domain (Doong et al., 2002). The anti-apoptotic activities of
BAG-family proteins are dependent on their interactions with the heat shock
protein 70 or binding to Bcl-2. Heat shock proteins are a highly conserved
family of molecular chaperones with diverse functions, including mediating
protein folding and degradation, transport across cellular membranes, and
assembly into macromolecular structures (Maheswaran et al., 1998). HSP-70
and its constitutive form, HSC-70, are molecular chaperones activated by varied
cellular stresses (For review see Hartle, 1996). DNA-PKcs is a DNA-dependent
protein kinase (DNA-PK) that is essential for the repair of DNA double-strand
breaks that form in cells that have undergone some form of stress e.g irradiation
(For review see Lee and Kim, 2002).
Nedd4 and annexin XI are also differentially expressed between the El4 and K1
ES clones. Nedd4 (Neural precursor cell Expressed Developmentally
Downregulated) was down-regulated 3.2-fold at 48 hours and up-regulated by
6-fold following 96 hours of treatment with RA in the K1 ES cell. Nedd4 was
originally identified as being down-regulated during development of the mouse
brain (Kumar et al., 1992). Subsequently, it has been demonstrated that Nedd4
is expressed in many other tissues and cell types (Kumar et al., 1997). The
Nedd4 gene encodes an evolutionarily conserved ubiquitin-protein ligase. In
addition to an ubiquitin-protein ligase domain, the Nedd4 protein contains a
multiple WW domain and a calcium/lipid domain (Kanelis et al., 2001).
Through its WW domain, Nedd4 has been shown to interact with the epithelial
sodium channel subunits, the haematopoetic transcription factor p45 and RNA
polymerase II (Gavva et al., 1997). Its interaction with these proteins partners
probably mediates their turnover via ubiquitin-mediated pathways. Therefore,
the role of Nedd4 may be to regulate a number of cellular proteins through
ubiquitination. It has also been reported that Nedd4 is specifically cleaved by
caspases during apoptosis (Harvey et al., 1998). The significance of this
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cleavage during apoptosis is unclear, however the function of Nedd4 may be
required for the regulation of a protein(s) that are required for apoptosis.
Annexin XI was up-regulated at 48 hours and also 96 hours in the K1 clone. An
early event in apoptosis is the loss of membrane asymmetry of phospholipids
(For review see Hacker, 2000). Annexin XI belongs a family of calcium-
dependent phospholipid-binding proteins. Annexins are commonly used to
detect apoptosis in cells, and therefore the up-regulation of this transcript may
indicate the onset of apoptosis.
Therefore, in the K1 clones there is an increase in transcripts involved in cell
survival, and also transcripts that may indicate the onset of apoptosis.
5.5.4.2 Retinoid Synthesis
WT1 null ES cells display differential expression of two genes involved in the
in vivo regulation of retinoic acid synthesis. Cellular retinoic acid binding
protein II (CRABP-II) was up-regulated 3.7-fold in the K1 clone at 96 hours.
Cellular retinoic acid-binding proteins, CRABPs, are encoded by two distinct
transcriptionally regulated genes that produce two highly conserved proteins,
type I and II CRABP (CRABP-I and II) (Ruberte et al., 1992; Lampron et al.,
1995). These two proteins differ in their tissue expression, as well as in ligand
binding affinities. CRABP-II is expressed in the developing kidney, brain,
spinal cord, stomach and limbs (Ruberte et al., 1992; Ruberte et al., 1993). In
the kidney, at E10.5, CRABP-II is expressed in the developing mesonephros,
whilst at E12.5, it is expressed in the developing metanephros. By E14.5 it can
be detected in both the developing nephrons and surrounding stromal cells
(Ruberte et al., 1992). In the developing spinal cord at El0.5, CRABP-II was
detected in the neuroepithelium and also in the differentiating motor neurons
(Ruberte et al., 1993). It has been proposed that CRABPs have multiple RA-
related functions, including sequestering RA to lower functional intracellular
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pools, transporting RA to nuclear receptors, and mediating RA metabolism to
lower RA levels below teratogenic concentrations (Lampron et al., 1995;
Ruberte et al., 1992). However, the actual function of CRABPs remains unclear
as the double mouse knockouts of CRABP-I and CRABP-II are normal,
indicating that CRABPs are dispensable in vivo for the control/modulation of
RA during murine embryogenesis (Lampron et al., 1995). In relation to WT1
and Wilms' tumour biology, in the analysis of gene expression in Wilms'
tumours with Affymetrix Gene chip arrays, identified CRABP-II as being up-
regulated (Li et al., 2002).
RALDH-2 was down-regulated by 2.7-fold at 48 hours and 3-fold at 96 hours in
the K1 ES cell clone. The RALDH2 gene encodes a protein that is crucial for the
in vivo synthesis of RA. Retinoic acid, the active derivative of vitamin A
(retinol) is generated through two steps. The first step is the oxidisation of
retinol to retinaldehyde, which is carried out by alcohol dehydrogenases
(ADH1, ADH3 and ADH4). The second step is the oxidation of retinaldehyde
to RA, which is carried out by retinaldehyde dehydrogenases (RALDH1,
RALDH2 and RALDH3). Genetic analysis of enzymes regulating RA synthesis
indicates that retinol is ubiquitously oxidised to retinal by alcohol
dehydrogenases (Molotkov et al., 2002), whilst retinal is tissue-specifically
oxidised to RA by retinaldehyde dehydrogenases (Niederreither et al., 1999).
RALDH2 has been shown by in situ hybridisations and enzymatic studies to be
the prominent RALDH involved in early mouse embryogenesis (Niederreither
et al., 1997; McCaffery et al., 1995). RALDH2 is expressed from around E7.5
in trunk mesoderm, with additional expression by E8.5 in the optic vesicles
(Niederreither et al., 1997). Other sites of expression for RALDH2 is primarily
in the mesodermal derivatives including somites, flank mesoderm, posterior
hindbrain mesenchyme, and posterior heart mesoderm (Niederreither et al.,
1997; Niederreither et al., 2002). Expression is also present in the nephrogenic
zone of the kidney, and also in the motor neurons of the spinal cord
(Sockanathan and Jessell, 1998; Haselbeck et al., 1999; Niederreither et al.,
154
Chapter 5 Generation ofWT1 Null Embryonic Stem Cells
2002). Knockout of the RALDH2 gene results in early embryonic lethality
(E9.5-E10.5), with the ablation of RALE1D2 resulting in an almost total lack of
retinoic acid synthesis (Niederreither et al., 1999). RALDH2 knockout mice
exhibit major patterning defects along the anteroposterior body axis and
developing hindbrain, and also defects in the development of the heart
(Niederreither et al., 1999; Niederreither et al., 2001).
5.5.4.3 IGFBPs and the CCN Family of Proteins
IGFBP-5 showed a 3.7-fold down-regulation in expression in the WT1 null ES
cells at 48 hours and a 3.2-fold down-regulation at 96 hours. IGFBP-5 belongs
to the Insulin Like Growth Factor Binding Protein (IGFBP) family. Insulin-like
growth factors (IGFs) play a pivotal role in tissue homeostasis, regulating cell
proliferation, differentiation and migration during development and in the adult.
The actions of IGFs are modulated by high affinity interactions with a family of
structurally related IGF-binding proteins, IGFBP-1 to IGFBP-6 (For review see
Jones and Clemmons, 1995). IGFBPs are known to regulate the bioavailability
of IGFs in the circulation; however, their functions at the cellular level are not
fully understood. IGFBPs have been reported to both inhibit and enhance IGF-I
action depending on the system employed (For review see Jones and
Clemmons, 1995). IGFBP-5 has been shown to be involved in the regulation of
several physiological processes in the ovary and kidney (Kelley et al., 1996).
Particularly in the kidney, IGFBP-5 was isolated in a screen for genes changing
during mesenchymal-epithelial transition in the developing metanephric
mesenchyme, a process characterised by up-regulation of WT1 (Plisov et al.,
2000). During this developmental process, IGFBP-5 expression increased. Also,
the screening of gene expression in Wilms' tumours containing decreased WT1
exon 5 +/- isoform ratios with cDNA macroarrays demonstrated that IGFBP-5
was down-regulated (Baudry et al., 2002). In the ES cell differentiation system,
loss-of-function for WT1 results in a decrease in expression of IGFBP-5.
Therefore, this correlates well with a potential regulation of IGFBP-5 by WT1.
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WISP-1 was down-regulated 2.8-fold at 48 hours. WISP-1 is a member of the
CCN family, which also includes connective tissue growth factor (CTGF),
Cyr61 and Neproblastomas overexpressed (Nov). These proteins are cysteine-
rich, secreted proteins associated with the extracellular matrix. Several members
of the CCN family have been shown to support cell adhesion, induce focal
adhesion complexes and stimulate adhesive signalling (Kireeva et al., 1996;
Chen et al., 2001). One of the features of the CCN family of proteins is that all
contain a domain that has homology to insulin-like growth factor binding
proteins (IGFBPs). WISP-1 (Wnt-1 induced secreted protein 1) was originally
identified in a differential screen for genes that were induced by Wnt-1 (Pennica
et al., 1998). Subsequently, it has been shown that WISP-1 is a (3-catenin-
regulated oncogene that can contribute to tumourigenesis (Xu et al., 2000).
Over-expression ofWISP-1 in a normal rat kidney fibroblast cell line results in
morphological transformation, accelerated cell growth and enhanced saturation
density. When these WISP-1 over-expressing cells were injected into nude
mice, they readily formed tumours (Xu et al., 2000). WISP-1 has also been
shown to be aberrantly expressed in both mammary tumours and colon cancer
(Pennica et al., 1998). Interestingly two other members of the CCN family, Nov
and CTGF, have both been reported to be regulated by WT1 (Martinerie et al.,
1996; Stanhope-Baker and Williams, 2000).
5.5.4.4 Genes Involved in Kidney Development
There was an 8-fold reduction in the levels of Wnt-4 at 96 hours in the RA
treated K1 ES cells. The Wnt-4 gene encodes a protein belonging to the Wnt
gene family of secreted glycoproteins. Wnt-4 is expressed in the metanephric
mesenchyme of the kidney and its derivatives (Stark et al., 1994). Expression is
initiated in the aggregating mesenchyme that surrounds the invading ureteric
bud at El 1.5. Wnt-4 expression is maintained in the comma-shaped bodies, but
later becomes restricted to the S-shaped bodies. There is also expression in
domains outside the kidney, including the dorsal spinal cord, floor plate,
pituitary gland, mammary gland and female gonads (Parr et al., 1993; Vainio et
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al., 1999). Deficiency in Wnt-4 results in abnormal development of the kidney,
pituitary gland, female reproductive system, and mammary gland (Stark et al.,
1994; Vainio et al., 1999; Heikkila et al., 2002). The finding that Wnt-4
expression decreases on loss-of-WTl is particularly interesting because Wnt-4
is believed to be involved in regulating the mesenchymal-epithelial transition
involved in nephron differentiation, and this process fails in Wnt-4 null mice
(Stark et al., 1994). Recently, evidence for Wnt-4 being a potential WT1 target
gene has been described using transfection of a dominant-negative WT1 variant
into the Ml5 cells (Sim et al., 2002).
Brain factor-2 (BF-2) or FoxDl demonstrated a 3.7-fold reduction in expression
in the K1 ES cell at 96 hours. BF-2 belongs to the family of winged helix
transcription factors, which all share an evolutionarily conserved DNA binding
domain (Lai et al., 1993). In the mouse, BF-2 has a neuronal and mesenchymal
expression pattern. In the nervous system, BF-2 is expressed predominantly in
the diencephalon (Hatini et al., 1994). Mesenchymal expression is detected in
the mesenchyme of the head, the metanephric mesenchyme of the developing
kidney and also cortex of the adrenal gland (Hatini et al., 1994). Expression has
also been reported in the testis (Pierrou et al., 1994). In the kidney, BF-2 is first
expressed in El 1.5 metanephric mesenchyme. Its expression marks a population
of cells that are peripheral to the condensing mesenchyme around the tips of the
invading ureteric bud that gives rise to nephrogenic lineages. Therefore, BF-2
expression indicates an early step in the partitioning of the metanephric
mesenchyme into stromal and nephrogenic lineages. A mouse knockout of BF-2
has been generated and there are defects observed in two components of the
kidney; the ureteric bud epithelium and the nephrogenic mesenchyme (Hatini et
al., 1996). The ureter and the collecting system are smaller and the
differentiation of the metanephric mesenchyme to nephrons is inhibited. The
kidneys of BF-2 null mice are hypoplastic, fused longitudinally and exhibit
short ureters (Hatini et al., 1996). They also exhibit decreased branching
morphogenesis and are arrested in the mesenchymal-epithelial transition, with
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large mesenchymal aggregates present. Given that BF-2 is not expressed in the
nephrogenic mesenchyme of the kidney, nor in the epithelia of the nephron
intermediates, it seems likely that the BF-2 transcription factor regulates the
expression of a stromal secreted molecule which in turn regulates the
differentiation of the nephrogenic lineages.
Sprouty-4 demonstrates 3.3-fold down-regulation in the WT1 null ES cells after
48 hours. The first Sprouty gene was identified in Drosophila as a regulator of
branching morphogenesis in the trachea, where it acts as an antagonist to
fibroblast growth factor signalling pathways (Hacohen et al., 1998). Further
analysis has shown that it acts as an antagonist of epidermal growth factor, as
well as the FGF signalling pathway (Reich et al., 1999). To date, four Sprouty
genes have been identified in mouse, with each shown to possess distinctive
overlapping expression patterns (Minowada et al., 1999; Zhang et al., 2001).
Sprouty-4 has a mainly neuronal and mesenchymal expression pattern, with
expression detected in the cerebellum, spinal cord and ganglia, lung, nasal
mesenchyme, digestive tract, limb buds and kidney (Minowada et al., 1999;
Zhang et al., 2001). In the developing kidney, Sprouty-4 is expressed in the
ureteric bud and the metanephric mesenchyme at around E10.5, whilst at E14.5
it is expressed in the developing glomeruli (Zhang et al., 2001).
5.5.4.5 Other Transcripts
Peripherin was represented twice on the Affymetrix Genechip array, once as an
annotated transcript, the other as an EST entry. At 48 hours, both entries for
peripherin demonstrated similar values of fold change, with a 3.3-fold and 3.1-
fold up-regulation in the K1 ES clone. At 96 hours both entries for peripherin
also show an up-regulation, with a 4.3-fold and 9.1-fold change. Peripherin is a
type III neuron specific intermediate filament protein, that is primarily
expressed in the peripheral nervous system and only at low levels in defined
neuronal populations of the central nervous system (Troy et al., 1990; Escurat et
al., 1990). Peripherin expression is first detected at E9 in the mouse, with
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expression detected in the myelencephalon (Troy et al., 1990). Between E9.5-
E12 of mouse embryogenesis, expression of peripherin can be detected in the
developing motor neurons of the ventral neural tube and also the developing
dorsal root ganglia (Troy et al., 1990). In Chapter 4, WT1 expression was
detected in the developing motor neurons in the neural tube, and therefore WT1
may act to regulate its expression in these domains.
CYP1B1 was down-regulated 3.7-fold at 48 hours and 3.2-fold at 96 hours in
the K1 ES cells treated with RA. CYP1B1 is a member of the cytochrome P450
multigene superfamily of proteins, which are enzymes involved in the
metabolism of a wide range of structurally diverse substrates (For review see
Stoilov et al., 2001). Cytochrome P450 (CYP) proteins are ubiquitous in nature,
appearing in almost all phyla, with each isoform exhibiting distinct temporal
and spatial expression patterns during embryogenesis (Stoilov et al., 2001).
From the study of numerous identified isoforms of cytochrome P450 during
embryogenesis, it has been proposed that their function is to serve as facilitators
of morphogenesis in the embryonic tissues (Stoilov et al., 2001). The
cytochrome P450 isoforms may either function to generate morphogenic
molecules or to keep regions free of them, thereby creating temporal and spatial
regions of morphogen action to support region-specific changes in cells.
CYP1B1 has a pattern of expression that differs from the other two CYP1
family P450s (CYP1A1 and CYP1A2); it is expressed constitutively in
steroidogenic tissues like the adrenal gland, ovary, and testes, and is inducible
by adrenocorticotropin, cAMP, peptide hormones, and aryl hydrocarbon
receptor ligands (Zhang et al., 1998; Buters et al., 1999). CYP1B1 is also
expressed in steroid-responsive tissue such as the uterus, kidney, breast, and
prostrate (Savas et al., 1994; Buters et al., 1999). The conservation of CYP1B1
and its expression in reproductive tissue would suggest that it has an important
developmental or physiological role in mammals. However, the precise role of
CYP1B1 in fertility and reproduction is unclear as a mouse knockout of
159
Chapter 5 Generation ofWT1 Null Embryonic Stem Cells
CYP1B1 has no gross phenotype and homozygous CYP1B1 null mice develop
normally and are fertile (Buters et al., 1999).
Mutations in the CYP1B1 gene have been demonstrated to be the common cause
of human primary congenital glaucoma (Stoilov et al., 1997). These mutations
are thought to generate a null allele of CYP1B1. Primary congenital glaucoma
(PCG) is an autosomal recessive eye disorder that is believed to arise from
development defects in the anterior eye segment. Closer analysis of the
CYP1B1 knockout mice demonstrates that the CYPlBE'mice have ocular
drainage structure abnormalities resembling those reported in human PCG
patients (Libby et al., 2003). The possible regulation of CYP1B1 by WT1, and
its link to ocular disorders, is intriguing, given that patients with Wilms' tumour
are at an increased risk for developing ocular disorders including aniridia and,
less frequently, optic nerve hypoplasia (Nelson et al., 1984; Bickmore and
Hastie, 1989). These eye abnormalities in Wilms' tumour patients are thought to
result from concomitant disruption of the aniridia gene PAX6, which lies
telomeric of WT1 on human chromosome 1 lpl3 (Ton et al., 1991). However
ocular defects have been recently described in the WT1 null mice (Wagner et
al., 2002).
5.5.6 Verification of Microarrays
Examining the list of differentially expressed genes that were down-regulated in
the K1 clone array, Wnt-4 and BF-2 were chosen to verify the finding of the
microarrays. Wnt-4 was down-regulated 8-fold in the K1 clone, whilst BF-2
exhibited a 3.7-fold reduction in levels of expression compared to the wild-type
ES cell after 96 hours. Semi-quantitative RT-PCR was carried out for BF-2 and
Wnt-4 on replicate samples of RNA collected from the original differentiation
of E14 and K1 ES cells described in section 5.4. Also, to ensure that the down-
regulation ofBF-2 and Wnt-4 was not a clonal artifact, RNA was collected from
the differentiation of the second WT1 null clone, K46, following 96 hours with







Figure 5.16 Semi-Quantitative RT-PCR Confirms Differential Expression of BF-2 and Wnt-4
Transcripts in the RA Treated WT1 Null ES Clones
Total RNA was collected from wild-type, WT1 heterozygote and WTInull whole E9.5 embryos, and
from replicate experiments of RA treated E14 and K1 ES clones. Total RNA from an independent
RA differentiation of E14 and K1, in addition to the second WT1 null ES cell line, K46, was also
collected. 5 ng of RNA was reverse transcribed to produce cDNA. To control for the levels of cDNA,
the samples were normalised with respect to the expression levels of p-actin and GAPDH (26 cycles).
RT-PCR for Wnt-4 (27 cycles) and BF-2 (26 cycles) was carried out.
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passage of E14 and K1 ES cells. By semi-quantitative RT-PCR, both BF-2 and
Wnt-4 were down-regulated in both the replicate sample of K1 RNA and also in
the K46 RNA samples at 96 hours (Figure 5.16). This down-regulation therefore
confirms the findings of the microarray, and also confirms that the down-
regulation of gene expression is not due to clonal variation.
Whether the transcripts differentially expressed between E14 and K1 during the
differentiation of the ES clones are due to direct regulation by WT1 is difficult
to ascertain at this point. However, it can be established whether or not the
expression of WT1 and a certain potential target are cell specific, in that they
are both expressed in the same cell populations. If the cells co-express both
WT1 and the transcript of interest, then this might add further evidence to
indicate that the regulation of the transcript by WT1 maybe be cell specific and
direct, and not through an indirect process such as a paracrine/autocrine loop.
From the array data, Wnt-4 represented the highest fold change across the two
time points, with an 8-fold reduction in expression in the K1 sample compared
to the El4 sample at 96 hours. Given its relevance physiologically and also the
recent data indicating that this might be a target of WT1 (Sim et al., 2002), the
expression ofWnt-4 in the wild-type differentiated ES cells was monitored by
immunofluorescence to see whether Wnt-4 is co-expressed with WT1. Wild-
type ES cells were co-stained with WT1 and Wnt-4 in an undifferentiated state
and following 96 hours of treatment with RA (Figure 5.17). In the
undifferentiated state there was no detection of either Wnt-4 or WT1. After 96
hours of differentiation, WT1 staining can be detected in approximately 75-80%
of cells. In differentiated ES cells with high levels ofWT1 expression, there is
co-expression of Wnt-4 (Figure 5.17 (b) and Figure 5.17 (c)). The staining
pattern for Wnt-4 is distinctive and appears to localise Wnt-4 to the
endoplasmic reticulum or the golgi apparatus of the cells. This is consistent with
the previous report of localisation of transiently expressed Wnt proteins in COS
cells where antibody staining demonstrated that all Wnt proteins were primarily
retained in the endoplasmic reticulum (Burrus and McMahon, 1995).
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5.5.7 Published WT1 Target Genes
Next the expression profiles of previously reported candidate target genes were
analysed to determine whether their expression was altered in the K1 ES cells
after 48 hours and 96 hours in comparison to El4 cells at the same time points
(Figure 5.18). Amphiregulin, BF-2, and Wnt-4 were the only previously
reported candidate WT1 target genes that were differentially expressed more
than the 2.5-fold value (Lee et al., 1999; Ernstsson et al., 1996; Sim et al.,
2002). However changes were seen in the system for some of the putative WT1
targets below the 2.5-fold change.
A 2.2-2.5-fold induction of c-Myc expression in the K1 clone from 48-96 hours
is observed, consistent with the published transcriptional repression of the c-
Myc gene by WT1 (Hewitt et al., 1995). IGFBP-4 was identified as being down-
regulated in ES cells that were homozygous for a truncated form of WT1
(Wagner et al., 2001). In this study the similar down-regulation of IGFBP-4
observed (2.3-fold), adds support to the possibility that IGFBP-4 is regulated by
WT1. However there was no change in cyclin Gl, another gene identified as
being down-regulated in the RA treated DDS ES cell lines (Wagner et al.,
2001).
Some of the WT1 target genes do not respond in this system in a manner that
was originally described. For example, amphiregulin was identified as
transcriptionally activated by WT1 (Lee et al., 2001). Therefore, in comparing
the El4 and K1 expression profile, one might expect a reduction in the levels of
amphiregulin in the K1 samples. However there is a 3-fold increase in
amphiregulin expression in the K1 sample. The same phenomenon is observed
when expression levels of CTGF are compared. CTGF was identified from gene
expression profiles of a Wilms' tumour cell line stably expressing aDDS-WTl
construct (Stanhope-Baker and Williams, 2000). In this system, CTGF was up-
regulated in the DDS-Wilms' tumour cell lines. In vitro luciferase assays
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Figure 5.18 The Expression Profile of Published WT1 Target Genes in the K1 Clone in an Undifferentiated
State, Treated with RA for 48 hours and Treated with RA for 96 hours.
Published WT1 target genes, which were present on the Affymetrix Mouse Gene Chip U74A array, were analysed to
see if any exhibited differential expression between E14 and K1 ES cells at the three time points. The published effect
of WT1 upon the behaviour of the target gene is shown, along with the expected directional change of gene expression
that would be present in the K1 clone in comparison to the E14 ES cells.
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demonstrated that the CTGF promoter was repressed by WT1. Therefore, one
might expect that in the K1 sample there would be an up-regulation of CTGF,
however CTGF is down-regulated by 2-fold in the K1 sample compared to the
El4 sample. Some caution must be observed in the analysis of the effects of
WT1 loss-of-function on the expression of CTGF, as CTGF was down-
regulated 3-fold in the K1 ES clone in the undifferentiated state compared to the
undifferentiated E14 ES cells. Overall, the differences observed in the
behaviour of amphiregulin and CTGF, and the lack of confirmation of other
published putative WT1 targets, may indicate differences in the cell system used
in this study and the system used to originally identify them as putative WT1
target genes.
5.6 Discussion
The generation of the WT1 null ES cells in this chapter has provided an
important resource to further investigate the role of WT1 in the molecular
control of cellular differentiation. From the use of the RA differentiation
protocol, in conjunction with the Affymetrix Genechip microarrays, has pointed
towards various cellular changes that are occurring following WT1 loss-of-
function in K1 cells during RA differentiation, and also identified a set of novel
candidate WT1 target genes.
The initial aim of the project was to generate WT1 null ES cells using the
conditional targeting vector described in Chapter 3. In employing this targeting
vector, correct homologous targeting of the remaining wild-type allele would
have generated a heterozygote clone in which complete ablation ofWT1 would
have been under the temporal control of Cre recombinase. However attempts to
generate a conditional null ES cell line proved difficult due to problems
associated with the targeting of the remaining wild-type allele with the
pWTlLoxP targeting vector. One clone was obtained in which the targeting
vector was partially incorporated into the WT1 endogenous locus, but with the
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5' end of the vector (containing the final loxP site) absent. The failure to
incorporate the 5' loxP site into the locus could reflect the fact that the selection
cassette is approximately 4 kb away from this region and therefore is under
reduced selective pressure. The relative ease in which the second allele was
successfully targeted with the pWTlKre targeting vector may be due to the fact
that this targeting vector has longer arms of homology to WT1, and is not
dependent upon the insertion of a 34 bp loxP site in the 5' region. The
successful generation of a correctly targeted ES cell lines with the pWTlKre
construct, and the demonstration that these clones were WT1 null ES cells,
indicates that the Cre/LoxP inactivation of the first allele does produce a true
null allele. This is crucial as it demonstrates the Cre/LoxP modifications to the
WT1 locus will produce a WT1 null allele in vivo.
Examination of the WT1 null ES cell lines in an undifferentiated state indicated
that the WT1 null ES cells were phenotypically similar to wild-type ES cells. In
the analysis of WT1 null ES cells during treatment with RA, morphologically
the cells appeared to be comparable, however there were differences in the cell
number after 48 hours. At 72 hours of treatment with RA, there was a 50%
reduction in WT1 null ES cells in comparison to wild-type controls. Whether
this reduction in cell numbers is due to apoptosis or a decrease in proliferation is
unknown. Elowever, it is clear that this event was specific for the absence of
WT1, as WT1 heterozygote null ES cells behaved in a similar manner to wild-
type ES cells when treated with RA. This therefore provides an excellent system
to study the role ofWT1 in the regulation ofproliferation and/or apoptosis..
A similar response was seen in myeloid leukaemia cell lines in which WT1 was
"knocked down" using WT1 antisense oligonucleotides that were targeted to the
translation initiation site of WT1 (Algar et ai, 1996). In cell lines treated with
the WT1 antisense oligonucleotide, there was a significant reduction in cellular
proliferation and increase in apoptosis. The authors suggested that was
necessary for cell proliferation and maintaining viability in these cell lines. A
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similar scenerio is observed in the metanephric mesenchyme of the kidney,
where in the WT1 null embryo the absence of WT1 results in apoptosis of the
metanephric mesenchyme. Therefore, could the expression of WT1 be
necessary for maintaining the viability of some lineages that are generated in the
RA treatment of the WT1 null ES cells? This appears to be unlikely, as the
analysis of gene expression at 96 hours indicates that there is not a radical shift
in the expression profiles between the wild-type and WT1 null ES cells
(Discussed below).
In Chapter 4, a limited analysis of E14 differentiated ES cells by a selection of
antibodies and RT-PCR analysis demonstrated the presence of neuronal
lineages, and the absence of mesodermal lineages, within the monolayer
cultures following 96 hours of treatment with RA. The Affymetrix Genechip
array analysis of the differentiated wild-type E14 ES cells confirms some of
these findings. However, it also suggests that there maybe other lineages arising
from the RA differentiation of the cells. Interestingly, the analysis of transcripts
that are down-regulated when El4 ES cells are treated with RA has identified
several genes and ESTs that might be involved in maintaining ES pluripotency.
Affymetrix Genechip arrays containing 12,000 transcripts were screened to
identify novel candidate WT1 target genes in RA differentiating ES cells.
Overall the ablation ofWT1 appears not to have induced massive differences in
gene expression at the time points that were chosen. This is demonstrated by the
analysis of the gene expression profiles by scatter plot analysis and confirmed
by the fact that across the two time points, there were in total only 102
transcripts that were differentially expressed greater than 2.5-fold between the
wild-type and WT1 null ES cells. Within this set of differentially expressed
transcripts, several are present that have been previously reported in other
systems to represent WT1 downstream targets, notably amphiregulin and Wnt-4
(Lee et al., 1999; Sim et al., 2002). Although amphiregulin has been reported to
be a direct target for WT1, in the ES cell differentiation system described in this
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chapter, the loss of WT1 leads to an increase in the expression levels of
amphiregulin, an effect that is in contradiction to the reported transcriptional
activation of amphiregulin by WT1. However the dramatic down-regulation of
Wnt-4 in the WT1 null ES cells is consistent with the previous reports ofWnt-4
regulation by WT1 (Sim et al., 2002), and further supports the notion that Wnt-
4 is directly regulated by WT1. Further evidence that WT1 directly regulates
Wnt-4 expression has come from work using RNA interference (RNAi) in
mesonephric cell lines and kidney organ cultures. Knockdown ofWT1 by RNAi
in the M15 cell lines results in a down-regulation of Wnt-4 (Davies, Ladomery,
Hohenstein, Michael, Spraggon, Freeman and Hastie, 2003, Manuscript
submitted).
The human homologue of BF-2, FREAC-4, has previously been shown be a
potential WT1 target gene (Ernstsson et al., 1996). Using transient transfections,
a construct containing 2 kb of genomic sequence upstream of the FREAC-4 start
site, linked to a luciferase reporter, demonstrated a 3-fold induction when co-
transfected with a WT1 expression plasmid into a kidney derived cell line
(Ernstsson et al., 1996). Transfections of 5' deletions of the 2 kb FREAC-4
luceriferase construct, followed by gel shift assays using recombinant WT1,
identified a WT1 binding site within the FREAC-4 promoter (Ernstsson et al.,
1996). In the ES differentiation system, the loss WT1 results in a down-
regulation of the murine homologue of FREAC-4, BF-2. From the results
presented in this chapter, and also the previous work using transient
transfections of reporter constructs of human homologue of BF-2, FREAC-4, it
suggests that WT1 may activate the expression of BF-2/FREAC-4. However,
it's difficult to tie this into the in vivo situation with regards to WT1 regulation
of BF-2. It is clear that BF-2 and WT1 do have overlapping expression patterns
during embryogenesis, with expression in the metanephric kidney, testis and
CNS. It has already been demonstrated that BF-2 is necessary for normal
development, not only of the stroma but also of the nephrogenic lineages,
suggesting that it regulates stromal production of diffusible regulators of
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nephron differentiation. Loss of BF-2 results in the appearance of aggregates of
proliferating, poorly-differentiated mesenchyme in place of where nephrons
would normally be expected to form, a similar phenotype noted in the Wnt-4
knockout mice (Stark et al., 1994). Although it is unclear whether stromal cells
and metanephric mesenchyme originate from a common precursor or from
distinct lineages, stromal cell progenitors can be distinguished from epithelial
progenitors at the earliest stages of renal morphogenesis (Hatini et al., 1996),
consistent with the proposed role of stroma as an essential and independent
component of the reciprocal signalling pathways. Since WT1 expression
precedes that of BF-2 in the metanephric mesenchyme, it is possible that during
these early stages WT1 activates BF-2 expression, which then proceeds to
define the stromal component of the metanephric mesenchyme from the
nephrogenic component.
From the analysis of gene expression profiles between wild-type and WT1 null
ES cells, a novel set of candidate WT1 regulated genes has been identified. The
potential regulation of RALDF12 by WT1 points to an intriguing possibility that
WT1 may be involved in the regulation of the retinoid acid synthesis pathway.
Retinoic acid has profound effects in vivo stimulating proliferation,
differentiation and morphogenesis (For review see Mark et al., 1999). A link for
WT1 within the retinoic acid pathway has previously been reported, with WT1
shown to repress the retinoic acid receptor a gene (RAR-a) (Goodyer et al.,
1995). However this study was carried out using transient transfection, deletion
analysis and EMSA, and hence the physiological significance of this regulation
has yet to be established. Also RAR-a possesses a ubiquitous expression pattern
(Dolle et al., 1990), whilst WT1 is tissue specific. In comparison, RALDH2 is
highly tissue specific and does have an overlapping expression pattern with that
ofWT1. In the epicardium and the epicardially derived cells of the heart, WT1
and RALDH2 are co-expressed (Perez-Pomares et al., 2002).
Reducing/abolishing the expression ofWT1 within these cells, as is the case of
the WT1 knockout mouse or in experimental perturbation of epicardial
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development in vitro, has the effect of reducing the levels of RALDH2 (Perez-
Pomares et ah, 2002; Professor Munoz-Chapuli, personal communication). In
Chapter 4, the observation that WT1 is expressed in motor neurons in the spinal
cord is also a site for expression of RALDH2 (Sockanathan and Jessell, 1998;
Haselbeck et al., 1999; Niederreither et al., 2002). In the context of the spinal
cord, RALDH2 expression and the subsequent local generation ofRA has been
shown to specify the subtype identity of spinal motor neurons (Sockanathan et
al., 1998). It would be interesting to analyse whether the down-regulation of
RALDH2 in the epicardium of the heart in the WT1 null embryos is mimicked
in the spinal cord of WT1 null embryos. This may have implications for
changes in subtype patterning in the spinal cord of the WT1 null embryos.
IGFBP-5 and WISP-1 represent another set of potentially interesting transcripts
that were differentially expressed in the WT1 null ES cells. IGFBP-5 belongs to
the family of Insulin like growth factor binding proteins (IGFBPs) which are a
component of the insulin-like growth factor system. These proteins form high-
affinity complexes with IGF-I and IGF-II, and thereby either inhibit or
potentiate their effects in vivo. To date, the IGFBP family comprises 10 proteins
that includes a superfamily of 6 proteins (IGFBP-1 to -6) which bind with high
affinity and specificity to IGFs. Recently, a smaller family, the Insulin-like
Growth Factor Binding Protein related peptides (IGFBPrp 1-4), that include
IGFBP-7 and putative IGFBP-8, -9, and -10 that bind with a lower affinity,
have been identified (Kim et al., 1997, Ferry et al., 1999). Previously, IGFBP-4
was identified as being differentially expressed in RA treated ES cells that
contained a modification to the zinc finger domain of WT1 (Wagner et al.,
2001). In WT1 null ES cells, IGFBP-4 was similarly down-regulated, as was
IGFBP-5. Therefore, WT1 may regulate some of the IGFBP proteins, and in
doing so modulates the regulation of free levels of IGF-I and IGF-II. WISP-1
belongs to the CCN family, which includes connective tissue growth factor
(CTGF) and Neproblastomas overexpressed (Nov). Both of these genes encode
proteins which are structurally related to the IGFBP family of proteins. Also
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CTGF and Nov have been reported previously to be regulated by WT1
(Stanhope-Baker and Williams, 2000; Martinerie et al., 1996), and therefore
WISP-1 is another member of the CNN family that might be regulated by WT1.
The Affymetrix Genechip arrays have proved an extremely powerful tool for the
discovery of WT1 candidate target genes. However, it is important to address
the limitations of the work presented in this chapter. The Affymetrix Genechip
arrays have provided preliminary data sets. Replicate arrays will be required to
confirm the findings presented in this thesis. Also, the results described in this
chapter do not address the question of whether the effects observed in the gene
expression profile are directly mediated by WT1, or indirectly mediated by
another gene product. No single well-defined consensus sequence for promoter
binding by WT1 has been identified. Sequences bound by WT1 include the
WTE (5'-GCCTGGGAGT-3'), WRE (5'-GCGTGGGAGT-3') and EGR1 (5'-
GCGGGGCG-3') (Lee and Haber, 2001). The analysis of the murine promoters
of Peripherin, CYP1B1, CRABP-II, RALHD2, IGFBP-5, WISP-1 and Wnt-4
failed to detect the presence of a complete EGR1, WTE or WRE sites in the lkb
upstream promoter sequence of this genes (Data not shown).
In summary, the data presented in this chapter shows that ablation ofWT1 in ES
cells, coupled with Affymetrix Genechip arrays of gene expression profiles, is a
useful approach which has identified a set of differentially expressed transcripts
which may represent candidate WT1 regulated genes. Future work will be
required to verify whether these transcripts are directly regulated by WT1, and
also whether the mis-regulation of these transcripts has any effect on the
pathological state of diseases, such as Wilms' tumours or diseases associated
with loss-of-function mutations in WT1.
172
Chapter 6 Identification of a Novel
WT1 Interacting Protein
Chapter 6 Identification of a Novel WT1 Interacting Protein
Chapter 6 Identification of a Novel WT1 Interacting
Protein
6.1 Introduction
The identification of additional components of the cellular machinery with
which WT1 interacts will permit a greater understanding of the molecular
pathways that WT1 is involved in. There are many examples of transcription
factors interacting with other proteins to exert their function within the cell, one
of the best being the GATA transcription factors.
6.1.1 GATA Transcription Factors & Friends of GATA (FOG)
Proteins
The GATA family of zinc finger transcription factors are important regulators
of development in Caenorhabditis, Drosophila and vertebrates. They have been
shown to play a crucial role in various developmental processes including the
differentiation of hematopoietic cells such as T cells, cardiac and coronary
vasculature development and liver, lung and gut morphogenesis (Cantor and
Orkin, 2002).
GATA transcription factors bind to a DNA consensus sequence of GATA. The
transcriptional activities of the GATA proteins are modulated by interaction
with both transcriptional co-activators and repressors. For example, the
transcription factors SP1 and EKLF interact with the C-terminal zinc finger of
GATA-1 to synergistically activate erythroid-specific gene expression (Fischer
et al., 1993; Merika & Orkin, 1995). Similarly Nkx2.5 associates with the C-
terminal zinc finger of GATA-4 to activate the transcription of cardiac-
restricted genes (Durocher et al., 1997; Sepulveda et al., 1998).
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More recently, a family of multi-type zinc finger proteins has been identified
which also interact with GATA factors. These zinc finger proteins belong to the
FOG (Friends of GATA) family and include FOG1, FOG2, xFOG and USH
(Tevosian et al., 1999; Fossett et al., 2001; Cantor & Orkin, 2001). An example
of the importance of the interaction between GATA factors and FOG proteins
has recently been demonstrated during gonadal differentiation. Direct
association between GATA-4 and FOG2 is required for normal gonadal
differentiation, sex determination and normal expression of the Sertoli-specific
transcription factor SRY (Tevosian et al., 2002). In mice homozygous null for
either FOG2 or GATA-4, a direct association between the two proteins can not
occur, leading to abnormalities during gonadogenesis. It was found that Sry
transcript levels were significantly reduced in XY Fog2—/— gonads at El 1.5,
which is the time when Sry expression normally reaches its peak. In addition,
three genes crucial for normal Sertoli cell function (Sox9, Mis and Dhh) and
three leydig cell steroid biosynthetic enzymes (p450scc, 3BHSD and p450cl7)
were not expressed in XY Fog2-/- and Gata4 -/- gonads, whereas Wnt-4, a
gene required for normal ovarian development, was expressed ectopically
(Tevosian et al., 2002). Therefore the loss either the transcription factor itself,
or its partner proteins, can have dramatic developmental and biological
consequences.
Another example is the monocyte enhancer factor 2 proteins (MEF2). MEF2
proteins are MADS-box transcription factors that are essential for differentiation
of all muscle lineages. In mammals, the MEF2 family is composed of four
members: MEF2A; MEF2B; MEF2C; and MEF2D. The earliest site of MEF2
expression is within the heart, where expression ofMEF2C is detected at E7.5.
Inactivation ofMEF2C in mice leads to severe cardiac developmental arrest and
down-regulation of a number of cardiac markers. One of the cardiac genes
shown to be down-regulated was aMHC (Lin et al., 1997). Closer inspection of
the aMHC promoter indicates the presence of two low-affinity MEF2 binding
sites. However, in vitro co-transfection assays fail to show that MEF2 can
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activate aMHC-driven reporters (Morin et al., 2000). Subsequent work now
indicates that the MEF2 proteins are recruited to the promoter region by the
cardiac- specific transcription factor GATA-4, to synergistically activate
aMHC, in addition to several other MEF2C target promoters (Morin et al.,
2000).
6.1.2 Published WT1 Interacting Proteins
A number of different approaches have been employed to identify potential
protein partners ofWT1. From these studies, proteins have been identified that
either modulate the function ofWT1 as a transcription factor, affect the activity
of WT1 in cell cycle regulation and apoptosis, or which implicate a role for
WT1 in RNA splicing and post-transcriptional regulation (Refer to Table 6.1).
6.1.2.1 Transcriptional Regulation
Using immunoprecipitations techniques, WT1 has been shown to interact with
p53 (Masheswaran et al., 1993). Immunoprecipitations for WT1 from
transformed Baby Rat Kidney (BRK) cells and a Wilm's tumour sample, both
of which express WT1, demonstrated that WT1 was associated with p53
(Masheswaran et al., 1993). This protein-protein interaction was mediated
through zinc fingers 1 and 2 of WT1. In a particular cellular context, the
association of p53 with WT1 converts it from a transcriptional activator to a
transcriptional repressor. Further work has established that the interaction of
WT1 with p53 modulates the activity of p53 (Masheswaran et al., 1995). In
BRK cells stably transfected with WT1, an increased level of endogenous p53
protein was observed. This increase in the level of p53 protein was assumed to
be due the increase of the steady state levels of p53, by prolonging the half-life
of the p53 protein. The stabilised p53 demonstrated enhanced trans-activation
properties. In addition, WT1 association with p53, inhibited p53-mediated
apoptosis, but did not affect p53-mediated cell cycle arrest.
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Recently, WT1 has been shown to interact with p73 and p63, two genes that
share sequence homology with the transactivation, DNA binding and
tetramerization domains of p53 (Kaghad et al., 1997; Yang et al., 1998;
Scharnhorst et al., 2000). In contrast to p53, which is dispensable for embryonic
development, p73 and p63 are intimately involved in differentiation and
development. P73 knockout mice exhibit profound neurological developmental
defects, chronic infections and inflammation, as well as abnormalities in
pheromone sensory pathways (Yang et al., 2000). P63 knockout mice have
absent or truncated limbs, defects that are caused by the failure of the apical
ectodermal ridge to differentiate. Structures dependent upon epithelial-
mesenchymal interactions during embryonic development, such as hair follicles,
teeth and mammary glands, are absent in p63-deficient mice (Mills et al., 1999).
The association of WT1 with p73 is mediated via the zinc fingers of WT1 and
consequently, binding of WT1 to p73 diminishes DNA binding and
transactivation by WT1. Similarly, WT1 inhibits p73-induced transcriptional
activation in reporter assays and counteracts p73-induced expression of
endogenous Mdm2. Overall the association between WT1 and the members of
the p53 family of proteins may be an important determinant of their functions in
cell growth and differentiation.
Ciao-1 was identified as a novel WT1-interacting protein which associates with
the zinc finger domain (Johnstone et al., 1998). GST-binding and co-
immunoprecipitation of ectopically expressed WT1 and Ciao-1 demonstrated
that a physical interaction occurs between these two proteins. Ciao-1 belongs to
a family of proteins that contain WD40 or transducing repeats. Proteins
containing WD40 repeats have several functions including cell cycle regulation,
RNA splicing and transcription (Neer et al., 1994). The significance of this
interaction is unclear, although Ciao-1 may have a role in the modulating the
transactivation activity ofWT1.
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Recently affinity chromatography of nuclear extracts from HeLa cells passed
over immobilised WT1 protein, followed by mass spectrometric analysis of
specifically retained proteins, identified Bone Marrow Zinc Finger 2 (BMZF2)
as a protein which interacts with the zinc fingers ofWT1 (Lee et al., 2002). The
function of this interaction appears to be to modulate the transactivation
properties ofWT1 resulting in a reduced transcriptional activity ofWT1 (Lee et
al., 2002).
6.1.2.2 Cell Cycle Regulation
Other WT1 protein partners have been identified which regulate the effects of
WT1 on cell cycle progression, to inhibit or induce apoptosis. WT1 has been
shown to interact with the heat shock protein 70 (Hsp70) (Maheswaran et al.,
1998). This was demonstrated by establishing an osteosarcoma cell line with
inducible, tetracycline-regulated WT1, coupled to immunoprecipitation ofWT1
and microsequencing analysis ofWT1 associated proteins. Hsp70 was identified
in this screen, and further analysis showed that in fetal kidney Hsp70 was
recruited to the characteristic subnuclear clusters that contain WT1. The
domains of interaction with Hsp70 were shown to lie in the N-terminal region of
WT1. The significance of this interaction is thought to modulate the growth-
suppressive function ofWT1. The N-terminal region ofWT1 has been shown to
be required for growth inhibition by WT1, which is mediated through the
induction of the cyclin dependent kinase, p21, which leads to G1 phase cell
cycle arrest (Englert et al., 1997).
Prostrate Apoptosis Response Protein 4 (par4) has been identified as a WT1
interacting protein (Johnstone et al., 1996; Richard et al., 2001). The original
identification of par4 as a WT1-interacting protein proposed that par4 enhances
transcriptional repression by WT1 as shown by transient transfection studies
(Johnstone et al., 1996). In addition, this study showed that the zinc fingers of
WT1 mediate the interaction between WT1 and par4. Recently it has been
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shown that par4 also interacts with the 17 amino acid mammalian-specific
alternative splice form ofWT1 (Richard et al., 2001). These 17 amino acids are
encoded by exon 5 and have been shown to constitute a separate transcriptional
activation domain (Richard et al., 2001). The function of the alternative splice
activation domain requires a direct interaction with par4. Analysis of this
interaction demonstrated that par4 enhances the ability of WT1 to regulate cell
survival and proliferation (Richard et al., 2001).
Using the N-terminal domain of WT1 as bait in a yeast two-hybrid screen
identified a hUBC9 as an interacting partner (Wang et al., 1996). HUBC9
encodes the human homologue of the yeast ubiquitin-conjugating enzyme 9. In
yeast, UBC9 is a nuclear protein involved in the degradation of S- and M-phase
cyclins, however the significance of an interaction with WT1 has yet to be
ascertained. The association ofWT1 and hUCB9 may impose a cell cycle block
by affecting the fate of the S- and M-phase cyclins that are degraded by
ubiquitination.
6.1.2.3 RNA Metabolism
Involvement of WT1 in RNA splicing and post-transcriptional regulation and
has been demonstrated by the association of WT1 with U2AF65 and WTAP.
Given the subnuclear localisation of WT1 +KTS isoforms in splicing speckles
and the observation that WT1 co-localises and co-immunoprecipitates with
splicing factors (Larsson et al., 1995), a yeast two-hybrid screen was employed
to investigate the ability of WT1 to interact directly with components of the
splicing machinery. From the components tested, only U2AF65 was identified
as a potential binding partner (Davies et al., 1998). Extending this work the
authors showed that the domain of WT1 that interacts with U2AF65 lay in the
zinc finger region, and that the KTS isoforms displayed differing binding
affinities to U2AF65 (Davies et al., 1998). Furthermore the +KTS isoforms
demonstrated a higher binding affinity to U2AF65.
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Using yeast-two hybrid screens, WTAP (WT1 -associating protein), a
ubiquitously expressed protein, was shown to interact with the C-terminal zinc
finger domains ofWT1 (Little et al., 2000). The biochemical role ofWTAP and
the functional significance of its interaction with WT1 are not yet fully
elucidated. However WTAP has recently been shown to be a putative
mammalian homologue of the protein encoded by the Drosophila female-lethal-
2-D gene,fl(2)d. Genetic studies have indicated fl(2)d is involved in regulation
of alternative splicing in Drosophila. In studying the functional conversation
between WTAP and Drosophila fl(2)d, in vitro assays have demonstrated that
WTAP is capable of replacing the function offl(2)d in splicing regulation of
Drosophila-specific transcripts, and therefore may have a role in splicing
(Ortega et al., 2002). Further evidence to implicate WTAP in splicing has been
provided by the proteomic analysis of the human splicesome, which identified
WTAP as being a member protein (Zhou et al., 2002). The observation of an
interaction of WT1 with U2AF65 and WTAP, has strengthened the case for
WT1 playing a role in post-transcriptional processing and RNA metabolism by
linking it directly to the components of the splicing machinery.
Overall, WT1 is a multi-functional protein that has been implicated in a diverse
range of cellular activities including transcriptional control, cell cycle
regulation, apoptosis and RNA splicing. The aim of the work presented in this
chapter was to isolate and identify novel WT1-interacting proteins. By
identifying novel WT1-interacting proteins, a greater understanding of the
molecular pathways that WT1 is involved in can be gained.
The majority of studies that have identified interacting WT1 partners have
employed co-immunoprecipitation of ectopically expressed WT1 isforms or
yeast two-hybrid screens. These approaches have produced a list of potential
WT1 interacting proteins (Table 6.1). To date, however there have been no
reports of techniques that have utilised immunoprecipitaiton (IP) of endogenous
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Nuclear Zinc Fingers Repress WT1 mediatedtranscription
Table 6.1 Published WT1 Interacting Proteins
(Compiled from Reviews by Little etal., 1997 and Lee and Haber, 2001)
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retinoic acid (RA) induction of wild-type ES cells (El4) results in high level
expression of endogenous WT1. Therefore, the aim of this work was to use this
in vitro system in conjunction with WT1 IPs and MALDI-TOF to identify
endogenous proteins which interact with WT1. The establishment ofWT1 null
ES cells provides an ideal control for the identification of endogenous WT1
associated proteins. Comparing IPs from the differentiated wild-type ES cells
alongside the WT1 null ES cell (Kl), permits a control to be included. Simply,
anything which is shown to be present in the IPs from the WT1 null ES cells
can be discounted as artifactual due to the absence ofWT1 in this system.
6.2 Immunoprecipitation of Endogenous WT1 from RA
Differentiated ES Cells
To identify WT1-associated protein partners, immunoprecipitation of
endogenous WT1 was carried out on nuclear extracts prepared from El4 ES
cells treated with RA for 96 hours. As a control for the immunoprecipitation, the
Kl (WT1~~) ES cell line was also differentiated with RA for 96 hours, and
nuclear extracts prepared. The immunoprecipitations for WTl were carried out
using the C-19 antibody, which recognises the C-terminal region of WTl,
bound covalently to protein A-Sepharose beads. Following IP, approximately
lOpg of total nuclear protein, lOpg of unbound material and lOpg of elutions
from the sepharose beads were separated on a 10% SDS-PAGE gel and
transferred onto nitro-cellulose. Western Blot detection for WTl was carried
using the WTl monoclonal antibody (H2) (Figure 6.1). Western blot clearly
shows an enrichment ofWTl in the IPs from the differentiated E14 ES cells,
whilst WTl was not detected in samples immmunoprecipitated from
differentiated Kl ES cells.
The WTl IP samples from El4 and Kl were then separated on a gradient SDS-
PAGE gel and stained with Coomassie Blue (Figure 6.2). Five bands were





















Figure 6.1 The C-19 antibody immunoprecipitates WT1 from wild-type RA differentiated
ES cells (E14 IP), but not from RA differentiated WT1 null ES Cells (K1 IP)
ES cells (E14 and K1) were differentiated for 96 hours with 1ptM all-trans Retinoic Acid
and nuclear protein was prepared. The nuclear extracts were immunprecipitated with the
C-19 antibody. Approximately 10 ng of T=Total nuclear protein, UN=unbound material,
E1/E2=eluate was loaded for Western blotting. Immunoblot for WT1 was carried out



















Figure 6.2 Coomassie Blue Stained Gradient SDS-PAGE gel of WT1 IP from
E14 and K1 RA Treated ES Cells
20^g of protein from the C19 IP from E14 and K1 was separated on a gradient
SDS-PAGE gel and stained with Coomassie blue. Bands that were present in the
E14 IP and absent in the K1 IP were labeled L1-L5. These bands were excised from
the E14 IP lane for protein identification by MALDI-TOF.
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from the K1 null ES cells. These bands were excised from the gel. along with
the corresponding regions from the K1 control lane (LN1-LN5).
6.3 Identification of WT1 Interacting Proteins by
MALDI-TOF
A tryptic digestion of each of the 5 samples (L1-L5) was performed and the
molecular mass of the tryptic fragments determined by MALDI-TOF. The
proteins were identified from each band by matching the observed proteolytic
masses obtained from the MALDI-TOF spectra with the hypothetical tryptic
peptide masses derived from the NCBI non-redundant protein database (MS-
Fit) (Table 6.2).
L1 was shown to be highly similar to heterogeneous nuclear ribonucleoprotein
U (hnRNP U). Analysis of the LN1 sample from the WT1 null ES cells
produced no protein match. Analysis of L4 showed high similarity to either y or
(3-actin, whilst L5 showed no protein matches with the NCBI MIS-FIT database.
Due to technical problems associated with the analysis of the samples by
MALDI-TOF, samples L2 and L3 could not be processed or identified.
6.4 Heterogeneous Nuclear Ribonucleoprotein U
(hnRNP U)
From the MALDI-TOF analysis, the protein identified from the LI band,
hnRNP U, was chosen for further investigation. This band was the most
prominent in the Coomassie-stained SDS-PAGE gel of the El4 WT1 IP.
HnRNP U (also known as Scaffold Attachment Factor A, SAF-A) is a 120 kDa
protein belonging to the heterogeneous nuclear ribonucleoproteins family of
proteins (hnRNPs) that are abundant in the cell nucleus (Kiledjian and Dreyfuss,
1992).
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L1 > 97 kDa 17 hnRNPU gj :14044052
L2 45 kDa - 60 kDa
L3 45 kDa - 60 kDa
L4 45 kDa 12 y/a-actin gi: 809561
L5 30 kDa - 45 kDa No Match No Match No Match
Table 6.2 Analysis of L1-L5 Bands by MALDI-TOF
Samples L1-L5 were excised from the Coomassie stained gradient gel and analysed by MALDI-TOF.
Interpretation of the data generated from the MALDI-TOF was carried out using the MS-Fit program.
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6.4.1 WT1 and HnRNP U Interact in vivo
To ensure that hnRNP U is present in cell types that have arisen from the WT1
null ES cells following exposure to RA, nuclear protein from RA differentiated
wild-type El4 ES cells and K1 ES cells were probed for hnRNP U using 3G6, a
mouse monoclonal antibody against hnRNP U (Gift Dr. Gideon Dreyfuss).
Nuclear protein (40 pig) was separated on a 10% SDS-PAGE gel, transferred to
nitrocellulose and probed with the 3G6 antibody. Figure 6.3 (b) shows the
Western blot for hnRNP U. In both E14 and K1 nuclear protein, a single band
migrating above 97 kDa can be detected. This is in comparison to the Western
blot for WT1 which demonstrates its presence only in the RA induced E14 ES
cells (Figure 6.3 (a)). The blot was then stripped and reprobed with an antibody
for PI 16 to ensure equal loading of nuclear protein (6.3 (c)). The Western blot
analysis shows that the absence of a band corresponding to LI in the K1 WT1
null ES cells is not due to an absence of hnRNP U in the original sample.
To confirm that hnRNP U interacts with WT1, an independent set of IP
experiments were carried out on further nuclear protein extracts collected from
wild-type ES cells differentiated for 96 hours with RA. IPs for WT1 (using C-
19), hnRNP U (using the mouse monoclonal antibody 3G6), and a negative
control IP (using rabbit IgG), were carried out. Proteins (10pg) from the
elutions of the IPs (El and E2) were separated on a 10% SDS-PAGE gel and
transferred to nitrocellulose. Figure 6.4 shows the Western blot analysis of the
different IPs.
Figure 6.4 (a) is a Western blot of the C-19 WT1 IP elutions probed with both
H2 (a WT1) and 3G6 (a hnRNP U). It shows that a doublet migrating between
45 kDa and 60 kDa was detected corresponding to WT1, and also a single band
















Figure 6.3 HnRNP U is Expressed in Both RA Treated E14 and K1 ES Cells After 96 Hours
ES cells (E14 and K1) were treated with RA for 96 hours and nuclear protein was prepared.
Immunoblot of the nuclear protein (40 |xg) for WT1, HnRNP U and P116 was carried out.
a) Both samples were probed for WT1 using the C-19 antibody, demonstrating an absence
of WT1 in the K1 clone.
b) Both samples were probed for hnRNP U using 3G6 antibody, demonstrating that hnRNP U is
present in both clones.
c) To control for loading, the blot was stripped and probed with an antibody to P116, a U5

























Figure 6.4 WT1 interacts with hnRNP U in vivo
E14 ES cells were treated with RA for 96 hours and nuclear protein extracts prepared.
a) Immunoprecipitations for WT1 were carried out using C-19. 10 ng of protein from the IP was separated
on a SDS PAGE gel and transferred onto nitrocellulose. The immunoblot was probed with the
monoclonal antibodies for WT1 (H2) and hnRNP U (3G6). WT1 and hnRNP U are both present in the
elutions from the WT1 IP.
b) Immunoprecipitations for hnRNP U were carried out using 3G6. The immunoblot was probed with the
3G6 antibody to ensure that hnRNP U can be immunprecipitated. HnRNP U can be detected in the elutions.
c) Immunoblot from (b) was stripped and reprobed for WT1 using the rabbit polyclonal C-19. WT1 can be detected in the
elutions (E1 and E2) from the hnRNP U IP.
d) Control immunoprecipitations using a rabbit IgG were carried out on nuclear extract from RA treated E14 ES cells.
The elutions were probed with for both WT 1 (H2) and hnRNP U (3G6). There was no detection of hnRNP U or WT1.
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WT1 and hnRNP U in the WT1 IP elution El indicates that they physically
interact in so far as they co-precipitate together.
The hnRNP U IP using the 3G6 antibody, was then probed again with the same
antibody to ensure that hnRNP is immunoprecipitated from the nuclear protein.
In the elutions from the hnRNP U IP, hnRNP U has been enriched in
comparison to the total nuclear protein (Figure 6.4 (b)). The bands at
approximately 66 kDa and 30 kDa are non specific and correspond to the
product of cross reactivity from the anti-mouse secondary HRP antibody used in
the Western blot detection, which interacts with the mouse IgG chains from the
mouse monoclonal hnRNP U antibody (3G6).
The blot for the hnRNP U IP was then stripped and reprobed with the WT1 C-
19 antibody (Figure 6.4 (c)). In the hnRNP U IPs, a band above 45 kDa
corresponding to WT1 can be detected in the IP (Figure 6.4 (c)). Western
blotting of the IgG IP with both H2 and 3G6 showed no detectable bands for
either WT1 or hnRNPU (Figure 6.4 (d)).
6.5 Discussion
Utilising endogenous immunoprecipitations from differentiated ES cells,
coupled to MALDI-TOF analysis, we have identified an interaction of WT1
with hnRNP U. The precise role of hnRNP U in vivo is not fully understood, but
evidence suggests that it is most likely involved in at least three different
processes. It has been demonstrated that hnRNP U acts as a transcriptional
repressor (Kim and Nikodem, 1999). Secondly, as a constituent of the hnRNP
particles, hnRNP U is involved in the packaging and processing of RNA
(Dreyfuss et al., 1993). And, finally, several reports have indicated that hnRNP
U has a high binding-specificity for specialised AT-rich DNA regions termed
SARs (Scaffold-Associated Regions). Each of the proposed functions for
hnRNP U will be discussed in the context of the association of WT1 with
hnRNP U.
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6.5.1 Transcriptional Repression
A recent study has identified hnRNP U as an RNA polymerase II elongation
inhibitor (Kim and Nikodem, 1999). Eukaryotic mRNA synthesis is catalysed
by the multi-subunit RNA polymerase II (RNA Pol II) and proceeds through
multiple steps, designated pre-initiation, initiation and elongation. The RNA Pol
II transcription complex possesses a unique structural feature, the carboxyl
terminal domain (CTD). The phopshorylation state of this CTD domain
regulates the transcriptional activity of RNA Pol II. In an unphosphorylated
state, the RNA Pol II CTD is believed to mediate multiple protein-protein
interactions involved in the assembly of the pre-initiation complex. However,
once initiation of transcription begins, kinases phosphorylate the CTD domain
to generate the elongation-competent RNA Pol II and the generation of a
primary transcript (For review see Bentley, 1998). One of the kinases that is
believed to phosphorylate the CTD is the multi-subunit general transcription
factor, TFIIH.
It has been demonstrated that a fraction of hnRNP U is found associated with
the RNA Pol II complex and is recruited to a promoter as part of the pre-
initiation complex (Kim and Nikodem, 1999). HnRNP U then dissociates from
the RNA Pol II complex at an early stage of transcription and is therefore absent
from the elongation competent form of RNA Pol II. The authors were able to
demonstrated that hnRNP U acts as an elongation inhibitor by inhibiting the
kinase activity of TFIIH, thereby preventing the phosphorylation of the CTD
and acting as a transcriptional repressor (Kim and Nikodem, 1999). How does
this fit into a situation regarding the known function ofWT1?
Transcriptional regulation by WT1 appears complex, with a number of different
factors know to influence whether WT1 acts as a repressor or activator of
transcription. Dissection of the WT1 transcriptional regulation domains using
GAL-4 fusion proteins has identified distinct domains responsible for either
190
Chapter 6 Identification of a Novel WT1 Interacting Protein
transcriptional activation or repression (McKay et al., 1999; Wang et al., 1995;
Madden et al., 1993). Studies have indicated that a transcriptional repressor
domain is located between amino acids 70-180 in the N-terminal domain of
WT1 (Wang et al., 1995; Madden et al., 1993). More recent studies have further
refined the repressor domain to amino acids 71-101 (McKay et al., 1999). This
30 amino acid domain was demonstrated to function as a transcriptional
repressor in a WT1-independent context by fusing this domain to the activation
domain of SP1 (McKay et al., 1999). However, questions still remain as to how
the WT1 transcriptional repressor domain exert its effects and the level at which
WT1 induces transcriptional repression in the context of the molecular pathway
ofRNA Pol II.
Both studies by Wang et al and McKay et al, have suggested that this WT1
repressor domain associates with another nuclear protein which in turn mediates
the effects ofWT1 as a transcriptional repressor (Wang et al., 1995; McKay et
al., 1999). With regard to the issue of at which point WT1 represses
transcription, a study by Lee et al has shown that the same WT1 domain is
capable of repressing co-activators that stimulate the initiation and/or elongation
steps of RNA Pol II (Lee et al., 1999). The authors suggested that a possible
mechanism by which WT1 could achieve this repression of co-activators is by a
direct interference with the basal transcriptional complex. Therefore it could be
suggested that the association of WT1 with hnRNP U facilitates the
transcriptional repression elicited by WT1. This would seem feasible, as there
has yet been no description of a direct association ofWT1 with the components
of the RNA Pol II complex. Therefore, hnRNP U may provide a bridging
partner via which WT1 may mediate some aspects of transcriptional regulation.
6.5.2 RNA Processing
Whilst the elongating RNA Pol II complex is generating a primary transcript,
the messenger RNA processing reactions of capping, splicing and
polyadenylation are occurring co-transcriptionally. The hnRNP family of
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proteins are RNA processing factors that associate with the pre-mRNAs as it
emerges from the RNA Pol II, acting to facilitate the various stages ofmRNA
biogenesis (For review see Dreyfuss et al., 2002). This interaction with RNA is
mediated through the presence of an RNA- binding domain. Most, if not all, of
the hnRNP proteins contain one or more of a small number of RNA-binding
motifs. HnRNP U contains a RGG domain that mediates its association to RNA,
and also to other hnRNP proteins to form hnRNP particles. Given the reported
association ofWT1 with U2AF65 and WTAP, both components of the splicing
machinery, an association with hnRNP U might be another protein partner that
facilitates the RNA-processing function of WT1 (Davies et al., 1998; Little et
al., 2000). This association might be governed, as with U2AF65, through the
zinc fingers ofWT1, and in particular the +KTS isoforms. Added to this is the
fact that WT1 has a putative RRM domain and also the zinc fingers of WT1
have been shown to bind RNA (Kennedy et al., 1995; Caricasole et al., 1996).
6.5.3 Scaffold Attachment Regions
Within the eukaryotic nucleus, chromosomal DNA is organised into higher
order structures called chromatin which itself is organised within the nucleus.
These chromatin structures are established by attaching the chromosomal DNA
to proteins of the nuclear matrix, a proteinaceous structure that serves as a
scaffold. This association is mediated by DNA regions termed Scaffold
Attachment Regions (or SARS), that anchor the chromosomal DNA to the
nuclear matrix. In addition to their role in organising nuclear architecture, SARs
have also been implicated in the regulation of gene expression. This has been
proposed due to a number of observations. Firstly they are frequently found in
genomic locations close to enhancers (Cockerill et al., 1986) Secondly, they can
also stimulate gene expression of heterologous reporter gene when integrated
into the genome (Stief et al., 1989), and thirdly, they can regulate chromatin
accessibility (Jenuwein et al., 1997). Several SAR binding proteins have be
characterised including hnRNP U (otherwise know as Scaffold Attachment
Factor A, SAF-A). Apart from possessing an RNA-binding domain, hnRNP U
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also contains a novel DNA-binding domain which specifically associates to the
scaffold-associated region (SAR) (Gohring et al., 1997). This domain is
independent of the RNA-binding domain.
In some cases the activation of gene expression is thought to be dependent on
processes involving changes to the chromatin structure (Tolhuis et al., 2002).
Therefore, in the context of WT1 an association ofWT1 with hnRNP U might
lead to alterations in chromatin structure, hence leading to transcriptional
activation or repression by WT1. It is interesting to note that WT1 has been
observed to exert repression over a large distance during in vitro transcriptional
assays (Lee et al., 1999). Therefore, an association with hnRNP U might
facilitate this effect by modulating chromatin structure.
In summary, the association ofWT1 with hnRNP U, a multifunctional protein,
may mediate all facets of WT1 function at both the transcriptional and post-
transcriptional level.
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7.1 Generation of Genetic Model Systems to Investigate
the Role of WT1
The WT1 gene was identified as a tumour suppressor gene involved in the etiology
of Wilms' tumour. To date, it is clear that the biology of WT1 is complex. Studies
have indicated that in addition to its function as a tumour suppressor, this gene has
multiple roles during development. This is exemplified in the WT1 mouse models,
which have demonstrated the critical importance of WT1 expression for the
development of several organs, including the kidneys, gonads, spleen and, more
recently, the retina. This complexity of WT1 action during development is also
reflected at the molecular level. Alternative splicing and the use of alternative
translation initiation sites, generate a multitude of isoforms which seem to have
overlapping, but also distinct, functions during embryonic development. The WT1
proteins seem to perform two main functions. They regulate the transcription of a
variety of target genes and may be involved in post-transcriptional processing of
RNA. Over the last few years our understanding ofWTl function has significantly
improved, however there are still many unanswered questions. What are the
transcriptional targets of WTl? What is the function of WTl in the later stages of
embryogenesis and post-natally? Therefore, the aim of this thesis was to develop
new genetic models to begin to address some of these questions, and gain further
insight into WTl gene function.
7.1.1 Generation of a Conditional Allele for WT1
The first part of this project was to develop a conditional allele for WTl utilising
the Cre/LoxP system. This strategy would bypass the embryonic lethality of the
original WTl knockout, and enable the role of WTl during embryogenesis and
195
Chapter 7 General Discussion and Future Directions
post-natal development to be further investigated (Kreidberg et al., 1993). Initially,
the generation of mice carrying the germline modifications of the WT1 locus was
problematic. The likely cause of this was a Cre-mediated genomic rearrangement at
the 3' end of the targeted WT1 allele, which occurred during the transient
expression of Cre-recombinase. Analysis of an ES cell line carrying the targeted
allele following Cre recombination demonstrated that the intronic region where the
3' loxP site resided had undergone genomic rearrangement. Therefore, another
independent ES cell line was treated with Cre and carefully analysed. Individual
clones selected from this transfection did not demonstrate any aberrant
rearrangements in the 3' region, and ES clones with loxP sites flanking exon 1 of
WT1 were successfully used to obtain germline transmission of the WT1 conditional
allele. To ensure that the modifications to the WT1 allele did not produce a
phenotype, heterozygote WT1 conditional mice were mated. Normal-sized litters
were obtained with the expected Mendelian frequency of wild-type, heterozygote
and homozygote genotypes and homozygous WT1 conditional mice were
phenotypically normal after 12 weeks.
The conditional WT1 mouse line can now be employed to address some of the
questions surrounding the function of WT1 in development and disease. One of the
first questions that could be addressed would be the consequence of ablating WT1
during the early stages of metanephric kidney development. Could this induce the
onset of a Wilms' tumour? Wilms' tumours are thought to arise from the
pluripotent metanephric blastemal cells following the induction of differentiation of
the metanephric mesenchyme by the ureteric bud. Ideally, one would like to ablate
WT1 following induction of the metanephric mesenchyme. At present, there are no
suitable transgenic Cre lines available to conditionally inactivate WT1 during this
stage of kidney development. This makes it difficult to examine the role of WT1
during this inductive phase of nephrogenesis, and whether loss of WT1 function
would lead to a predisposition to Wilms' tumours in this model. To overcome this
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difficulty, the conditional WTI mouse would be crossed onto transgenic mice that
carry an inducible form of Cre-recombinase under the control of the human WTI
YAC. These transgenic lines are currently in this laboratory (Hastie et al.,
unpublished). This human WTI YAC has been show to direct beta-galactosidase
expression in a manner that recapitulated the endogenous WTI expression pattern
(Moore et al., 1998; Moore et al., 1999). Therefore, this approach might be suitable
to ablate WTI during this phase of kidney development.
What is the consequence of knocking out WTI in the adult podocyte? Although
WTI expression has been reported in a variety of tissues during development, one
site of WTI expression that is maintained into adulthood is in the glomerular
podocytes of the kidney. Recent observations indicate that WTI expression in this
cell-type is required for the maintenance of normal kidney function in adulthood
(Guo et al., 2002; Menke et al., in press). The analysis of heterozygote WTI mice
demonstrates that they exhibit an increased mortality rate due to adult onset renal
failure. Whether WTI expression is crucial to podocyte function can now be
directly tested by crossing the conditional WTI mouse onto the recently published
transgenic mouse line carrying a glomerular-specific inducible Cre-recombinase
(Bugeon et al., 2003).
In summary, the successful generation of a conditional WTI mouse leaves us well-
placed to address the numerous questions relating to the role of WTI in
development and disease, which is limited only by the availability of suitable
transgenic Cre lines.
7.1.2 Generation of WT1 Null ES Cell Lines
The second part of this approach was to generate WTI null ES cell lines. These ES
cell lines would then be used in an in vitro differentiation system to identify
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candidate WT1 regulated transcripts. In generating the WT1 null ES cells, the
original strategy was to engineer ES cells that carried a conditional allele of WTl.
In this system, the loss-of-function for WT1 would be under the spatial-temporal
control of Cre-recombinase. However targeting of the second wild-type WT1 allele
proved difficult, as several attempts failed to correctly target the WT1 allele and
incorporate the three loxP sites. Therefore, the original targeting vector used in the
generation of the WT1 knockout mouse (Kreidberg et al., 1993) was used to target
the second remaining WT1 to produce two independent lines ofWT1 null ES cells.
7.2 Identification of Candidate WT1 Regulated
Transcripts
A number of approaches have been employed over the last decade in an attempt to
elucidate the network of genes that are regulated by WT1. The majority of
published downstream targets of WT1 have been identified from experimental
approaches that have employed either the over-expression of single WT1 isoforms
followed by analysis of gene expression profiles, or transient transfections with
engineered reporter constructs. The results from these experiments have produced a
list of putative WTl target genes which includes other transcription factors, growth
factors, growth factor receptors, extracellular matrix genes, cell survival genes and
signaling molecules amongst others (For review see Lee and Haber, 2001).
However, such studies suffer from several disadvantages. From the over-expression
of WT1 isoforms and subsequent analysis of downstream gene expression profiles,
differentially expressed genes identified by this process may not necessarily be
direct targets ofWTl. Rather, it is possible that the differential expression of a gene
is due solely to indirect effects of over-expression ofWTl. More importantly, it is
unclear whether the genes influenced from over-expression of WTl represent true
in vivo targets of WTl, where WTl is present at physiologically relevant
concentrations. Also, the over-expression studies have focused on single isoforms
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of WT1, whereas it is clear that WT1 isoforms and their relative ratios are crucial
for normal physiology. Similarly the results from the transient transfections of
reporter constructs vary significantly depending upon experimental parameters such
as the choice of cell line and expression vectors, the WT1 isoform expressed and
the promoter architecture of the putative target (Reddy and Licht, 1996). More
importantly, often the in vivo relevance of the previously reported candidate
downstream WT1 target gene remains unclear.
In an attempt to address some of these issues, it was critical to develop a system in
which endogenous targets of WT1 could be identified under biologically relevant
conditions. A previous report demonstrated that the differentiation of embryonic
stem cells with all-trans retinoic acid (RA) as a monolayer culture induced high
level endogenous expression of WT1 (Scharnhorst et al., 1997). Hence this system
provided an ideal platform with which to study WT1 function in a pluripotent, non-
transformed cell line which retains the potential to differentiate into multiple
lineages. Therefore the approach taken in this thesis was to develop WT1 null ES
cell lines (described above) and to use these in a RA differentiation system.
Coupled to Affymetrix Genechip arrays, this would permit the identification of
candidate WT1 regulated genes, which were affected by loss-of-function for WT1
following differentiation.
Of the 12,000 transcripts present on the array, only a small number (102) showed a
difference of greater than 2.5-fold change in expression between wild-type and
WT1 null ES cells. The list of differentially expressed transcripts included genes
that had previously been identified as being regulated by WT1, including
amphiregulin, Wnt-4 and the murine homologue of FREAC-4, BF-2 (Lee et al.,
1999; Sim et al., 2002; Ernstsson et al., 1996). However, the remaining transcripts
represent a novel set of candidate WT1 regulated genes.
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An important caveat to this study is that the data sets generated from the initial
Affymetrix analysis of wild-type and WT1 null ES cell gene expression profiles is
preliminary. Whilst providing some very interesting candidate WT1 targets, this
study requires further replicate samples to be analysed by microarray, to provide a
comprehensive statistical analysis. However differential expression of a number of
those putative targets was confirmed by RT-PCR analysis. Following on from this,
it is vital to determine whether these differentially expressed transcripts are directly
regulated by WT1. Various co-transfection approaches could be employed to
determine this. However Chromatin immunoprecipitation (ChIP) analysis is a
useful technique which detects a direct in vivo interaction between any transcription
factor and its binding site on genomic DNA. This approach has been successful in
identifying transcripts which are regulated by other transcription factors, including
E2F (Weinmann et al., 2002) and c-Myc (Fernandez et al., 2003).
Briefly this experimental approach would require wild-type and WT1 null ES cells
to be treated with RA, followed by formaldehyde cross-linking, chromatin isolation
and DNA shearing by sonication. Immunoprecipitation would then proceed using
the WT1 antibody to selectively precipitate WT1 protein and any DNA fragments
cross-linked to it. Thus, DNA sequence elements associated with WT1, in the
context of the cellular environment, would be enriched in the immunoprecipitated
sample. A PCR screen using primers specific for promoters of candidate WT1
target genes would indicate whether it had been bound by WT1.
In summary, the identification of a novel set of candidate WT1 regulated genes
may lead to the elucidation to the mechanism by which WT1 mediates its
downstream effects in vivo.
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7.3 Neuronal Expression of WT1
During embryogenesis, WT1 is expressed in a tissue specific manner. Studies have
identified sites of expression in the urogenital system, the epicardium of the heart,
the spleen, and mesothelium (Armstrong et al., 1993; Moore et al., 1998; Moore et
al., 1999). Consistent with this expression pattern is the phenotype of the WT1
knockout mouse, which displays gonadal and renal agenesis in addition to heart,
spleen and adrenal abnormalities. To date, the role of WT1 in kidney development
has received the most attention. However the reported expression of WT1 in
neuronal lineages is yet to be further characterised. Initial reports have described
discrete pockets of expression in the developing eye, spinal cord and brain
(Armstrong et al., 1993; Rackely et al., 1993; Moore et al., 1998). A recent study
has indicated that WT1 expression in the eye has a role in the development of the
retina. Analysis of WT1 knockout mice has revealed abnormalities in retinal
development, with optic nerve hypoplasia and apoptotic loss of retinal ganglia cell
precursors (Wagner et al., 2002). The data presented in this thesis extends the
analysis of WT1 expression in neuronal lineages.
In the analysis of the differentiating ES cells, it was observed that a sub-population
of WT1 positive cells co-expressed nestin. This indicated that WT1 was being
induced in a subpopulation of neuronal progenitor cells. To confirm this finding,
the expression of WT1 in neuronal progenitors that were derived from the
differentiation of a genetically modified ES cell line was analysed (Li et al., 1998).
This in vitro lineage selection protocol enables the efficient purification of
neuroepithelial progenitor cells, which subsequently differentiate efficiently into
neuronal networks at the expense of other cell types. Semi-quantitative RT-PCR
demonstrated the up-regulation of WT1 expression during the initial stages of
neuronal progenitor cell differentiation.
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Next, the analysis of WT1 expression in neuronal lineages was extended in vivo.
Interestingly expression of WT1 appeared to be present in a domain where neuronal
progenitors are generated. Focusing on E9.5-E10.5, it was evident at E10.5 that
WT1 was expressed in the ventral neural tube. Closer examination indicated that in
the developing ventral neural tube, WT1 expression was present in domains that
contained neuronal progenitors, as demonstrated by co-localisation of WT1 with
Nkx6.1. However, it was unclear exactly which specific neuronal progenitor
subtype expressed WT1. In the ventral neural tube, the combinatorial expression of
a group of homeodomain proteins generates five different neural progenitor
subtypes (For review see Briscoe and Ericson, 2000). Nkx6.1 marks the three most
ventral progenitors subtypes (p3, pMN, p2). To specifically identify which domain
expresses WT1, double immunofluorosence using specific markers for the p3, pMN
and p2 domain alongside WT1 would need to be carried out. However is was clear
that WT1 was expressed in differentiated motor neurons, as demonstrated by co-
localisation of WT1 with the Lim homeodomain protein, Islet-1. Therefore, this
data indicates that WT1 is expressed in certain neuronal progenitor cell populations
and also in differentiated motor neuron populations of the developing spinal cord.
To further characterise this the analysis of WT1 expression will be extended to later
stages of neuronal development, beyond E10.5. This would indicate whether WT1
expression persists in these populations of motor neurons, or whether it is
subsequently down-regulated. Does expression in the motor neurons persist into
adulthood? What is the function of WT1 in the developing neural tube? Does WT1
have a role in the maintenance of neuronal progenitors, or is it involved in the
differentiation of these progenitors towards motor neuron lineage? The two systems
described in this thesis will allow further examination, both in vitro and in vivo, of
the function of WT1 in these neuronal lineages. Recently, it has been demonstrated
that embryonic stem cells can be directed to differentiate into motor neurons under
the correct inductive signals (Wichterle et al., 2002). During this differentiation
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process, the ES cell derived motor neurons follow a developmental pathway that
recapitulates the situation in vivo. It would be interesting to utilise the both wild-
type and WT1 null ES cells in this differentiation system to examine if WT1 has a
fundamental role in motor neuron generation.
Complementary to the in vitro work, the conditional WT1 mouse will prove
invaluable in dissecting whether the specific ablation of WT1 expression in the
motor neuron populations results in a phenotype. If future co-localisation studies
indicates that WT1 is expressed in motor neuron progenitors, then the use of a Cre-
recombinase under the control of the 01ig2 promoter (Takebayashi et al., 2002)
will allow the ablation of WT1 in these specific progenitors. To ablate WT1
expression specifically within the motor neurons, a transgenic mouse line with Cre
recombinase under the control of Lim3 could be employed (Sharma et al., 1998).
Given that this study has identified WT1 as being expressed in the ventral neural
tube, future work will address the target genes that WT1 regulates in the neural
tube. The Affymetrix Genechip analysis of gene expression profiles of wild-type
and WT1 null ES cells during RA mediated differentiation identified RALDH2 as a
differentially expressed transcript. Whether WT1 directly regulates RALDH2 is yet
to be established, however it is interesting to note that RALDH2 plays a crucial role
in the generation of certain types of motor neuron in the developing spinal cord
(Sockanathan and Jessell, 1998). A potential regulation of RALDH2 by WT1 has
been already been suggested by studies from co-workers (Professor Munoz-
Chapuli, unpublished data). Work focusing on the epicardium of the heart has
shown that WT1 and RALDH2 are co-expressed in the same populations of
epicardially derived cells. Closer inspection of the WT1 null mice has indicated that
RALDH2 expression is down-regulated these cell populations within the
epicardium (Professor Munoz-Chapuli, personal communication). This effect is
consistent with the observation that RALDH2 expression is down-regulated in
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WT1 null ES cells. If RALDH2 represents an authentic target for WT1, the down-
regulation of RALDH2 should be a generic feature in the WT1 knockout mice
resulting in the down-regulation of RALDH2 in the neural tube.
During spinal cord development, motor neurons with common targets of
innervation are clustered into discrete nuclei, termed motor pools. In the neural
tube, RALDH2 plays a crucial role in the specification of the lateral motor neuron
cell type (LMC) (Sockanathan and Jessell, 1998). This class of motor neurons is
generated selectively at branchial and lumbar levels of the spinal cord, and their
axons innervate target muscles in the limb. Preliminary analysis of branchial
sections from the neural tube of El 1.5 WT1 null embryos indicates that RALDH2
expression is in fact down-regulated (Professor Munoz-Chapuli, personal
communication). This observation would suggest one of two possibilities: that WT1
is a direct activator of RALDH2 or specification of LMCs has been abolished in the
WT1 null, which leads to the observed down-regulation of RALDH2. To address
this issue, WT1 null embryos would be analysed with other LMC markers to test
for loss of LMC specification. Also, since down-regulation of RALDH2 expression
has been shown to effect the number of motor neurons generated (Sockanathan and
Jessell, 1998), staining for Islet-1 on WT1 null embryos would address whether the
numbers of motor neurons generated has been reduced at the branchial and lumbar
regions.
In summary, this study describes the expression of WT1 in neuronal progenitors (in
vitro and in vivo) and also differentiated motor neurons of the developing spinal
cord. The demonstration of WT1 expression in both neuronal progenitors and
differentiated neurons supports the notion of a role for WT1 in neuronal
differentiation. The failure to detect gross abnormalities within the CNS of WT1
null embryos suggests this role may be a subtle one, and closer analysis of these
animals is now required to substantiate the initial findings described herein.
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7.4 Identification of WT1 Interacting Proteins
The biological function of WT1 in vivo is affected by interactions with other
proteins. A number of protein partners are known to associate with WT1 and these
include p53, SF-1, Par-4, U2AF65 and WTAP (For Review see Lee and Haber,
2001). The interaction of these proteins with WT1 has been shown to modify the
transcriptional properties of WT1 and also implicate WT1 in post-transcriptional
regulation. Previously, identification of WT1 interacting proteins was based around
yeast two hybrid screens, or over-expression of WT1-GST fusions followed by
pull-downs to find WT1 protein partners. The approach taken in this thesis was to
carry out endogenous immunoprecipitations for WT1 from RA treated ES cells, and
then couple this to MALDl-ToF analysis. The data obtained from this strategy
identified an interaction of WT1 with a member of the heterogeneous ribonuclear
protein family, hnRNP U. Confirmation of this association was achieved by
carrying out reciprocal IPs for hnRNP U and WT1, and demonstrating that both co-
precipitate together.
The precise function of hnRNP U is unclear. It is known that hnRNP U is involved
in transcriptional repression, RNA splicing and possibly, chromatin remodeling.
The functional significance of the interaction of WT1 with hnRNP U should now
be examined. The first approach will be to identify which domains of WT1 are
interacting with hnRNP U. Is their interaction mediated through the zinc fingers of
WT1? To determine this, yeast two hybrid studies would be carried out. Is the
interaction mediated via common set of RNA transcripts? Does the interaction of
WT1 with hnRNP U modulate the transcriptional behaviour of WT1? In summary
there are numerous questions relating to the functional significance of the
interaction of WT1 with hnRNP U, however it is clear that endogenous WT1 IPs,
coupled to mass spectrometry, is a powerful approach to identify WT1 interacting
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proteins from complex samples. Future work could extend this approach to identify
additional WT1 interacting proteins.
7.5 Conclusion
Following over a decade of study on the biology ofWT1, it is clear that this gene is
a multifunctional protein that has a complex role in normal development. Whilst the
WT1 knockout mice represented an enormous step forward towards the elucidation
of these roles, their significance was constrained due to the midgestation lethality
observed in this model. The establishment of the two genetic systems described in
this thesis will therefore increase the understanding of the functional properties of
WT1 and its downstream targets, thereby providing unique insights into the link
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